References

cardiovascular

Кардиоваскулярная терапия и профилактика

Cardiovascular Therapy and Prevention

1728-88002619-0125

«SILICEA-POLIGRAF» LLC

10.15829/1728-8800-2024-3996

AVZLPJ

cardiovascular-3996

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство

Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines

https://orcid.org/0000-0002-4453-8430

Драпкина

О. М.

Drapkina

O. M.

Д.м.н., профессор, академик РАН, главный внештатный специалист Минздрава по терапии и общей врачебной практике, директор, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-2062-1536

Концевая

А. В.

Kontsevaya

A. V.

Д.м.н., доцент, зам. директора по научной и аналитической работе, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

akontsevaya@gnicpm.ru

https://orcid.org/0000-0003-2458-3629

Калинина

А. М.

Kalinina

A. M.

Д.м.н., профессор, заслуженный деятель науки РФ, руководитель отдела первичной профилактики ХНИЗ в системе здравоохранения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-5999-2150

Авдеев

С. Н.

Avdeev

S. N.

Д.м.н., профессор, академик РАН, зав. кафедрой пульмонологии Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет).

Москва

https://orcid.org/0000-0002-4982-628X

Агальцов

М. В.

Agaltsov

M. V.

К.м.н., с.н.с. лаборатории кардиовизуализации, вегетативной регуляции и сомнологии отдела фундаментальных и прикладных аспектов ожирения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-7017-0898

Алексеева

Л. И.

Alekseeva

L. I.

Д.м.н., начальник отдела метаболических заболеваний костей и суставов, ФГБНУ НИИР им. В.А. Насоновой; профессор кафедры ревматологии терапевтического факультета ФГБОУ ДПО РМАНПО Минздрава России.

Москва

https://orcid.org/0000-0001-6330-5264

Алмазова

И. И.

Almazova

I. I.

К.м.н., доцент кафедры терапии, общей врачебной практики с курсом гастроэнтерологии ИПОА, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-7167-3067

Андреенко

Е. Ю.

Andreenko

E. Yu.

С.н.с. отдела клинической кардиологии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-9267-4931

Антипушина

Д. Н.

Antipushina

D. N.

К.м.н., с.н.с. лаборатории профилактики хронических болезней органов дыхания отдела первичной профилактики ХНИЗ в системе здравоохранения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-2062-1536

Баланова

Ю. А.

Balanova

Yu. A.

Д.м.н., в.н.с. отдела эпидемиологии ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-1002-1895

Бернс

С. А.

Berns

S. A.

Д.м.н., профессор, зав. кафедрой терапии и общей врачебной практики с курсом гастроэнтерологии, руководитель отдела изучения патогенетических аспектов старения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-1171-2746

Будневский

А. В.

Budnevsky

A. V.

Д.м.н., заслуженный изобретатель РФ, профессор, проректор по научно-инновационной деятельности, зав. кафедрой факультетской терапии, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России.

Воронеж

https://orcid.org/0000-0001-9928-926X

Гайнитдинова

В. В.

Gainitdinova

V. V.

Д.м.н., профессор кафедры пульмонологии ИКМ им. Н.В. Склифосовского, ФГАОУ ВО Первый МГМУ им. И.М. Сеченова (Сеченовского университета) Минздрава России.

Москва

https://orcid.org/0000-0001-6665-1533

Гаранин

A. А.

Garanin

A. A.

К.м.н., директор научно-практического центра дистанционной медицины, ФГБОУ ВО СамГМУ Минздрава России.

Самара

https://orcid.org/0000-0001-5195-8997

Горбунов

В. М.

Gorbunov

V. M.

Д.м.н., профессор, руководитель лаборатории применения амбулаторных диагностических методов в профилактике ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-1423-214X

Горшков

А. Ю.

Gorshkov

A. Yu.

К.м.н., руководитель лаборатории микроциркуляции и регионарного кровообращения, зам. директора по научной и амбулаторно-поликлинической работе, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-8120-6267

Григоренко

Е. А.

Grigorenko

E. A.

Д.м.н., доцент, зам. директора по международному сотрудничеству и аналитической работе государственного учреждения "Республиканский научно-практический центр "Кардиология" Министерства здравоохранения Республики Беларусь.

Минск

https://orcid.org/0000-0003-3334-3520

Джонова

Б. Ю.

Jonova

B. Yu.

К.м.н., начальник отдела бизнес планирования и анализа развития семейной медицины государственного учреждения "Республиканский учебно-клинический центр семейной медицины" Республики Таджикистан.

Душанбе

https://orcid.org/0000-0002-4529-3308

Дроздова

Л. Ю.

Drozdova

L. Yu.

К.м.н., руководитель лаборатории поликлинической терапии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0009-0003-3721-4379

Друк

И. В.

Druk

I. V.

Д.м.н., доцент, зав. кафедрой внутренних болезней и семейной медицины ДПО, ФГБОУ ВО "Омский государственный медицинский университет" Минздрава России.

Омск

https://orcid.org/0000-0003-0143-0849

Елиашевич

С. О.

Eliashevich

S. O.

Врач-диетолог, руководитель лаборатории изучения и коррекции пищевого поведения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-1191-5831

Елисеев

М. С.

Eliseev

M. S.

К.м.н., зав. лабораторией микрокристаллических артритов, ФГБНУ НИИР им В.А. Насоновой.

Москва

https://orcid.org/0000-0001-5376-3034

Жарылкасынова

Г. Ж.

Zharylkasynova

G. Zh.

Д.м.н., профессор, проректор по учебной работе Бухарского государственного медицинского института им. Абу Али ибн Сино Республики Узбекистан.

Бухара

https://orcid.org/0009-0004-0349-3653

Забровская

С. А.

Zabrovskaya

S. A.

К.м.н., врач-эндокринолог, зав. отделением плановой госпитализации Московского научно-исследовательского онкологического института им. П.А. Герцена — филиала ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России.

Москва

https://orcid.org/0000-0002-9332-0622

Имаева

А. Э.

Imaeva

A. E.

К.м.н., в.н.с. отдела эпидемиологии ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-1190-7391

Камилова

У. К.

Kamilova

U. K.

Д.м.н., профессор, зам. директора по научной работе Республиканского специализированного научно-практического медицинского центра терапии и медицинской реабилитации, главный специалист по терапии Министерства здравоохранения Республики Узбекистан.

Ташкент

https://orcid.org/0000-0001-8784-8415

Каприн

А. Д.

Kaprin

A. D.

Д.м.н., профессор, академик РАН, академик РАО, главный внештатный специалист онколог Минздрава России, генеральный директор, ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России.

Москва

https://orcid.org/0000-0002-5873-1768

Кобалава

Ж. Д.

Kobalava

Zh. D.

Д.м.н., профессор, член-корреспондент РАН, зав. кафедрой внутренних болезней и клинической фармакологии ФПК медицинских работников РУДН.

Москва

https://orcid.org/0000-0003-0306-6139

Корсунский

Д. В.

Korsunsky

D. V.

Врач-методист, м.н.с., ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-3138-054X

Куликова

О. В.

Kulikova

O. V.

К.м.н., с.н.с. лаборатории персонализированной диагностики, профилактики и терапии некоронарогенных заболеваний сердца, в.н.с. отдела клинической кардиологии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-8498-7030

Курехян

А. С.

Kurekhyan

A. S.

К.м.н., н.с. лаборатории профилактики хронических болезней органов дыхания отдела первичной профилактики ХНИЗ в системе здравоохранения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-6395-2584

Кутишенко

Н. П.

Kutishenko

N. P.

Д.м.н., в.н.с. лаборатории фармакоэпидемиологических исследований отдела профилактической фармакотерапии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-1429-8154

Лавренова

Е. А.

Lavrenova

E. A.

Эндокринолог, н.с. отдела научно-стратегического развития первичной медико-санитарной помощи, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-6572-0592

Лопатина

М. В.

Lopatina

M. V.

К.м.н., руководитель лаборатории интегрированных программ профилактики, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-8252-3099

Лукина

Ю. В.

Lukina

Yu. V.

К.м.н., в.н.с. лаборатории фармакоэпидемиологических исследований отдела профилактической фармакотерапии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-5784-4525

Лукьянов

М. М.

Lukyanov

M. M.

К.м.н., руководитель отдела клинической кардиологии ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-7640-638X

Люсина

Е. О.

Lyusina

E. O.

К.м.н., н.с. отдела фундаментальных и прикладных аспектов ожирения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-7131-8049

Мамедов

М. Н.

Mamedov

M. N.

Д.м.н., профессор, руководитель отдела вторичной профилактики ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0009-0009-3834-6502

Марданов

Б. У.

Mardanov

B. U.

К.м.н., с.н.с. отдела вторичной профилактики ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-1939-7189

Мареев

Ю. В.

Mareev

Yu. V.

К.м.н., с.н.с. отдела клинической кардиологии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-7717-4362

Марцевич

С. Ю.

Martsevich

S. Yu.

Д.м.н., профессор, руководитель отдела профилактической фармакотерапии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-9088-721X

Митьковская

Н. П.

Mitkovskaya

N. P.

Д.м.н., профессор, директор государственного учреждения "Республиканский научно-практический центр "Кардиология" Министерства здравоохранения Республики Беларусь, главный внештатный кардиолог Министерства здравоохранения Республики Беларусь.

Минск

https://orcid.org/0000-0002-9024-5364

Мясников

Р. П.

Myasnikov

R. P.

К.м.н, руководитель лаборатории персонализированной диагностики, профилактики и терапии некоронарогенных заболеваний сердца, в.н.с. отдела клинической кардиологии, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-5265-3164

Небиеридзе

Д. В.

Nebieridze

D. V.

Д.м.н, профессор, руководитель отдела профилактики метаболических нарушений, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-8749-8504

Орлов

С. А.

Orlov

S. A.

К.м.н., с.н.с. отдела научно-стратегического развития первичной медико-санитарной помощи, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-6141-8994

Переверзева

К. Г.

Pereverzeva

K. G.

Д.м.н., профессор кафедры госпитальной терапии с курсом медико-социальной экспертизы, ФГБОУ ВО РязГМУ Минздрава России.

Рязань

https://orcid.org/0000-0002-8674-8575

Поповкина

О. Е.

Popovkina

O. E.

К.м.н., зав. отделом фотодинамической диагностики и терапии Медицинского радиологического научного центра им. А.Ф. Цыба — филиала ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России.

Москва

https://orcid.org/0000-0002-2459-7273

Потиевская

В. И.

Potievskaya

V. I.

Д.м.н., зав. научной группой кардиоонкологии, зав. отделением кардиологии и медицинской реабилитации Московского научно-исследовательского онкологического института им. П.А. Герцена — филиала ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России, профессор кафедры кардиологии Академии постдипломного образования Федерального медико-биологического агентства России.

Москва

https://orcid.org/0000-0002-1763-0725

Скрипникова

И. А.

Skripnikova

I. A.

Д.м.н.. руководитель отдела профилактики остеопороза и коморбидных состояний, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-6208-3038

Смирнова

М. И.

Smirnova

M. I.

К.м.н., руководитель лаборатории профилактики хронических болезней органов дыхания отдела первичной профилактики ХНИЗ в системе здравоохранения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-6511-5963

Сооронбаев

Т. М.

Sooronbaev

T. M.

Д.м.н., профессор, директор Национального центра кардиологии и терапии им. акад. Мирсаида Миррахимова, главный внештатный пульмонолог Минздрава Кыргызской Республики.

Бишкек

https://orcid.org/0000-0003-4739-4302

Торопцова

Н. В.

Toroptsova

N. V.

Д.м.н., зав. лабораторией остеопороза, ФГБНУ НИИР им. В.А. Насоновой.

Москва

Хайлова

Ж. В.

Khailova

Zh. V.

К.м.н., зам. директора МРНЦ им. А.Ф. Цыба — филиала ФГБУ "НМИЦ радиологии" Минздрава России, президент Ассоциации онкологов и онкологических учреждений Центрального федерального округа.

Москва

https://orcid.org/0000-0001-8845-9913

Хороненко

В. Э.

Khoronenko

V. E.

Д.м.н., профессор, начальник отдела анестезиологии и реанимации Московского научно-исследовательского онкологического института им. П.А. Герцена — филиала ФГБУ "Национальный медицинский исследовательский центр радиологии" Минздрава России.

Москва

https://orcid.org/0000-0001-6292-3837

Чащин

М. Г.

Chashchin

M. G.

К.м.н., н.с. лаборатории микроциркуляции и регионарного кровообращения, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-1371-0848

Черник

Т. А.

Chernik

T. A.

К.м.н., ассистент кафедры факультетской терапии ФГБОУ ВО ВГМУ им. Н. Н. Бурденко Минздрава России.

Воронеж

https://orcid.org/0000-0003-2087-6483

Шальнова

С. А.

Shalnova

S. A.

Д.м.н., профессор, руководитель отдела эпидемиологии ХНИЗ, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0001-9252-7093

Шаповалова

М. М.

Shapovalova

M. M.

К.м.н., доцент кафедры факультетской терапии ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России.

Воронеж

https://orcid.org/0000-0002-8984-9056

Шепель

Р. Н.

Shepel

R. N.

К.м.н., зам. директора по перспективному развитию медицинской деятельности, ФГБУ "НМИЦ ТПМ" Минздрава России; доцент кафедры терапии и профилактической медицины, ФГБОУ ВО "МГМСУ им. А.И. Евдокимова" Минздрава России.

Москва

https://orcid.org/0000-0001-7230-0780

Шептулина

А. Ф.

Sheptulina

A. F.

К.м.н., в.н.с., руководитель лаборатории экспериментальной и профилактической гастроэнтерологии отдела фундаментальных и прикладных аспектов ожирения, ФГБУ "НМИЦ ТПМ" Минздрава России; доцент кафедры терапии и профилактической медицины, ФГБОУ ВО "Российский университет медицины" Минздрава России.

Москва

https://orcid.org/0000-0002-1042-4275

Шишкова

В. Н.

Shishkova

V. N.

Д.м.н., в.н.с., руководитель отдела профилактики когнитивных и психоэмоциональных нарушений, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0003-4936-6006

Юлдашова

Р. У.

Yuldashova

R. U.

К.м.н., доцент, декан факультета последипломного образования Бухарского государственного медицинского института им. Абу Али ибн Сино.

Бухара

https://orcid.org/0000-0003-2816-1183

Явелов

И. С.

Yavelov

I. S.

Д.м.н., руководитель отдела фундаментальных и клинических проблем тромбоза при неинфекционных заболеваниях, ФГБУ "НМИЦ ТПМ" Минздрава России.

Москва

https://orcid.org/0000-0002-1394-3791

Якушин

С. С.

Yakushin

S. S.

Д.м.н., зав. кафедрой госпитальной терапии с курсом медико-социальной экспертизы, ФГБОУ ВО РязГМУ Минздрава России.

Рязань

2024

01042024

23339963996

Copyright © Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Алексеева Л.И., Алмазова И.И., Андреенко Е.Ю., Антипушина Д.Н., Баланова Ю.А., Бернс С.А., Будневский А.В., Гайнитдинова В.В., Гаранин A.А., Горбунов В.М., Горшков А.Ю., Григоренко Е.А., Джонова Б.Ю., Дроздова Л.Ю., Друк И.В., Елиашевич С.О., Елисеев М.С., Жарылкасынова Г.Ж., Забровская С.А., Имаева А.Э., Камилова У.К., Каприн А.Д., Кобалава Ж.Д., Корсунский Д.В., Куликова О.В., Курехян А.С., Кутишенко Н.П., Лавренова Е.А., Лопатина М.В., Лукина Ю.В., Лукьянов М.М., Люсина Е.О., Мамедов М.Н., Марданов Б.У., Мареев Ю.В., Марцевич С.Ю., Митьковская Н.П., Мясников Р.П., Небиеридзе Д.В., Орлов С.А., Переверзева К.Г., Поповкина О.Е., Потиевская В.И., Скрипникова И.А., Смирнова М.И., Сооронбаев Т.М., Торопцова Н.В., Хайлова Ж.В., Хороненко В.Э., Чащин М.Г., Черник Т.А., Шальнова С.А., Шаповалова М.М., Шепель Р.Н., Шептулина А.Ф., Шишкова В.Н., Юлдашова Р.У., Явелов И.С., Якушин С.С., 2024

2024

Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Алексеева Л.И., Алмазова И.И., Андреенко Е.Ю., Антипушина Д.Н., Баланова Ю.А., Бернс С.А., Будневский А.В., Гайнитдинова В.В., Гаранин A.А., Горбунов В.М., Горшков А.Ю., Григоренко Е.А., Джонова Б.Ю., Дроздова Л.Ю., Друк И.В., Елиашевич С.О., Елисеев М.С., Жарылкасынова Г.Ж., Забровская С.А., Имаева А.Э., Камилова У.К., Каприн А.Д., Кобалава Ж.Д., Корсунский Д.В., Куликова О.В., Курехян А.С., Кутишенко Н.П., Лавренова Е.А., Лопатина М.В., Лукина Ю.В., Лукьянов М.М., Люсина Е.О., Мамедов М.Н., Марданов Б.У., Мареев Ю.В., Марцевич С.Ю., Митьковская Н.П., Мясников Р.П., Небиеридзе Д.В., Орлов С.А., Переверзева К.Г., Поповкина О.Е., Потиевская В.И., Скрипникова И.А., Смирнова М.И., Сооронбаев Т.М., Торопцова Н.В., Хайлова Ж.В., Хороненко В.Э., Чащин М.Г., Черник Т.А., Шальнова С.А., Шаповалова М.М., Шепель Р.Н., Шептулина А.Ф., Шишкова В.Н., Юлдашова Р.У., Явелов И.С., Якушин С.С.

Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.N., Agaltsov M.V., Alekseeva L.I., Almazova I.I., Andreenko E.Y., Antipushina D.N., Balanova Y.A., Berns S.A., Budnevsky A.V., Gainitdinova V.V., Garanin A.A., Gorbunov V.M., Gorshkov A.Y., Grigorenko E.A., Jonova B.Y., Drozdova L.Y., Druk I.V., Eliashevich S.O., Eliseev M.S., Zharylkasynova G.Z., Zabrovskaya S.A., Imaeva A.E., Kamilova U.K., Kaprin A.D., Kobalava Z.D., Korsunsky D.V., Kulikova O.V., Kurekhyan A.S., Kutishenko N.P., Lavrenova E.A., Lopatina M.V., Lukina Y.V., Lukyanov M.M., Lyusina E.O., Mamedov M.N., Mardanov B.U., Mareev Y.V., Martsevich S.Y., Mitkovskaya N.P., Myasnikov R.P., Nebieridze D.V., Orlov S.A., Pereverzeva K.G., Popovkina O.E., Potievskaya V.I., Skripnikova I.A., Smirnova M.I., Sooronbaev T.M., Toroptsova N.V., Khailova Z.V., Khoronenko V.E., Chashchin M.G., Chernik T.A., Shalnova S.A., Shapovalova M.M., Shepel R.N., Sheptulina A.F., Shishkova V.N., Yuldashova R.U., Yavelov I.S., Yakushin S.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://cardiovascular.elpub.ru/jour/article/view/3996

Создание руководства поддержано Советом по терапевтическим наукам отделения клинической медицины Российской академии наук.

коморбидностьмультиморбидностьхронические неинфекционные заболеванийлечениепрофилактикасердечно-сосудистые заболевания

polymorbiditymultimorbiditychronic non-communicable diseasestreatmentpreventioncardiovascular diseases

References1

Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. Journal Chronic Diseases. 1970;23(7):455-68. doi:10.1016/0021-9681(70)90054-8.

Верткин А. Л. Коморбидный пациент. Руководство для практических врачей. М.: Эксмо, 2015. 151 с. ISBN: 978-5-699-83378-8.

Vertkin AL. Comorbid patient. A guide for practitioners. Moscow: Eksmo, 2015. 151 p. (In Russ.) ISBN: 978-5-699-83378-8.

Оганов Р. Г., Денисов И. Н., Симаненков В. И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):7-54. doi:10.15829/1728-8800-2017-6-5-56.

Oganov RG, Denisov IN, Simanenkov VI, et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.) doi:10.15829/1728-8800-2017-6-5-56.

Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66. doi:10.15829/1728-8800-2019-1-5-66.

Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi:10.15829/1728-8800-2019-1-5-66.

Первичная медико-санитарная помощь, общественное здоровье и организация здравоохранения. Справочник понятий и терминов. Сост. Калинина А. М., Савченко Д. О., Вошев Д. В. и др. М.: РОПНИЗ, ООО "Силицея-Полиграф", 2023. с. 76. ISBN: 978-5-6050061-1-4. doi:10.15829/ROPNIZ-k1-2023. EDN EDXLEM. https://gnicpm.ru/wp-content/uploads/2020/01/spr_pmsp_oz_org.pdf

Primary health care, public health and health organization. Handbook of concepts and terms. Comp. Kalinina AM, Savchenko DO, Voshev DV, et al. M.: ROPNIZ, LLC “Silicea-Polygraph”, 2023. p. 76. (In Russ.) ISBN: 978-5-6050061-1-4. doi:10.15829/ROPNIZ-k1-2023. EDN EDXLEM. https://gnicpm.ru/wp-content/uploads/2020/01/spr_pmsp_oz_org.pdf

Оганов Р. Г. Сосудистая коморбидность: общие подходы к профилактике и лечению. Рациональная фармакотерапия в кардиологии. 2015;11(1):4-7.

Oganov RG. Vascular comorbidity: general approaches to prevention and treatment. Rational Pharmacotherapy in Cardiology. 2015;11(1):4-7. (In Russ.)

Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2.

Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today’s healthcare systems. BMC Fam Pract. 2015;16:129. doi:10.1186/s12875-015-0344-4.

GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544. doi:10.1016/S0140-6736(16)31012-1.

Zhang X, Padhi A, Wei T, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022;7(9):e008880. doi:10.1136/bmjgh-2022-008880.

Makovski TT, Schmitz S, Zeegers MP, et al. Multimorbidity and quality of life: systematic literature review and meta-analysis. Ageing Res Rev. 2019;53:100903. doi:10.1016/j.arr.2019.04.005.

Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2016;67:130-8. doi:10.1016/j.archger.2016.07.008.

Cassell A, Edwards D, Harshfield A, et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study Br J Gen Pract. 2018;68(669):e245-e251. doi:10.3399/bjgp18X695465.

Tong B, Stevenson C. 2007. Comorbidity of cardiovascular disease, diabetes and chronic kidney disease in Australia. Cardiovascular Disease Series no. 28. Cat. no. CVD 37.Canberra:AIHW. ISBN: 978 1 74024 705 4.

Андреев Е. М, Кваша Е. А., Харькова Т.Л. Продолжительность жизни в России: восстановительный рост. Демоскоп Weekly. 2014;(621-622):1-22. EDN VSKRCL.

Andreev EM, Kvasha EA, Kharkova TL. Life expectancy in Russia: recovery growth. Demoscope Weekly. 2014;(621-622):1-22. (In Russ.) EDN VSKRCL.

Шальнова С.А., Оганов Р.Г., Деев А. Д. и др. Сочетания ишемической болезни сердца с другими неинфекционными заболеваниями в популяции взрослого населения: ассоциации с возрастом и факторами риска. Кардиоваскулярная терапия и профилактика. 2015;14(4):44-51. doi:10.15829/1728-8800-2015-4-44-51

Shalnova SA, Oganov RG, Deev AD, et al. Comorbidities of ischemic heart disease with other non-communicable diseases in adult population: age and risk factors association. Cardiovascular Therapy and Prevention. 2015;14(4):44-51. (In Russ.) doi:10.15829/1728-8800-2015-4-44-51

Nguyen H, Manolova G, Daskalopoulou C, et al. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorb. 2019;9. doi:10.1177/2235042x19870934.

Chowdhury SR, Chandra Das D, Sunna TC, et al. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine. 2023;57:101860. doi:10.1016/j.eclinm.2023.101860.

Larsen FB, Pedersen MH, Friis K, et al. A latent class analysis of multimorbidity and the relationship to socio-demographic factors and health-related quality of life. A national population-based study of 162,283 Danish adults. PLoS One. 2017;12(1). doi:10.1371/JOURNAL.PONE.0169426.

Pati S, Swain S, Knottnerus JA, et al. Magnitude and determinants of multimorbidity and health care utilization among patients attending public versus private primary care: a cross-sectional study from Odisha, India. Int J Equity Health. 2020;19(1):57. doi:10.1186/s12939-020-01170-y.

Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205-14. doi:10.1093/gerona/glv128.

van Oostrom SH, Picavet HS, de Bruin SR, et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam Pract. 2014;15:61. doi:10.1186/1471-2296-15-61.

Wallace E, Salisbury C, Guthrie B, et al. Managing patients with multimorbidity in primary care. BMJ. 2015;350:h176. doi:10.1136/BMJ.H176.

Марцевич С. Ю., Кутишенко Н. П., Лукина Ю. В. и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная терапия и профилактика. 2021;20(2):2786. doi:10.15829/1728-8800-2021-2786.

Martsevich SYu, Kutishenko NP, Lukina YuV, et al. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovascular Therapy and Prevention. 2021;20(2):2786. (In Russ.) doi:10.15829/1728-8800-2021-2786.

Sullivan TR, Yelland LN, Lee KJ, et al. Treatment of missing data in follow-up studies of randomised controlled studies: A systematic review of the literature. Clin Trials. 2017;14(4):387-95. doi:10.1177/1740774517703319.

Austin PC, White IR, Lee DS. Missing data on clinical research: A tutorial on multiple imputation. Can J Cardiol. 2021;37(9):1322-31. doi:10.1016/j.cjca.2020.11.010.

Singhal R, Rana R. Intricacy of missing data in clinical trials: Deterrence and management. Int J Appl Basic Med Res. 2014; 4(Suppl 1):S2-S5. doi:10.4103/2229-516X.140706.

Schambroth C. Management of acute coronary syndrome in South Africa: insights from the ACCESS registry. Cardiovasc J Afr. 2012;23(7):365-70. doi:10.5830/CVJA-2012-017.

Boulton C, Wilkinson JM. Use of public datasets in the examination of multimorbidity: Opportunities and challenges. Mech Ageing Dev. 2020;190:111310. doi:10.1016/j.mad.2020.111310.

Kabir A, Tran A, Ansari S, et al. Impact of multimorbidity and complex multimorbidity on mortality among older Australians aged 45 years and over: a large population-based record linkage study. BMJ Open 2022;12:e060001. doi:10.1136/bmjopen-2021-060001.

Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780-5. doi:10.1016/j.ijcard.2014.10.149.

Willadsen TG, Siersma V, Nicolaisdóttir DR. Multimorbidity and mortality. A 15-year longitudinal registry-based nationwide Danish population study. J Comorb. 2018;8(1):2235042X18804063. doi:10.1177/2235042X18804063.

Yildiz B, Schuring M, Knoef MG, et al. Chronic diseases and multimorbidity among unemployed and employed persons in the Netherlands: a register-based cross-sectional study. BMJ Open 2020;10:e035037. doi:10.1136/bmjopen-2019-035037.

Бойцов С. А., Лукьянов М. М., Якушин С. С. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50. doi:10.15829/1728-8800-2014-6-3-8.

Boytsov SA, Luk’yanov MM, Yakushin SS, et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50. (In Russ.) doi:10.15829/1728-8800-2014-6-3-8.

Chang SS, Dong JZ, Ma CS, et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke. 2016;47(7):1803-10. doi:10.1161/STROKEAHA.116.012988.

Лукьянов М.М., Андреенко Е. Ю., Марцевич С.Ю. и др. Больные с фибрилляцией предсердий в клинической практике: коморбидность, медикаментозное лечение и исходы (данные регистров РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2020;16(6):888-98. doi:10.20996/1819-6446-2020-12-01.

Loukianov MM, Andreenko EYu, Martsevich SYu, et al. Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries). Rational Pharmacotherapy in Cardiology. 2020;16(6):888-98. (In Russ.) doi:10.20996/1819-6446-2020-12-01.

Guo Y, Wang Y, Li X, et al. Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. BMJ Open 2018;8:e020191. doi:10.1136/bmjopen-2017-020191.

Mannucci PM, Nobili A. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014;9(7):723-34. doi:10.1007/s11739-014-1124-1.

Pasina L, Ottolini BB, Cortesi L, et al. Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Med Princ Pract. 2019;28(6):501-8. doi:10.1159/000499692.

Бойцов С. А., Лукьянов М. М., Якушин С. С. и др. Амбулаторно-поликлинический регистр РЕКВАЗА: данные проспективного наблюдения, оценка риска и исходы у больных с кардиоваскулярными заболеваниями. Кардиоваскулярная терапия и профилактика. 2015;14(1):53-62. doi:10.15829/1728-8800-2015-1-53-62.

Boytsov SA, Lukyanov ММ, Yakushin SS, et al. The out-patient based registry RECVASA: prospective follow-up data, risk evluation and outcomes in cardiovascular patients. Cardiovascular Therapy and Prevention. 2015;14(1):53-62. (In Russ.) doi:10.15829/1728-8800-2015-1-53-62.

Bagai A, Ali FM, Gregson J, et al. Multimorbidity, functional impairment, and mortality in older patients stable after prior acute myocardial infarction: Insights from the TIGRIS registry. Clin Cardiol. 2022; 45(12):1277-86. doi:10.1002/clc.23915.

Переверзева К. Г., Лукьянов М. М., Андреенко Е. Ю. с соавт. Амбулаторный регистр пациентов, перенесших инфаркт миокардА (РЕГАТА): данные проспективного наблюдения и исходы. Кардиология. 2022;62(2):12-9. doi:10.18087/cardio.2022.2.n1712.

Pereverzeva KG, Lukyanov MM, Andreenko EYu, et al. Out-patient register of patients who have suffered a myocardial infarction (REGATA): prospective follow-up data and outcomes. Kardiologiia. 2022;62(2):12-9. (In Russ.) doi:10.18087/cardio.2022.2.n1712.

Gudnadottir GS, Gudnason T, Wilgelmson K, Ravn-Fisher AR. Multimorbidity and Readmissions in Older People with Acute Coronary Syndromes Cardiology. 2022;147(2):121-32. doi:10.1159/000522016.

Vanbeselaere V, Truyers C, Elli S, et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord. 2016;16:61. doi:10.1186/s12872-016-0235-1.

Guo X, Li M, Du X, et al. Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study. Front Cardiovasc Med. 2022;9:988799. doi:10.3389/fcvm.2022.988799.

Takeuchi S, Kohno T, Goda A, et al.; West Tokyo Heart Failure Registry Investigators. Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients. ESC Heart Fail. 2022;9(4):2500-10. doi:10.1002/ehf2.13954.

Tromp J, Tay WT, Ouwerkerk W, et al.; ASIAN-HF authors. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018;15(3):e1002541. doi:10.1371/journal.pmed.1002541. Erratum in: PLoS Med. 2018;15(5):e1002583.

Драпкина О. М., Бойцов С. А., Омельяновский В. В. и др. Социально-экономический ущерб, обусловленный хронической сердечной недостаточностью, в Российской Федерации. Российский кардиологический журнал. 2021;26(6):4490.

Drapkina OM, Boytsov SA, Omelyanovskiy VV, et al. Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology. 2021;26(6):4490. (In Russ.)

Драпкина О.М., Концевая А. В., Муканеева Д. К. и др. Прогноз социально-экономического бремени хронической обструктивной болезни легких в Российской Федерации в 2022 году. Пульмонология. 2022;32(4):507-16. doi:10.18093/0869-0189-2022-32-4-507-516.

Drapkina OM, Kontsevaya AV, Mukaneeva DK, et al. Forecast of the socioeconomic burden of COPD in the Russian Federation in 2022. PULMONOLOGIYA. 2022;32(4):507-16. (In Russ.) doi:10.18093/0869-0189-2022-32-4-507-516.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8.

Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2022;91(1):8-35. doi:10.1159/000521288.

Holman CDJ, Preen DB, Baynham NJ, et al. A multipurpose comorbidity scoring system performed better than the Charlson index. J Clin Epidemiol. 2005;58(10):1006-14. doi:10.1016/j.jclinepi.2005.01.020.

Harris M, Taylor G, Jackson D. Clinical evidence made easy. Banbury 2014, с. 212. ISBN: 1907904204, 9781907904202.

Kostis JB, Dobrzynski JM. Limitations of Randomized Clinical Trials. Am J Cardiol. 2020;129:109-15. doi:10.1016/j.amjcard.2020.05.011.

Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233-40. doi:10.1001/jama.297.11.1233.

Huntley AL, Johnson R, Purdy S, et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med. 2012;10(2):134-41. doi:10.1370/afm.

Watson JM, Torgerson DJ. Increasing recruitment to randomized trials: a review of randomised controlled trials. BMC Med Res Methodol. 2006;6:34. doi:10.1186/1471-2288-6-34.

He J, Morales DR, Guthrie B. Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. Trials. 2020;21(1):228. doi:10.1186/s13063-020-4139-0.

Pitkala K, Strandberg T. Clinical trials in older people. Age and Ageing. 2022;51:1-9 doi:10.1093/ageing/afab282.

Hanlon P, Hannigan L, Rodriguez-Perez J, et al. Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. BMC Med. 2019;17(1):201. doi:10.1186/s12916-019-1427-1.

Saunders C, Byrne CD, Guthrie B, et al.; Scottish Diabetes Research Network Epidemiology Group. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300-8. doi:10.1111/dme.12047.

Leinonen A, Koponen M, Hartikainen S. Systematic Review: Representativeness of Participants in RCTs of Acetylcho-linesterase Inhibitors. PLoS One. 2015;10(5):e0124500. doi:10.1371/journal.pone.0124500.

Khan MS, Samman Tahhan A, Vaduganathan M, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail. 2020;22(6):1032-42. doi:10.1002/ejhf.1818.

Patel MR, Mahaffey KW, Garg J, и et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.

Марцевич С. Ю., Навасардян А. Р., Захарова Н. А., Лукьянов М. М. Новые оральные антикоагулянты: можно ли результаты международных контролируемых исследований с этими препаратами переносить на российских больных? Кардиоваскулярная терапия и профилактика 2015;14(5):48-52. https://cardiovascular.elpub.ru/jour/article/view/165.

Martsevich SYu, Navasardian AR, Zakharova NA, Lukianov ММ. New oral anticoagulants: is that plausible to implement the data from international trials to russian population? Cardiovascular Therapy and Prevention. 2015;14(5):48-52. (In Russ.) https://cardiovascular.elpub.ru/jour/article/view/165.

Camm AJ, Amarenco P, Hess S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J. 2016;37:1145-53. doi:10.1093/eurheartj/ehv466.

Mehra MR, Vaduganathan M, Fu M, et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J. 2019;40(44):3593-602. doi:10.1093/eurheartj/ehz427.

Afshar S, Roderick PJ, Kowal P, et al. Global Patterns of Multimorbidity: A Comparison of 28 Countries Using the World Health Surveys. Pub. online 2017:381-402. doi:10.1007/978-3-319-43688-3_21.

Abebe F, Schneider M, Asrat B, Ambaw F. Multimorbidity of chronic non-communicable diseases in low- and middle-income countries: A scoping review. J Comorb. 2020;10: 2235042X2096191. doi:10.1177/2235042X20961919.

Palladino R, Lee JT, Ashworth M, et al. Associations between multimorbidity, healthcare utilisation and health status: evidence from 16 European countries. Age Ageing. 2016;45(3):431-5. doi:10.1093/AGEING/AFW044.

Kadam UT, Uttley J, Jones PW, Iqbal Z. Chronic disease multimorbidity transitions across healthcare interfaces and associated costs: a clinical-linkage database study. BMJ Open. 2013;3(7). doi:10.1136/BMJOPEN-2013-003109.

McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag Healthc Policy. 2016;9:143-56. doi:10.2147/RMHP.S97248.

Charlson M, Wells MT, Ullman R, King F, Shmukler C. The Charlson comorbidity index can be used prospectively to identify patients who will incur high future costs. PLoS One. 2014;9(12). doi:10.1371/JOURNAL.PONE.0112479.

Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017;15(1). doi:10.1186/S12916-017-0978-2.

Blakely T, Kvizhinadze G, Atkinson J, et al. Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand. PLoS Med. 2019;16(1). doi:10.1371/JOURNAL.PMED.1002716.

Tran PB, Kazibwe J, Nikolaidis GF et al. Costs of multimorbidity: a systematic review and meta-analyses. BMC Med. 2022;20(1). doi:10.1186/S12916-022-02427-9.

Cabral GG, Dantas de Souza AC, Barbosa IR, et al. Multimorbidity and Its Impact on Workers: A Review of Longitudinal Studies. Saf Health Work. 2019;10(4):393-9. doi:10.1016/J.SHAW.2019.08.004.

Troelstra SA, Straker LM, Harris M, et al. Multimorbidity is common among young workers and related to increased work absenteeism and presenteeism: Results from the population-based raine study cohort. Scand J Work Environ Health. 2020;46(2):218-27. doi:10.5271/sjweh.3858.

Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database of Systematic Reviews. 2021;2021(1). doi:10.1002/14651858.CD006560.pub4.

Драпкина О. М., Концевая А. В., Калинина А. М. Организационные аспекты амбулаторного ведения коморбидных пациентов. М.: Видокс, 2020, 144 с. ISBN: 978-5-6042718-2-7

Drapkina OM, Kontsevaya AV, Kalinina AM. Organizational aspects of outpatient management of comorbid patients. M.: Vidox, 2020, 144 p. (In Russ.) ISBN: 978-5-6042718-2-7

Значкова Е. А., Гришина Н. К., Сердюковский С. М. и др. Оказание медицинской помощи людям старше 60 лет с множественными хроническими заболеваниями в Москве. Проблемы социальной гигиены, здравоохранения и истории медицины. 2017;25(3):163-7. doi:10.18821/0869-866X-2017-25-3-163-167.

Znachkova EA, Grishina NK, Serdyukovsky SM, et al. Providing medical care to people over the age of 60 with multiple chronic diseases in Moscow. Problems of social hygiene, health care and the history of medicine. 2017;25(3):163-7. (In Russ.) doi:10.18821/0869-866X-2017-25-3-163-167.

Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. и др. Международный регистр “Анализ динамики Коморбидных заболеваний у пациенТов, перенесших инфицирование SARS-CoV-2” (АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021;26(4):4470. doi:10.15829/1560-4071-2021-4470.

Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology. 2021;26(4):4470. (In Russ.) doi:10.15829/1560-4071-2021-4470.

Sutton RT, Pincock D, Baumgart DC, et al. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17. doi:10.1038/s41746-020-0221-y.

Гусев А. В., Зарубина Т. В. Поддержка принятия врачебных решений в медицинских информационных системах медицинской организации. Врач и информационные технологии. 2017;(2):60-72. EDN YSZMEL.

Gusev AV, Zarubina TV. Support for medical decision-making in medical information systems of a medical organization. Doctor and information technology. 2017;(2):60-72. (In Russ.) EDN YSZMEL.

Bates DW, Cohen M, Leape LL, et al. Reducing the frequency of errors in medicine using information technology. J Am Med Inform Assoc. 2001;8(4):299-308. doi:10.1136/jamia.2001.0080299.

Bates DW, Kuperman GJ, Wang S, et al. Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J Am Med Inform Assoc. 2003;10(6):523-30. doi:10.1197/jamia.M1370.

Гусев А. В., Добриднюк С. Л. Искусственный интеллект в медицине и здравоохранении. Информационное общество. 2017;(4-5):78-93. http://infosoc.iis.ru/article/view/211.

Gusev AV, Dobridnyuk SL. Artificial intelligence in medicine and healthcare. The Information Society. 2017;(4-5):78-93. (In Russ.) http://infosoc.iis.ru/article/view/211.

Sabaté E. Adherence to long-term therapies: evidence for action. Geneva (Switzerland): World Health Organization (WHO); 2003. 198p. ISBN: 92 4 154599 2.

Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295.

De Bacquer D, Astin F, Kotseva K, et al. Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. Eur J Prev Cardiol. 2022;29(2):383-95. doi:10.1093/eurjpc/zwab115.

Pedretti RFE, Hansen D, Ambrosetti M, et al. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2023;30(2):149-66. doi:10.1093/eurjpc/zwac204.

Maffoni M, Traversoni S, Costa E, et al. Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient’s experience. Eur Geriatr Med. 2020;11(3):369-81. doi:10.1007/s41999-020-00313-2.

Midão L, Giardini A, Menditto E, et al. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213-20. doi:10.1016/j.archger.2018.06.018.

Лукина Ю. В., Кутишенко Н. П., Марцевич С. Ю., Шепель Р. Н., Драпкина О. М. Методические рекомендации: "Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций". Профилактическая медицина. 2020;23(32):4260. doi:10.17116/profmed20202303242.

Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Methodological recommendations. Adherence to drug therapy in patients with chronic non-communicable diseases. Ad- dressing the problem in a number of clinical situations. Russian Journal of Preventive Medicine and Public Health. 2020;23(32):4260. (In Russ.) doi:10.17116/profmed20202303242.

Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112. doi:10.1186/s13643-019-1014-8.

Burgess E, Hassmén P, Pumpa KL. Determinants of adherence to lifestyle intervention in adults with obesity: a systematic review. Clin Obes. 2017;7:123-35. doi:10.1111/cob.12183.

Bhattarai B, Walpola R, Mey A, et al. Barriers and strategies for improving medication adherence among people living with COPD: a systematic review. Respir Care. 2020;65:1738-50. doi:10.4187/respcare.07355.

Cooke CE, Xing S, Gale SE, et al. Initial non-adherence to antihypertensive medications in the United States: a systematic literature review. J Hum Hyperten. 2022;36:3-13. doi:10.1038/s41371-021-00549-w.

Doherty AS, Boland F, Moriarty F, et al. Adverse drug reactions and associated patient characteristics in older community-dwelling adults: a 6-year prospective cohort study. Br J Gen Pract. 2023;73(728): e211-e219. doi:10.3399/BJGP.2022.0181.

100

Лукина Ю. В., Дмитриева Н. А., Кутишенко Н. П. и др. Взаимосвязь и взаимовлияние аспектов безопасности лекарственного лечения и приверженности терапии у больных сердечно-сосудистыми заболеваниями (по данным амбулаторного регистра “ПРОФИЛЬ”). Кардиоваскулярная терапия и профилактика. 2018;17(5):72-8. doi:10.15829/1728-8800-2018-5-72-78

Lukina YuV, Dmitrieva NA, Kutishenko NP, et al. The relationship and interinfluence of aspects of therapy safety and compliance in patients with cardiovascular diseases (by the data from outpatient registry “PROFILE”). Cardiovascular Therapy and Prevention. 2018;17(5):72-8. (In Russ.) doi:10.15829/1728-8800-2018-5-72-78

101

Schulz M, Krueger K, Schuessel K, et al. Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668-76. doi:10.1016/j.ijcard.2016.06.263.102.

102

de Vries ST, Keers JC, Visser R et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134-8. doi:10.1016/j.jpsychores.2013.11.003.

103

Viana M, Laszczynska O, Mendes S, et al. Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm. 2014;20(10):1018-26. doi:10.18553/jmcp.2014.20.10.1018.

104

Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8(5):e019101. doi:10.1136/bmjopen-2017-019101. Erratum in: BMJ Open. 2019;9(5):e019101corr1.

105

Nguyen HT, Nguyen TD, van den Heuvel ER, et al. Medication Errors in Vietnamese Hospitals: Prevalence, Potential Outcome and Associated Factors. PLoS One. 2015;10(9):e0138284. doi:10.1371/journal.pone.0138284.

106

Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. 2005;353:487-97. doi:10.1056/NEJMra050100.

107

Драпкина О. М., Концевая А. В., Калинина А. М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. doi:10.15829/1728-8800-2022-3235.

Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.

108

Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020;41(45):4317.

109

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. doi:10.1186/s12877-017-0621-2.

110

Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

111

Delara M, Murray L, Jafari B, et. al. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):601. doi:10.1186/s12877-022-03279-x.

112

Van der Heyden J, Berete F, Renard F, et al. Assessing polypharmacy in the older population: comparison of a self-reported and prescription based method. Pharmacoepidemiol Drug Saf. 2021;30:1716-26.

113

Ye L, YangHuang J, Franse CB, et al. Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study. BMC Geriatrics. 2022;22:841. doi:10.1186/s12877-022-03536-z.

114

Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32-8.

115

Brilleman SL, Salisbury C. Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study. Family Practice. 2013;30:172-8. doi:10.1093/fampra/cms060.

116

Ulley J, Harrop D, Ali A et al. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatrics. 2019;19:15. doi:10.1186/s12877-019-1031-4.

117

Gomes D, Ana Isabel Placido AI, Mó R, et al. Daily medication management and adherence in the polymedicated elderly: a cross-sectional study in Portugal. Int. J. Environ. Res. Public Health. 2020;17:200. doi:10.3390/ijerph17010200.

118

Liu J, Yu Y, Yan S, et al. Risk factors for self-reported medication adherence in community-dwelling older patients with multimorbidity and polypharmacy: a multicenter cross-sectional study. BMC Geriatrics. 2023;23:75. doi:10.1186/s12877-023-03768-7.

119

González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E. Factors associated with medication non-adherence among patients with multimorbidity and polypharmacy admitted to an intermediate care center. Int. J. Environ. Res. Public Health. 2021;18:9606. doi:10.3390/ijerph18189606.

120

Franchi C, Ludergnani M, Merlino L, et al. Multiple medication adherence and related outcomes in community-dwelling older people on chronic polypharmacy: a retrospective cohort study on administrative claims data. Int. J.Environ. Res. Public Health. 2022;19:5692. doi:10.3390/ijerph19095692.

121

Saadat Z, Nikdoust F, Aerab-Sheibani H, at al. Adherence to antihypertensives in patients with comorbid condition. Nephrourol Mon. 2015;7(4):e29863. doi:10.5812/numonthly.29863.

122

Leelakanok N, Holcombe AL, Lund BC, et al. Association between polypharmacy and death: a systematic review and metaanalysis. J Am Pharm Assoc. 2017;57(6):729-38. e710. doi:10.1016/j.japh.2017.06.002.

123

Davies LE, Spiers G, Kingston A, et al. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181-7. doi:10.1016/j.jamda.2019.10.022.

124

Jyrkkä J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20(5):514-22. doi:10.1002/pds.2116.

125

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):1-10. doi:10.1186/s12916-015-0322-7.

126

Chang TI, Park H, Kim DW, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10(1):18964. doi:10.1038/s41598-020-75888-8.

127

Brockhattingen KK, Anru PL, Masud T, et al. Association between number of medications and mortality in geriatric inpatients: a Danish nationwide register-based cohort study. Eur Geriatr Med. 2020;11(6):1063-71. doi:10.1007/s41999-020-00390-3.

128

Schöttker B, Saum K, Muhlack DC, et al. Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol. 2017;73:1041-8. doi:10.1007/s00228-017-2266-7.

129

Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82(5):1382-92. doi:10.1111/bcp.13055.

130

Wehling M, Petrovic M. Deprescribing or represcribing: not just a semantic dilemma. European Geriatric Medicine. 2022;13:529-30. doi:10.1007/s41999-021-00583-4.

131

Ibrahim K, Cox NJ, Stevenson JM, et al. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatrics. 2021;21:258. doi:10.1186/s12877-021-02208-8.

132

Rea F, Biffi A, Ronco R, et al. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy. JAMA Network Open. 2021;4(6):e2113186. doi:10.1001/jamanetworkopen.2021.13186.

133

McCarthy C, Clyne B, Boland F, et al. GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial. PLoS Med. 2022;19(1):e1003862. doi:10.1371/journal.pmed.1003862.

134

Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-23.

135

Справочник по клинической фармакологии и фармакотерапии. Под ред. И. С. Чекмана, А. П. Пелещука, О.А. Пятака. Киев: Здоровье; 1987. 736 с.

Handbook of Clinical Pharmacology and Pharmacotherapy. Edited by IS Chekman, AP Peleshchuk, OA Pyatak. Kiev: Zdorovye; 1987. 736 p. (In Russ.)

136

Мясников А. Л. Гипертоническая болезнь и атеросклероз. Монография. Москва: Медицина; 1965. 616 с.

Myasnikov AL. Hypertension and atherosclerosis. Monograph. Moscow: Medicine; 1965. 616 p. (In Russ.)

137

Авакян В. М. Дифференцированное лечение больных гипертонической болезнью в различных ее стадиях. Журнал экспериментальной и клинической медицины. 1964;4(5):21-30.

Avakian VM. Differentiated treatment of patients with hypertension in its various stages. Journal of Experimental and Clinical Medicine. 1964;4(5):21-30. (In Russ.)

138

Ланг Г. Ф. Гипертоническая болезнь. Л.,1950.

Lang GF. Hypertension. L., 1950. (In Russ.)

139

Cressman MD, Gifford RW. Controversies in hypertension: mild hypertension, isolated systolic and the choice of a step one drug. Clin. Cardiol. 1983;6(1):1-10.

140

Saklayen MG, Deshpande NV. Timeline of history of hypertension treatment. Front. Cardiovasc. Med. 2016;3:3.

141

Чазова И. Е., Жернакова Ю. В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31.

Chazova IE., Zhernakova YuV, on behalf of the experts. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019;16(1):6-31. (In Russ.)

142

Lewis CE, Fine LJ, Beddhu S, et al. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021;384(20):1921-30. doi:10.1056/NEJMoa1901281.

143

Чазова И.Е., Ратова Л.Г. Гипертоническая болезнь: от А. Л. Мясникова до наших дней. Кардиологический вестник. 2010;5(1):5-10.

Chazova IE, Ratova LG. Hypertension: from A. L. Myasnikov to the present day. Cardiological Bulletin. 2010;5(1):5-10. (In Russ.)

144

Yusuf S, Lonn E, Pais P, et al. Blood pressure and cholesterol in persons without cardiovascular diseases. N. Engl. J. Med. 2016;374:2032-43.

145

Verma AA, Khuu W, Tadrous M, et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: a population-based retrospective cohort study. PLoS Med. 2018;15(6):e1002584.

146

Weisser B, Predel HG, Gillessen A, et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. High Blood Press Cardiovasc Prev. 2020;27(2):157-64.

147

Webster R, Anushka P, Selak V, et al. Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016;205:147-56.

148

Карпов Ю. А. Тройная комбинация антигипертензивных и липид-снижающих препаратов — эффективное снижение риска сердечно-сосудистых осложнений у пациентов с артериальной гипертонией. Российский медицинский журнал. 2015;27:1580-83.

Karpov YuA. A triple combination of antihypertensive and lipid–lowering drugs is an effective reduction in the risk of cardiovascular complications in patients with arterial hypertension. Russian Medical Journal. 2015;27:1580-83. (In Russ.)

149

Бланкова З. Н., Асланян Н. С. Влияние комбинированной терапии на состояние сосудистой стенки у больных высокого сердечно-сосудистого риска. Системные гипертензии 2017;14 (2):51-5.

Blankova ZN, Aslanyan NS. The effect of combination therapy on the state of the vascular wall in patients with high cardiovascular risk. Systemic hypertension 2017;14 (2):51-5. (In Russ.)

150

Недогода С. В., Чумачек Е. В., Ледяева А. А. и др. Оптимизация контроля артериального давления, органопротекциии метаболических нарушений с помощью фиксированной комбинации лизиноприл+амлодипин+розувастатин у пациентов с артериальной гипертензией. Российский кардиологический журнал 2018;(4):49-55. doi:10.15829/1560-4071-2018-4-49-55.

Nedogoda SV, Chumachek EV, Ledyaeva AA, et al. Optimal organoprotection, control of blood pressure and metabolic disorder with the fixed combination of lisinopril, amlodipine and rosuvastatin in systemic hypertension. Russian Journal of Cardiology. 2018;(4):49-55. (In Russ.) doi:10.15829/1560-4071-2018-4-49-55.

151

Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384: 216-28.

152

Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672-83. doi:10.1016/S0140-6736(19)31791-X.

153

Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S0140-6736(21)01827-4.

154

Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.

155

Yusuf S, Pinto FJ. The polypill: from concept and evidence to implementation. Lancet. 2022;400(10364):1661-3. doi:10.1016/S0140-6736(22)01847-5.

156

Обновление Европейских рекомендаций по лечению артериальной гипертензии: анализ Европейского Общества Гипертензии. Артериальная гипертензия. 2010;16(1):4-42.

Updating European guidelines for the treatment of hypertension: an analysis of the European Hypertension Society. Arterial hypertension. 2010;16(1):4-42. (In Russ.)

157

Condelius A, Edberg AK, Jakobsson U, et al. Hospital admissions among рeople 65+ related to multimorbidity, municipal and outpatient care. Arch Gerontol Geriatr. 2008;46:41-55.

158

Smith SM, O’Dowd T. Chronic diseases: what happens when they come in multiples? Br J Gen Pract. 2007;57:268-70.

159

Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007;22 (Suppl 3):391-5.

160

Wehling M, Multimorbidity WM. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009;57:560-1.

161

Bayliss EA, Edwards AE, Steiner JF, et al. Processes of care desired by elderly patients with multimorbidities. Fam Pract. 2008;25:287-93.

162

Bodenheimer T, Fernandez A. High and rising health care costs. Part 4: can costs be controlled while preserving quality? Ann Intern Med. 2005;143:26-31.

163

Taylor AW, Price K, Gill TK, et al. Multimorbidity — not just an older person’s issue. Results from an Australian biomedical study. BMC Public Health. 2010;10:718.

164

Hersh L, Salzman B, Snyderman D. Health literacy in primary care practice. Am Fam Physician. 2015;92:92.

165

Bennett IM, Chen J, Soroui JS, et al. The contribution of health literacy to disparities in self-rated health status and preventive health behaviors in older adults. Ann Fam Med. 2009;7:204-11.

166

Van der Heide I, Uiters E, Sørensen K, et al. Health literacy in Europe: the development and validation of health literacy prediction models. Eur J Public Health. 2016;26:906-11.

167

Van der Heide I, Wang J, Droomers M, et al. The relationship between health, education, and health literacy: results from the Dutch Adult Literacy and Life Skills Survey. J Health Commun. 2013;18 (Suppl 1):172-84.

168

Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155:97-107.

169

Friis K, Lasgaard M, Osborne RH, et al. Gaps in understanding health and engagement with healthcare providers across common long-term conditions: a population survey of health literacy in 29,473 Danish citizens. BMJ Open. 2016;6:e009627.

170

Barrett SE, Puryear JS. Health literacy: improving quality of care in primary care settings. J Health Care Poor Underserved. 2006;17:690-7.

171

Al Sayah F, Majumdar SR, Williams B, et al. Health literacy and health outcomes in diabetes: a systematic review. J Gen Intern Med. 2013;28:444-52.

172

Seligman HK, Wang FF, Palacios JL, et al. Physician notification of their diabetes patients’ limited health literacy: A randomized, controlled trial. J Gen Intern Med. 2005;20:1077.

173

Smith SK, Nutbeam D, McCaffery KJ. Insights into the concept and measurement of health literacy from a study of shared decision-making in a low literacy population. J Health Psychol. 2013;18:1011-22.

174

Smith SG, Curtis LM, Wardle J, et al. Skill set or mind set? Associations between health literacy, patient activation and health. PLoS One. 2013;8:e74373.

175

Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655-79. doi:10.1016/j.euroneuro.2011.07.018.14.

176

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159): 1789-858. doi:10.1016/S0140-6736(19)31047-5.15.

177

Шальнова С. А., Евстифеева С. Е., Деев А. Д. и др. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социально-демографическими факторами (по данным исследования ЭССЕ-РФ). Терапевтический архив. 2014;86(2):52-9. doi:10.17116/terarkh2014861253-60.

Shalnova SA, Evstifeeva SE, Deev AD, et al. The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study). Therapeutic Archive. 2014;86(2):52-9. (In Russ.) doi:10.17116/terarkh2014861253-60.

178

Погосова Н. В., Соколова О. Ю., Юферева Ю. М. и др. Психосоциальные факторы риска у больных АГ/ИБС: первые результаты российского многоцентрового исследования КОМЕТА. Кардиология. 2018;59(8):54-63. doi:10.18087/cardio.2019.8.n469.

Pogosova NV, Sokolova OYu, Yufereva YuM, et al. Psychosocial Risk Factors in Patients With Most Common Cardiovascular Diseases Such as Hypertension and Coronary Artery Disease (Based on Results From the Russian Multicenter COMET Study). Kardiologiia. 2019;59(8):54-63. (In Russ.) doi:10.18087/cardio.2019.8.n469.

179

Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-8. doi:10.1016/S0140-6736(07)61415-9.

180

Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle income countries. Lancet. 2007;370(9603):1929-38. doi:10.1016/S0140-6736(07)61696-1.

181

Bisschop MI, Kriegsman DM, Deeg DJ, et al. The longitudinal relation between chronic diseases and depression in older persons in the community: the Longitudinal Aging Study Amsterdam. J Clin Epidemiol. 2004;57(2):187-194. doi:10.1016/j.jclinepi.2003.01.001.

182

Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54(3):227-40. doi:10.1016/s0006-3223(03)00587-0.

183

Olvera RL, Fisher-Hoch SP, Williamson DE, et al. Depression in Mexican Americans with diagnosed and undiagnosed diabetes. Psychol Med. 2016;46(3):637-46. doi:10.1017/S0033291715002160.

184

Tong A, Wang X, Li F, et al. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016,53(4):589-98. doi:10.1007/s00592-016-0845-1.

185

Palmer S, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179-91. doi:10.1038/ki.2013.77.

186

Xiao T, Qiu H, Chen Y, et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89. doi:10.1186/s12888-018-1671-5.

187

Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-oncology. 2014;23(2):121-30. doi:10.1002/pon.3409.

188

Fei K, Benn EK, Negron R, et al. Prevalence of Depression Among Stroke Survivors: Racial-Ethnic Differences. Stroke. 2016;47(2):512-5. doi:10.1161/STROKEAHA.115.010292.

189

Celano CM, Millstein RA, Bedoya CA, et al. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. 2015;170(6):1105-15. doi:10.1016/j.ahj.2015.09.013.

190

Krupchanka D, Mlada K, Winkler P, et al. Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study. Lancet Public Health. 2018;3(6):e289-e295. doi:10.1016/S2468-2667(18)30077-X.

191

Scott KM, de Jonge P, Alonso J, et al. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression. Int J Cardiol. 2013;168(6):5293-99. doi:10.1016/j.ijcard.2013.08.012.

192

Jha MK, Qamar A, Vaduganathan M, et al. Screening and Management of Depression in Patients with cardiovascular disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(14):1827-45. doi:10.1016/j.jacc.2019.01.041.

193

Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-29. doi:10.1038/nrcardio.2017.189.

194

Dar T, Radfar A, Abohashem S, et al. Psychosocial Stress and Cardiovascular Disease. Curr Treat Options Cardiovasc Med. 2019;21(5):23. doi:10.1007/s11936-019-0724-5.

195

Vaccarino V, Badimon L, Bremner JD,et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687-96. doi:10.1093/eurheartj/ehy913.

196

Daskalopoulou M, George J, Walters K, et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1. 9 Million Women and Men. PLoS One. 2016;11(4):e0153838. doi:10.1371/journal.pone.0153838.

197

Read JR, Sharpe L, Modini M, et al. Multimorbidity and depression: A systematic review and meta-analysis. Journal of Afective Disorders 2017;221:36-46. doi:10.1016/j.jad.2017.06.009.

198

Gould CE, O’Hara R, Goldstein MK, et al. Multimorbidity is associated with anxiety in older adults in the health and retirement study. International Journal of Geriatric Psychiatry 2016;31(10):1105-15. doi:10.1002/gps.4532.

199

Ronaldson A., de la Torre JA, Prina M, et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. The Lancet Regional Health-Europe. 2021;8:100149. doi:10.1016/j.lanepe.2021.100149.

200

Pedersen SS, von Känel R, Tully PJ, et al. Psychosocial perspectives in cardiovascular disease. Eur J Prev Cardiol. 2017;24(3_suppl):108-15. doi:10.1177/2047487317703827.

201

Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol 2019;108(11):1175-96. doi:10.1007/s00392-019-01488-w.

202

Peters A, McEwen BS. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev 2015;56:139-50. doi:10.1016/j.neubiorev.2015.07.001.

203

Smyth A. Physical activity and anger or emotional upset as triggers of acute myocardial infarction: the INTERHEART study. Circulation. 2016;134(15):1059-67. doi:10.1161/CIRCULATIONAHA.116.023142.

204

Евстифеева С. Е., Шальнова С. А., Макарова Ю. К. и др. Ассоциируется ли уровень тревоги и депрессии в популяции со смертностью населения? По данным исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021;20(5):3009. doi:10.15829/1728-8800-2021-3009.

Evstifeeva SE, Shalnova SA, Makarova YuK, et al. Is the population level of anxiety and depression associated with mortality? Data from the ESSE-RF study. Cardiovascular Therapy and Prevention. 2021;20(5):3009. (In Russ.) doi:10.15829/1728-8800-2021-3009.

205

Moise N, Khodneva Y, Jannat-Khah DP, et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. doi:10.1136/bmjopen-2017-017385.

206

Ye S, Muntner P, Shimbo D, et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61(6):622-30. doi:10.1016/j.jacc.2012.09.058.

207

Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439-48. doi:10.1016/j.jpsychores.2014.10.001.

208

Allen L, Williams J, Townsend N, et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. Lancet Glob Health. 2017;5(3):e277-e289. doi:10.1016/S2214-109X(17)30058-X.

209

Whalley B, Rees K, Davies P, et al. Psychological intervention for coronary heart disease (Review). Cochrane Database Syst Rev. 2011;(8):CD002902. doi:10.1002/14651858.CD002902.pub3.

210

Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290-306. doi:10.1177/2047487314543075.

211

Thompson DR, Ski SF. Psychosocial interventions in cardiovascular disease — what are they? Eur. J. Prev. Cardiol. 2013;20(6):916-7. doi:10.1177/2047487313494031.

212

Pizzi C, Rutjes AW, Costa GM, et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972-9. doi:10.1016/j.amjcard.2010.11.017.

213

Kim JM, Stewart R, Lee YS, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018;320(4):350-8. doi:10.1001/jama.2018.9422.

214

He W, Zhou Y, Ma J, et al. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919-26. doi:10.1007/s10741-019-09850-w.

215

Honkola J, Hookana E, Malinen S, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745-51. doi:10.1093/eurheartj/ehr368.

216

Драпкина О. М., Шишкова В. Н., Котова М. Б. Психоэмоциональные факторы риска хронических неинфекционных заболеваний в амбулаторной практике. Методические рекомендации для терапевтов. Кардиоваскулярная терапия и профилактика. 2022;21(10):3438. doi:10.15829/1728-8800-2022-3438.

Drapkina OM, Shishkova VM, Kotova MB. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Guidelines for internists. Cardiovascular Therapy and Prevention. 2022;21(10):3438. (In Russ.) doi:10.15829/1728-8800-2022-3438.

217

Long DJ, Ouyang Y, Duan H, et al. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary. Int J Chron Obstruct Pulmon Dis. 2020;15:1449-64. doi:10.2147/COPD.S245842.

218

Wen-Tao D, Xue-Xiu Ch, Zun-Jiang Ch, et al. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022;13:817727. doi:10.3389/fgene.2022.817727.

219

Volpato E, Toniolio S, Pagnini F, Banfi P. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2001-21. doi:10.2147/COPD.S313841.

220

Stallberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. doi:10.1038/s41533-018-0101-y.

221

Zareifopoulos N, Bellou A, Spiropoulou A, Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD. 2019;16(5-6):406-17. doi:10.1080/15412555.2019.1679102.

222

Moos RH, Holahan CJ. Adaptive tasks and methods of coping with illness and disability. //Erin M, Hanoch L, editors. Coping with chronic illness and disability. theoretical, empirical, and clinical aspects. New York: Springer 2018; p. 107-28. doi:10.1007/978-0-387-48670-3_6.

223

Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabetes Med. 2005;22(10):1379-85. doi:10.1111/j.1464-5491.2005.01644.x.

224

Perrin NE, Davies MJ, Robertson N, et al. The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Med. 2017;34(11):1508-20. doi:10.1111/dme.13448.

225

Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383-90. doi:10.2337/dc08-0985.

226

Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabetes Med. 2006;23(4):445-8. doi:10.1111/j.1464-5491.2006.01814.x.

227

Huang Ch, Hsieh HM, Tu HP, et al. Generalized anxiety disorder in type 2 diabetes mellitus: prevalence and clinical characteristics. Observational Study Braz J Psychiatry. 2020;42(6):621-9. doi:10.1590/1516-4446-2019-0605.

228

Deschênes S, Burns RJ, Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey--Mental Health (CCHS-MH). Psychosom Res. 2015;78(2):137-42. doi:10.1016/j.jpsychores.2014.11.023.

229

Ásbjörnsdóttir B, Vestgaard M, Do NC, et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Observational Study Diabet Med. 2021;38(3):e14506. doi:10.1111/dme.14506.

230

Van der Feltz-Cornelis C, Allen SF, Holt RIG, et al. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. doi:10.1002/brb3.1981.

231

Winkley K, Upsher R, Stahl D, et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1-232. doi:10.3310/hta24280.

232

Stasiak CES, Bazan KS, Kuss RS, et al. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325-31. doi:10.5935/0101-2800.20140047.

233

Nagler EV, Webster AC, Vanholder R, Zoccali C.Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736-45. doi:10.1093/ndt/gfs295.

234

Chilcot J, Farrington K. The case for selective withdrawal of antidepressants in patients with advanced kidney disease. J Am Soc Nephrol. 2019;30(7):1339-40. doi:10.1681/ASN.2019030308.

235

Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011;12(2):114-5. doi:10.1016/S1470-2045(11)70007-9.

236

Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487-99. doi:10.1038/s41380-019-0595-x.

237

Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020;41(44):4242.

238

Visseren FLG, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-37. doi:10.1093/eurheart/ehub484.

239

Бойцов С. А., Погосова Н. В., Аншелес А. А., Драпкина О. М. с соавт. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.

Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.) doi:10.15829/1560-4071-2023-5452.

240

Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104.

241

Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. American Heart Journal. 1991;121(4):1244-63. doi:10.1016/0002-8703(91)90694-D.

242

Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidene (rcisk factors through stable coronary artery disease). Circulation. 2006;114:2850-70 doi:10.1161/CIRCULATIONAHA.106.655688.

243

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.

244

Vidal-Petiot E, Ford I, Greenlaw N, et al. CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388:2142-52.

245

Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226-37.

246

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

247

McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195.

248

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200.

249

Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-8.

250

Velazquez EJ, Lee KL, Deja MA, et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-16.

251

Petrie MC, Jhund PS, She L, et al. STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134:1314-24.

252

Roger VL. Epidemiology of heart failure. Circ Res. 2013; 113(6):646-59. doi:10.1161/CIRCRESAHA.113.300268.

253

Ситникова М. Ю., Юрченко А. В., Лясникова Е. А. и др. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология. 2015;55(10):13-21.

Sitnikova MYu, Yurchenko AV, Lyasnikova EA, et al. The results of the Russian hospital registry of chronic heart failure in 3 subjects of the Russian Federation. Kardiologiia. 2015; 55(10):13-21. (In Russ.)

254

Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф. Т. и соавт.]. М.: ГЭОТАР-Медиа, 2010. c. 7-77.

Fomin IV. Epidemiology of chronic heart failure in the Russian Federation. In the book: Chronic heart failure [Ageev FT, et al.]. M.: GEOTAR-Media, 2010. pp. 7-77. (In Russ.)

255

Ho JE, Enserro D, Brouwers FP, et al. Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016;9:e003116. doi:10.1161/CIRCHEARTFAILURE.115.003116.

256

Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222-37. doi:10.1002/ehf2.13144.

257

Desta L, Jernberg T, Lofman I, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008. JACC Heart Fail. 2015;3:234-42.

258

Flachskampf FA, Schmid M, Rost C, et al. Cardiac imaging after myocardial infarction. Eur Heart J. 2011;32:272-83.

259

Sulo G, Igland J, Vollset SE, et al. Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation-wide Analysis Including 86 771 Patients From the Cardiovascular Disease in Norway (CVDNOR) Project. J Am Heart Assoc. 2016;5(1):e002667. doi:10.1161/JAHA.115.002667.

260

Masci PG, Ganame J, Francone M, et al. Relationship between location and size of myocardial infarction and their reciprocal influences on post-infarction left ventricular remodelling. Eur Heart J. 2011;32:1640-8.

261

Carvalho LSF, Bogniotti LAC, deAlmeida OLR, et al. Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. Eur Heart J Acute Cardiovasc Care. 2019;8:643-51.

262

Mok Y, Sang Y, Ballew SH, et al. Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. Am Heart J. 2019;216:62-73.

263

Niu X, Zhang J, Zhang L, et al. Weighted gene co-expression network analysis identifies critical genes in the development of heart failure after acute myocardial infarction. Front Genet. 2019;10:1214.

264

Shah RV, Rong J, Larson MG, et al. Associations of circulating extracellular RNAs with myocardial remodeling and heart failure. JAMA Cardiol. 2018;3:871-6.

265

Lakhani HV, Khanal T, Gabi A, et al. Developing a panel of biomarkers and miRNA in patients with myocardial infarction for early intervention strategies of heart failure in West Virginian population. PLoS ONE. 2018;13:e0205329.

266

CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90.

267

Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. JACC. 1997;29:229-36.

268

Spargias KS, Hall AS, Greenwood DC, Ball SG. β Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart. 1999;81:25-32.

269

Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-81.

270

Pfeffer MA, McMurray JJV, Velazquez EJ, et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med. 2003;349:1893-906. doi:10.1056/NEJMoa032292.

271

Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53. doi:10.1056/NEJM200001203420301.

272

Pitt B, Remme W, Zannad F, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.

273

Adamopoulos C, Ahmed A, Fay R, et al., EPHESUS Investigators. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009;11:1099-105.

274

Pfeffer MA, Claggett B, Lewis EF, et al., for the PARADISE-MI Investigators and Committees. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021;385:1845-55. doi:10.1056/NEJMoa2104508.

275

Strandberg TE, Holme I, Faergeman O, et al. IDEAL Study Group. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. Am J Cardiol. 2009;103:1381-5.

276

Scirica BM, Morrow DA, Cannon CP, et al., PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. JACC. 2006;47:2326-31.

277

Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.

278

Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.

279

Androulakis A, Aznaouridis KA, Aggeli CJ, et al. Transient ST-segment depression during paroxysms of atrial fibrillation in otherwise normal individuals: relation with underlying coronary artery disease. J Am Coll Cardiol. 2007;50:1909-11.

280

Лукьянов М. М., Марцевич С. Ю., Андреенко Е. Ю. и др. Сочетание фибрилляции предсердий и ишемической болезни сердца у пациентов в клинической практике: сопутствующие заболевания, фармакотерапия и исходы (данные регистров РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2021;17(5):702-11. doi:10.20996/1819-6446-2021-10-03.

Loukianov MM, Martsevich SYu, Andrenko EYu, et al. Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REСVASA Registries). Rational Pharmacotherapy in Cardiology. 2021;17(5):702-11. (In Russ.) doi:10.20996/1819-6446-2021-10-03.

281

Bhatt DL, Eagle KA, Ohman EM, et al. REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-7. doi:10.1001/jama.2010.1322.

282

Марцевич С. Ю., Кутишенко Н. П., Лукьянов М. М. и др. Госпитальный регистр больных, перенесших острое нарушение мозгового кровообращения (РЕГИОН): портрет заболевшего и исходы стационарного этапа лечения. Кардиоваскулярная терапия и профилактика. 2018;17(6):32-8. doi:10.15829/1728-8800-2018-6-32-38.

Martsevich SYu, Kutishenko NP, Lukyanov MM, et al. Hospital register of patients with acute cerebrovascular accident (REGION): characteristics of patient and outcomes of hospital treatment. Cardiovascular Therapy and Prevention. 2018;17(6):32-8. (In Russ.) doi:10.15829/1728-8800-2018-6-32-38.

283

Лукьянов М. М., Якушин С. С., Марцевич С. Ю. и др. Амбулаторно-поликлинический регистр РЕГИОН: данные проспективного наблюдения и исходы у больных, перенесших острое нарушение мозгового кровообращения. Рациональная фармакотерапия в кардиологии. 2019;15(6):847-53. doi:10.20996/1819-6446-2019-15-6-847-853.

Loukianov MM, Yakushin SS, Martsevich SYu, et al. Outpatient Registry REGION: Prospective Follow-up Data and Outcomes in Patients After Acute Cerebrovascular Accident. Rational Pharmacotherapy in Cardiology. 2019;15(6):847-53. (In Russ.) doi:10.20996/1819-6446-2019-15-6-847-853.

284

Lee JM, Kang J, Lee E, et al. Chronic kidney disease in the second-generation drug-eluting stent era: pooled analysis of the Korean Multicenter Drug-Eluting Stent Registry. JACC Cardiovasc Interv. 2016;9:2097-109.

285

Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662-73. doi:10.1016/S0140-6736(12)61350-6.

286

Schmidt A, Stefenelli T, Schuster E, Mayer G. Informational contribution of noninvasive screening tests for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis. 2001;37:5663.

287

Bangalore S. Stress testing in patients with chronic kidney disease: the need for ancillary markers for effective risk stratification and prognosis. J Nucl Cardiol. 2016;23:570-4.

288

Smilowitz NR, Gupta N, Guo Y, et al. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int J Cardiol. 2017;227:17.

289

Bangalore S, Guo Y, Samadashvili Z, et al. Revascularization in patients with multivessel coronary artery disease and chronic kidney disease: everolimus-eluting stents versus coronary artery bypass graft surgery. J Am Coll Cardiol. 2015;66:1209-20.

290

Wang Y, Zhu S, Gao P, Zhang Q.Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: a meta-analysis. Eur J Intern Med. 2017;43:2835.

291

Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;5:CD007784.

292

Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185:949-57.

293

Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-8. doi:10.1056/NEJM199601043340103.

294

Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med. 2009;150:170-7.

295

Laskey WK, Jenkins C, Selzer F, et al. NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584-90.

296

Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet.. 2005;366:2026-33.

297

Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747-52. doi:10.1016/s0140-6736(97)01187-2.

298

Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18(6):1959-65.

299

Chronic kidney disease: assessment and management. NICE guideline [NG203] London: National Institute for Health and Care Excellence (NICE); 2021. ISBN-13: 978-1-4731-4233-6.

300

Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043-140. doi:10.1093/eurheartj/ehad192.

301

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 — Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44.

302

Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407-18. doi:10.1056/NEJMoa1608664.

303

Magliano DJ, Chen L, Carstensen B, et al. Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data. Lancet Diabetes Endocrinol. 2022;10:112-9. doi:10.1016/S2213-8587(21)00327-2.

304

Krempf M, Parhofer KG, Steg PG, et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010;105:667-71. doi:10.1016/j.amjcard.2009.10.048.

305

Mak K-H, Vidal-Petiot E, Young R, et al. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. Eur J Prev Cardiol. 2021;28:1795-806 doi:10.1093/eurjpc/zwab011.

306

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83. doi:10.1016/S0140-6736(08)61242-8.

307

Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016;352:i438. doi:10.1136/bmj.i438.

308

Arnold SV, Bhatt DL, Barsness GW et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation 2020; 141:e779-e806. doi:10.1161/CIR.0000000000000766.

309

Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-6.

310

Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560_2572.

311

Dahlen T, Edgren G, Lambe M, et al.; Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a populationbased cohort study. Ann Intern Med. 2016;165:161-66.

312

Darby S, McGale P, Peto R, et al. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ. 2003;326:256-7.

313

Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768-801.

314

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm — 2017 executive summary. Endocr Pract. 2017;23(2):207-38. doi:10.4158/EP161682.CS.

315

Демидова Т. Ю., Кисляк О. А. Особенности течения и лечение артериальной гипертензии у пациентов с сахарным диабетом 2 типа. Рациональная Фармакотерапия в Кардиологии. 2020;16(4):623-34. doi:10.20996/1819-6446-2020-08-02.

Demidova TYu, Kislyak OA. The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. Rational Pharmacotherapy in Cardiology. 2020;16(4):623-34. (In Russ.) doi:10.20996/1819-6446-2020-08-02.

316

Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14:148. doi:10.1186/1471-2261-14-148.

317

Sarafidis PA, Lazaridis AA, Ruiz-Hurtado G, Ruilope LM. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nat Rev Endocrinol. 2017;13(6):365-74. doi:10.1038/nrendo.2016.209.

318

Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940. Erratum in: J Hypertens. 2019;37(1):226.

319

Lemmer B, Oster H. The Role of Circadian Rhythms in the Hypertension of Diabetes Mellitus and the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(5):43. doi:10.1007/s11906-018-0843-5.

320

Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-30. doi:10.15829/1560-4071-2018-6-123-130.

Balanova YuA, Shalnova SA, Deev AD, et al. Obesity in russian population — prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018;(6):123-30. (In Russ.) doi:10.15829/1560-4071-2018-6-123-130.

321

Doll S, Paccaud F, Bovet P, et al. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes. 2002;26:48-57.

322

Hall JE, Do Carmo JM, Da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991-1006.

323

Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003;42:1067-74.

324

Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement J Hypertens. 2021;39(7):1293-302. doi:10.1097/HJH.0000000000002843.

325

Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144:1212-26.

326

Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-10.

327

Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189.

328

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.

329

Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J Am Coll Cardiol. 2020;75:422-34.

330

Di Lorenzo N, Antoniou SA, Batterham RL, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surg Endosc. 2020;34:2332-58.

331

American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S100-S110. doi:10.2337/dc21-S008.

332

Kalaitzidis RG, Elisaf MS. Treatment of Hypertension in Chronic Kidney Disease. Curr Hypertens Rep. 2018;20(8):64. doi:10.1007/s11906-018-0864-0.

333

Peco-Antic A, Paripovic D. Renal Hypertension and Cardiovascular Disorder in Children With Chronic Kidney Disease. Srp Arh Celok Lek. 2014;142(1-2):113-7. doi:10.2298/sarh1402113p.

334

Agarwal R, Flynn J, Pogue V, et al. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25:1630-46. doi:10.1681/ASN.2013060601.

335

Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11:642-52.

336

Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588-98.

337

Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380:1649-61. doi:10.1016/S0140-6736(12)61272-0.

338

Kario K, Tomitani N, Kanegae H, et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/ Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring — The NOCTURNE Study. Circ J. 2017;81(7):948-57. doi:10.1253/circj.CJ-17-0109.

339

Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:792-9.

340

SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. New England Journal of Medicine. 2015;373(22):2103-16.

341

Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812-282.

342

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.

343

Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-25.

344

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi:10.1056/NEJMoa2024816.

345

Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. The ESMI study. Chest. 2012;142(5):1126-33. doi:10.1378/chest.11-2413.

346

Park HJ, Leem AY, Lee SH, et al. Comorbidities in obstructive lung disease in Korea: data from the fourth and fifth Korean National Health and Nutrition Examination Survey. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1571-82. doi:10.2147/COPD.S85767.

347

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95-109. doi:10.2147/COPD.S54473.

348

Camiciottoli G, Bigazzi F, Magni C, et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2229-36. doi:10.2147/COPD.S111724.

349

Rabahi MF, Pereira SA, Silva Júnior JL, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1525-9. doi:10.2147/COPD.S85588.

350

Haeusler KG, Herm J, Konieczny M, et al. Impact of chronic inflmmatory airway disease on stroke severity and long-term survival after ischemic stroke — a retrospective analysis. BMC Neurol. 2015;15:164. doi:10.1186/s12883-015-0414-1.

351

Portegies ML, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. Am. J. Respir. Crit. Care Med. 2016;193(3):251-8. doi:10.1164/rccm.201505-0962OC.

352

Kryuchkova ON, Turna EY, Martynyuk MA. Arterial hypertension in patients with chronic obstructive pulmonary disease: pathogenetic features and daily dynamics of blood. Crimean Journal of Internal Diseases. 2015;2:5-9.

353

Кароли Н. А., Долишняя Г. Р., Ребров А. П. Суточные показатели артериальной ригидности у мужчин с различными фенотипами хронической обструктивной болезни легких в сочетании с артериальной гипертензией. Клиницист. 2015;9(1):37-41.

Karoli NA, Dolishnyaya GR, Rebrov AP. 24-hour arterial stiffness values in men with different phenotypes of chronic obstructive pulmonary disease concurrent with hypertension. The Clinician. 2015;9(1):37-41. (In Russ.)

354

Гуревич М.А., Долгова Е. В., Кузьменко Н. А. Хронические обструктивные заболевания легких, артериальная гипертензия и ишемическая болезнь сердца: особенности патогенеза, клинической картины, терапии. РМЖ. 2016;16:1098-102.

Gurevich MA, Dolgova EV, Kuzmenko NA. Chronic obstructive pulmonary disease, arterial hypertension and coronary artery disease: features of pathogenesis, clinical picture and management. RMJ. 2016;16:1098-102. (In Russ.)

355

Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;10(7):1514-9. doi:10.1161/01.cir.0000056767.69054.b3.

356

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-9. doi:10.1183/09031936.00012408.

357

Mahishale V, Angadi N, Metgudmath V, et al. Prevalence and impact of diabetes, hypertension, and cardiovascular diseases in chronic obstructive pulmonary diseases: A hospital-based cross-section study. J Transl Int Med. 2015;3(4):155-60. doi:10.1515/jtim-2015-0019.

358

Задионченко В. С., Адашева Т.В., Федорова И.В. B и др. Артериальная гипертония и хроническая обструктивная болезнь легких: патогенетические параллели и клинико-функциональные особенности. CardioСоматика. 2010;1(1):32-37. doi:10.26442/CS44959.

Zadionchenko VS, Adasheva TV, Fedorova IV, et al. Arterial hypertension and chronic obstructive pulmonary disease: pathogenetic parallels and clinicofunctional features. CardioSomatics. 2010;1(1):31-7. (In Russ.) doi:10.26442/CS44959.

359

Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012;123(8):487-98.

360

Chiu KY, Li JG, Lin Y.Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;119(6):518-23.e3.

361

Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensinconverting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12:263-77.

362

Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.

363

Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3):281-5.

364

Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43.

365

Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study. JAMA Intern Med. 2014;174:336-44.

366

McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.

367

Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. doi:10.1016/j.cardfail.2022.02.010.

368

Shah RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis., Journal of cardiac failure 16.3(2010):260-7.

369

Zhang H, Huang T, Shen W, et al. Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7(6):3841-50. doi:10.1002/ehf2.12974.

370

Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16(1):246. doi:10.1186/s12872-016-0425-x.

371

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 — effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis., J Hypertens. 2018;36(8):1637-47. doi:10.1097/HJH.0000000000001777.

372

Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC: Heart Failure. 2013;1(4):308-14. doi:10.1016/j.jchf.2013.04.004.

373

Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator — Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856-63.

374

Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem, Postinfarction Research Group. Circulation. 1991;83:52-60.

375

Cohn JN, Pfeffer MA, Rouleau J, et al. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-67.

376

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75. Erratum in: JAMA 2002;288(23):2976.

377

Dorszewski A, Göhmann E, Dorsźewski B, et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. J Card Fail. 1997;3(2):91-6. doi:10.1016/s1071-9164(97)90040-3.

378

Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed). 1985;290:1861-5.

379

Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol. 2002;82:149-58.

380

Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.

381

Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020;142(13):1236-45. doi:10.1161/CIRCULATIONAHA.120.0.

382

Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/ Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141(5):352-61. doi:10.1161/CIRCULATIONAHA.119.044586.

383

Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis, of double-blind randomized trials. Eur Heart J. 2018;39:26-35.

384

Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across, the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230-9.

385

Solomon SD, Claggett B, Lewis EF, et al. TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart, failure with preserved ejection fraction. Eur Heart J. 2016;37:455-62.

386

Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98. doi:10.1056/NEJ.

387

Anker SD, Butler J, Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply. N Engl J Med. 2022;386(21):e57. doi:10.1056/NEJMc2118470.

388

Lin Y, Cai Z, Yuan J, et al. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2022;21(1):237. doi:10.1186/s12933-022-01679-2.

389

Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933. doi:10.1016/j.eclinm.2021.100933.

390

Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731.

391

Myhre PL, Vaduganathan M, Claggett BL, et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018;3(10):1000-5. doi:10.1001/jamacardio.2018.2568.

392

Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45.

393

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. doi:10.1016/S0140-6736(03)14285-7.

394

Martin N, Manoharan K, Thomas J, et al. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2018;6:CD012721.

395

Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with, Heart Failure) Registry. J Am Coll Cardiol. 2009;53(2):184-92.

396

Soliman EZ, Ambrosius WT, Cushman WC, et al.; SPRINT Research Study Group. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017;136(5):440-50. doi:10.1161/CIRCULATIONAHA.117.028441. Erratum in: Circulation. 2017;136(5):e136.

397

Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41-6. doi:10.1016/s0002-9343(03)00158-x.

398

Гориева Ш. Б., Рогоза А. Н. Точность измерения артериального давления при постоянной форме фибрилляции предсердий. РМЖ. 2013;21(12):629-33.

Gorieva ShB, Rogoza AN. Accuracy of blood pressure measurement with a constant form of atrial fibrillation. breast cancer. RMJ. 2013;21(12):629-33. (In Russ.)

399

Verberk WJ. Atrial fibrillation and 24-h ambulatory blood pressure pattern. J Clin Hypertens (Greenwich). 2022;24(7):848-50. doi:10.1111/jch.14522.

400

Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.

401

Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201-8.

402

Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37(7):1933-40. doi:10.1161/01.STR.0000227223.90239.13.

403

Lane D. A., Lip G. Y. H. Treatment of hypertension in peripheral arterial disease. Cochrane database of systematic reviews. 2009;(4):CD003075. doi:10.1002/14651858.CD003075.pub2. Update in: Cochrane Database Syst Rev. 2013;12:CD003075.

404

Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS–a randomized double-blind trial. Stroke. 2004;35:2807-12.

405

Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and courseon hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277-83.

406

Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure afterintravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factorassessment and improvement, intracerebral hemorrhage study. Stroke. 2013;44:1846-51.

407

Anderson CS, Heeley E, Huang Y, et al. INTERACT2Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-65.

408

Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43.

409

Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-9.

410

Steiner T, Al-Shahi Salman R, Beer R, et al.; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840-55. doi:10.1111/ijs.12309.

411

Hemphill JC 3rd, Greenberg SM, Anderson CS, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-60. doi:10.1161/STR.0000000000000069.

412

Powers WJ, Rabinstein AA, Ackerson T, et al.; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158.

413

Lee M, Ovbiagele B, Hong KS, et al. Effectof blood pressure lowering in early ischemic stroke: meta-analysis. Stroke. 2015;46:1883-9.

414

Zhao R, Liu FD, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine(Baltimore). 2015;94:e896.

415

Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International, StrokeThrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-9.

416

Wu W, HuoX, ZhaoX, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One. 2016;11:e0144260.

417

White CL, Szychowski JM, Pergola PE, et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study, experience. J Am Geriatr Soc. 2015;63:722-9.

418

Garrison SR, Kolber MR, Korownyk CS et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017;8(8):CD011575. doi:10.1002/14651858.CD011575.pub2.

419

Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375(9718):906-15. doi:10.1016/S0140-6736(10)60235-8.

420

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi: 10.1016/S0140-6736(01)06178-5. Erratum in: Lancet 2001;358(9292):1556. Erratum in: Lancet 2002;359(9323):2120.

421

Linhartová K, Filipovský J, Čerbák R, et al. Severe aortic stenosis and its association with hypertension: analysis of clinical and echo cardiographic parameters. Blood Press. 2007;16:122-8.

422

Bermejo J.The effects of hypertension on aortic valve stenosis. Heart. 2005;91:280-2.

423

Lindman BR, Otto CM. Time to treat hypertension in patients with aortic stenosis. Circulation. 2013;128:1281-3.

424

Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. Eur Heart J. 2018;39:3596-603.

425

Tastet L, Capoulade R, Clavel MA, et al. Systolic hyper tension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study. Eur Heart J Cardiovasc Imaging. 2017;18:70-8.

426

de Simone G, Izzo R, Aurigemma GP, et al. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. J Hypertens. 2015;33:745-54.

427

Rieck ÅE, Cramariuc D, Boman K, et al. Hypertension in aortic stenosis. Hypertension. 2012;60:90-7.

428

Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pressure in patients with asymptomatic aortic valve sten osis: the Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS). Circulation. 2016;134:455-68.

429

Nadir MA, Wei L, Elder DHJ, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570-6.

430

Bang CN, Greve AM, Køber L, et al. Renin–angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int J Cardiol. 2014;175:492-8.

431

Mancusi C, de Simone G, Brguljan Hitij J, et al. Management of patients with combined arterial hypertension and aortic valve sten osis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovasc. Eur Heart J Cardiovasc Pharmacother. 2021;7:242-50.

432

Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.

433

Имаева А. Э., Капустина А.В, Баланова Ю. А. и соавт. Влияют ли условия жизни в детстве на когнитивную функцию в зрелом возрасте? Российский кардиологический журнал. 2018;(6):147-51 doi:10.15829/1560-4071-2018-6-147-151.

Imaeva AE, Kapustina AV, Balanova YuA, et al. Do childhood conditions of life influence cognition at adult age? Russian Journal of Cardiology. 2018;(6):147-51. (In Russ.) doi:10.15829/1560-4071-2018-6-147-151.

434

Walker KA, Sharrett AR, Wu A, et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA. 2019;322:535-45.

435

Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA. 2015;314:170-80.

436

Nilsson SE, Read S, Berg S, et al. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudin al observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19:41-7.

437

Iadecola C, Gottesman RF. Neurovascular and cognitive dysfunction in hypertension. Circ Res. 2019;124:1025-44.

438

Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia. J Hypertens. 2013;31:1073-82.

439

Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s dis ease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61-70.

440

Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia. JAMA. 2019;321:553-61.

441

Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (syst-eur) study. Arch Intern Med. 2002;162:2046-52.

442

Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-75.

443

van Middelaar T, van Vught LA, van Charante EPM, et al. Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens. 2017;35:2095-101.

444

Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk. J Hypertens. 2016;34:1027-35. doi:10.1097/HJH.0000000000000868.

445

Tsao CW, Aday AW, Almarzooq ZI. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93-e621. doi:10.1161/CIR.0000000000001123.

446

Jones NR, Taylor CJ, Hobbs FDR, et al. Screening for atrial fibrillation: a call for evidence. Eur Heart J. 2020;41:1075-85. doi:10.1093/eurheartj/ehz834.

447

Diederichsen S., Haugan KJ., Kronborg C, et al. Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an Implantable Loop Recorder. Circulation. 2020;14:1510-22. doi:10.1161/CIRCULATIONAHA.119.044407.

448

Himmelreich JCL, Veelers L, Lucassen WAM, et al. Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020;22:684-94. doi:0.1093/europace/euaa005.

449

Fox KAA, Lucas JE, Pieper KS, et al. GARFIELD-AF Investigators. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7: e017157. doi:10.1136/bmjopen-2017-017157.

450

Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1555-66. doi:10.1177/204748731771576.

451

Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández A-I, et al. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. JACC. 2016;68:2508-21. doi:10.1016/j.jacc.2016.09.944.

452

Modi R, Patted SV, Halkati PC, et al. CHA2DS2-VASc-HSF score — New predictor of severity of coronary artery disease in 2976 patients. Int J Cardiol. 2017;228:1002-6. doi:10.1016/j.ijcard.2016.10.093.

453

Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298-307. doi:10.1161/CIRCULATIONAHA.111.055079.

454

Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23:1612-76. doi:10.1093/europace/euab065.

455

Barkas F, Liberopoulos E, Klouras E, et al. Correlation between the CHADS2, CHA2DS2-VASC scores and the incidence of cardiovascular disease in individuals without atrial fibrilation and their comparison with hellenic score and ASCVD risk. Atherosclerosis. 2017;263:E173. doi:10.1016/j.atherosclerosis.2017.06.553.

456

Siddiqi TJ, Usman MS, Shahid I, et al. Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:625-31. doi:10.1093/eurjpc/zwab018.

457

Бойцов С. А., Лукьянов М. М., Якушин с соавт. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом "фибрилляция предсердий" в условиях реальной амбулаторно-поликлинической практики (по данным Регистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная фармакотерапия в кардиологии, 2014, 4: 366-77. doi:10.20996/1819-6446-2014-10-4-366-377.

Loukianov MM, Boytsov SA, Yakushin SS, et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-77. (In Russ.) doi:10.20996/1819-6446-2014-10-4-366-377.

458

Степина Е. В., Лукьянов М. М., Бичурина М. А. с соавт. Назначение медикаментозной терапии, влияющей на прогноз у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью по данным регистра РЕКВАЗА-КЛИНИКА. Кардиоваскулярная терапия и профилактика. 2017;16(2):33-8. doi:10.15829/1728-8800-2017-2-33-38.

Stepina EV, Lukyanov MM, Bichurina MA, et al. Prescription of medications influencing prognosis in atrial fibrillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Therapy and Prevention. 2017;16(2):33-8. (In Russ.) doi:10.15829/1728-8800-2017-2-33-38.

459

Лукьянов М.М., Марцевич С.Ю., Мареев Ю. В. и др. Больные с сочетанием фибрилляции предсердий и хронической сердечной недостаточности в клинической практике: сопутствующие заболевания, медикаментозное лечение и исходы. Рациональная фармакотерапия в кардиологии. 2021;6:816-24. doi:10.20996/1819-6446-2021-12-05.

Loukianov MM, Martsevich SYu, Mareev YuV, et al. Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes. Rational Pharmacotherapy in Cardiology. 2021;17(6):816-24. (In Russ.) doi:10.20996/1819-6446-2021-12-05.

460

Warlow C, Sudlow C, Dennis M, et al. Stroke. Lancet. 2003;362(9391):1211-24. doi:10.1016/S0140-6736(03)14544-8.

461

Марцевич С. Ю., Кутишенко Н. П., Суворов А. Ю. и др. Характеристика пациентов с мозговым инсультом или транзиторной ишемической атакой, включенных в регистр ЛИС-2 (Люберецкое исследование смертности больных, перенесших мозговой инсульт). Рациональная Фармакотерапия в Кардиологии 2015;11(1):18-24. doi:10.20996/1819-6446-2015-11-1-18-24.

Martsevich SYu, Kutishenko NP, Suvorov AYu, et al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients after stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18-24. (In Russ.) doi:10.20996/1819-6446-2015-11-1-18-24.

462

de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003;56(3):221-9.

463

Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke. 2004;35(8):1941-5.

464

Kim J, Keshavjee S, Atun R. Trends, patterns and health consequences of multimorbidity among South Korea adults: Analysis of nationally representative survey data 2007-2016. J Glob Health. 2020;10(2):020426.

465

Carod-Artal FJ, Casanova Lanchipa JO, Cruz Ramírez LM, et al. Stroke subtypes and comorbidity among ischemic stroke patients in Brasilia and Cuenca: a Brazilian-Spanish cross-cultural study. J Stroke Cerebrovasc Dis. 2014;23(1):140-7.

466

Al Alawi AM, Al Busaidi I, Al Shibli E, et al. Health outcomes after acute ischemic stroke:retrospective and survival analysis from Oman. Ann Saudi Med. 2022;42(4):269-75.

467

Bergman EM, Henriksson KM, Åsberg S, et al. National registry-based case-control study: comorbidity and stroke in young adults. Acta Neurol Scand. 2015;131(6):394-9.

468

Magwood GS, White BM, Ellis C. Stroke-Related Disease Comorbidity and Secondary Stroke Prevention Practices Among Young Stroke Survivors. J Neurosci Nurs. 2017;49(5):296-301.

469

Hong Y, Tang HR, Ma M, et al. Multiple sclerosis and stroke: a systematic review and meta-analysis. BMC Neurol. 2019;19(1):139.

470

Kivimäki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017;2(6):e277-e285.

471

MacIntosh BJ, Cohen E, Colby-Milley J, et al. Diabetes Mellitus Is Associated With Poor In-Hospital and Long-Term Outcomes in Young and Midlife Stroke Survivors. J Am Heart Assoc. 2021;10(14):e019991.

472

Ouk M, Wu CY, Colby-Milley J, et al. Depression and Diabetes Mellitus Multimorbidity Is Associated With Loss of Independence and Dementia Poststroke. Stroke. 2020;51(12):3531-40.

473

Ding R, Zhu D, Ma Y, et al. Comparison of health service use and costs in stroke with and without comorbidities: a cross-sectional analysis using China urban medical claims data. BMJ Open. 2020;10(12):e037032. doi:10.1136/bmjopen-2020-037032.

474

Si Y, Xiao X, Xiang S, et al. Mortality-specific comorbidity among inpatients with ischemic stroke in West China. Acta Neurol Scand. 2019;140(2):100-6.

475

Barow E, Probst AC, Pinnschmidt H, et al. Effect of Comorbidity Burden and Polypharmacy on Poor Functional Outcome in Acute Ischemic Stroke. Clin Neuroradiol. 2023;33(1):147-54.

476

Falsetti L, Viticchi G, Tarquinio N, et al. Charlson comorbidity index as a predictor of in-hospital death in acute ischemic stroke among very old patients: a single-cohort perspective study. Neurol Sci. 2016;37(9):1443-8.

477

She R, Yan Z, Hao Y, et al. Comorbidity in patients with first-ever ischemic stroke: Disease patterns and their associations with cognitive and physical function. Front Aging Neurosci. 2022;14:887032.

478

Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis. Ann Neurol. 2021;89(2):380-8.

479

Sennfält S, Pihlsgård M, Petersson J, et al. Long-term outcome after ischemic stroke in relation to comorbidity — An observational study from the Swedish Stroke Register (Riksstroke). Eur Stroke J. 2020;5(1):36-46.

480

Bar B, Hemphill JC 3rd. Charlson comorbidity index adjustment in intracerebral hemorrhage. Stroke. 2011;42(10):2944-6.

481

Hall RE, Porter J, Quan H, Reeves MJ. Developing an adapted Charlson comorbidity index for ischemic stroke outcome studies. BMC Health Serv Res. 2019;19(1):930.

482

Denti L, Artoni A, Casella M, et al. Validity of the modified Charlson Comorbidity Index as predictor of short-term outcome in older stroke patients. J Stroke Cerebrovasc Dis. 2015;24(2):330-6.

483

Corraini P, Szépligeti SK, Henderson VW, et al. Comorbidity and the increased mortality after hospitalization for stroke: a population-based cohort study. J Thromb Haemost. 2018;16(2):242-52.

484

Chao TF, Lip GYH, Liu CJ, et al. Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018;71(2):122-32.

485

Proietti M, Esteve-Pastor MA, Rivera-Caravaca JM, et al. Relationship between multimorbidity and outcomes in atrial fibrillation. Exp Gerontol. 2021;153:111482.

486

Singleton MJ, Imtiaz-Ahmad M, Kamel H, et al. Association of Atrial Fibrillation Without Cardiovascular Comorbidities and Stroke Risk: From the REGARDS Study. J Am Heart Assoc. 2020;9(12):e016380.

487

Агеева Л. И., Александрова Г. А., Голубев Н. А. и др. Здравоохранение в России 2021. Стат.сб. Росстат. М., 2021. 171 с.

Ageeva LI, Alexandrova GA, Golubev NA, et al. Healthcare in Russia 2021. Stat.sat. Rosstat. M., 2021. 171 p. (In Russ.)

488

Wilmot KA, O’Flaherty M, Capewell S, et al. Coronary heart disease mortality declines in the United States from 1979 through 2011: Evidence for stagnation in young adults, especially women. Circulation. 2015;132(11):997-1002. doi:10.1161/CIRCULATIONAHA.115.015293.

489

Андреенко Е. Ю., Лукьянов М. М., Якушин С. С. с соавт. Ранняя кардиоваскулярная мультиморбидность в амбулаторной и госпитальной практике: возрастные характеристики и медикаментозное лечение пациентов (данные регистров РЕКВАЗА и РЕКВАЗА-КЛИНИКА). Кардиоваскулярная терапия и профилактика. 2020;19(5):2672. doi:10.15829/1728-8800-2020-2672.

Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Early cardiovascular multimorbidity in out- and in-patient care: age characteristics and medication therapy (data from the REKVAZA and REKVAZA-CLINIC registries). Cardiovascular Therapy and Prevention. 2020;19(5):2672. (In Russ.) doi:10.15829/1728-8800-2020-2672.

490

Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. The Public Library of Science. 2014;9(7):e102149. doi:10.1371/journal.pone.0102149.

491

Marengoni A, Fratiglioni L. Disease clusters in older adults: Rationale and need for investigation. Journal of the American Geriatrics Society. 2011;59(12):2395-6. doi:10.1111/j.1532-5415.2011.03687.x.

492

Espeland MA, Crimmins EM, Grossardt BR, et al. Clinical trials targeting aging and age-related multimorbidity. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2017;72(3):355-61. doi:10.1093/gerona/glw220.

493

Лазебник Л. Б., Верткин А. Л., Конев Ю. В. и др. Старение: профессиональный врачебный подход (Национальное руководство). М.: Эксмо, 2014. 320 с.

Lazebnik LB, Vertkin AL, Konev YuV, et al. Aging: a professional medical approach (National guidelines). Moscow: Eksmo, 2014. 320 p. (In Russ.)

494

Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: Patterns by age, sex, and race/ethnicity. Mayo Clinic Proceedings. 2014;89(10):1336-49. doi:10.1016/j.mayocp.2014.07.010

495

Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nature Reviews. Cardiology. 2018;(15):230-40. doi:10.1038/nrcardio.2017.154.

496

Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) Клинические рекомендации 2020. Стабильная ишемическая болезнь сердца. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.

Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.

497

2019 Рекомендации ЕSC по диагностике и лечению хронического коронарного синдрома. Российский кардиологический журнал. 2020;25(2):3757. doi:10.15829/1560-4071-2020-2-3757.

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2020;25(2):3757. (In Russ.) doi:10.15829/1560-4071-2020-2-3757.

498

Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.

Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.

499

Wong CM, Hawkins NM, Petrie MC, et al.; MAGGIC Investigators. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Eur Heart J. 2014;35(39):2714-21. doi:10.1093/eurheartj/ehu216.

500

Singer L, Green M, Rowe F, et al. Social determinants of multimorbidity and multiple functional limitations among the ageing population of England, 2002-2015. SSMPopul health. 2019;8:100413.

501

Андреенко Е. Ю., Лукьянов М. М., Якушин С. С. и др Больные с ранним развитием сердечно-сосудистых заболеваний в амбулаторно-поликлинической практике: демографические характеристики, факторы риска и приверженность медикаментозному лечению (данные регистра РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии 2020;16(2):258-65. doi:10.20996/1819-6446-2020-04-12.

Andreenkо EYu, Loukianov MM, Yakushin SS, et al. Patients with Premature Cardiovascular Diseases in Ambulatory Practice: Demographic Characteristics, Risk Factors and Adherence to the Medical Therapy (Data of RECVASA Registry). Rational Pharmacotherapy in Cardiology. 2020;16(2):258-65. (In Russ.) doi:10.20996/1819-6446-2020-04-12.

502

Андреенко Е. Ю., Лукьянов М. М., Якушин С. С. и др Больные с ранним развитием сердечно-сосудистых заболеваний в амбулаторной практике: возрастные и гендерные характеристики, коморбидность, медикаментозное лечение и исходы (данные регистра РЕКВАЗА). Кардиоваскулярная терапия и профилактика. 2019;18(6):99-106 doi:10.15829/1728-8800-2019-6-99-106.

Andreenko EYu, Lukyanov MM, Yakushin SS, et al. Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention. 2019;18(6):99-106. (In Russ.) doi:10.15829/1728-8800-2019-6-99-106.

503

Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.

Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.

504

Марцевич С.Ю., Семенова Ю.В., Кутишенко Н.П. и др Оценка приверженности пациентов к посещению лечебно-профилактических учреждений и ее влияния на качество терапии до развития острого коронарного синдрома в рамках регистра ЛИС-3. Российский кардиологический журнал. 2016;(6):55-60. doi:10.15829/1560-4071-2016-6-55-60.

Martsevich SYu, Semenova YuV, Kutishenko NP, et al. Assessment of patients compliance for ambulatory institutions visits and its influence on the quality of treatment before development of acute coronary syndrome, by the LIS-3 registry. Russian Journal of Cardiology. 2016;(6):55-60. (In Russ.) doi:10.15829/1560-4071-2016-6-55-60.

505

Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012;2:1143-211. doi:10.1002/cphy.c110025.

506

Foster HME, Celis-Morales CA, Nicholl BI, et al. The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort. Lancet Public Health. 2018;3(12):e576-e585. doi:10.1016/S2468-2667(18)30200-7.

507

Поляков ДC, Фомин ИВ, Беленков ЮН и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14. doi:10.18087/cardio.2021.4.n1628.

Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

508

Лукьянов М. М., Козминский А. Н., Марцевич С. Ю. и др. Больные с сочетанием хронической сердечной недостаточности, артериальной гипертонии и перенесенного ранее инфаркта миокарда: клинико-анамнестические характеристики и практика назначения ингибиторов ангиотензин-превращающего фермента, блокаторов рецепторов ангиотензина и β-адреноблокаторов, приверженность лечению (данные амбулаторного регистра РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии. 2017;13(2):207-12. doi:10.20996/1819-6446-2017-13-2-207-212.

Loukianov MM, Kozminsky AN, Martsevich SY, et al. Patients with combination of chronic heart failure, hypertension and history of myocardial infarction: Clinical and anamnestic characteristics, administration of ace inhibitors, angiotensin receptor blockers, β-blockers and adherence to the drug therapy. Ration Pharmacother Cardiol. 2017;13(2):207-12. (In Russ.) doi:10.20996/1819-6446-2017-13-2-207-212.

509

Российское кардиологическое общество (РКО) Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский к ардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.

Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.

510

Мареев В. Ю., Мареев Ю. В. Роль ЧСС в механизмах компенсации и декомпенсации у больных с ХСН при синусовом ритме и фибрилляции предсердий и методы безопасного и эффективного контроля сердечного ритма. Часть 2. Фибрилляция предсердий. Кардиология. 2017;57(2S):351-66. doi:10.18087/cardio.2401.

Mareev VYu, Mareev Yu V. Role of heart rate in mechanisms of compensation and decompensation in CHF patients with sinus rhythm and atrial fibrillation and methods for safe and efficient control of heart rhythm. Part 2. Atrial fibrillation. Kardiologiia. 2017;57(2S):351-66. (In Russ.) doi:10.18087/cardio.2401.

511

Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/nejmoa2022190.

512

Мареев В. Ю., Фомин И. В., Агеев Ф. Т. и др. Клинические рекомендации ОССН — РКО — РНМОТ. Сердечная недостаточность: хроническая (хсн) и острая декомпенсированная (одсн). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.

Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.

513

Zamorano JL, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/EURHEARTJ/EHU284.

514

Беленков Ю. Н., Арутюнов Г. П., Мареев В. Ю. и др. Перспективы применения верицигуата при хронической сердечной недостаточности со сниженной фракцией выброса: значение результатов исследования VICTORIA. Резолюция Совета экспертов. Кардиология. 2023;63(4):3-10. doi:10.18087/CARDIO.2023.4.N2403.

Belenkov YuN, Arutyunov GP, Mareev VYu, et al. Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary. Kardiologiia. 2023;63(4):3-10. (In Russ.) doi:10.18087/CARDIO.2023.4.N2403.

515

Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-93. doi:10.1056/NEJMoa1915928.

516

Kotecha D, Gill SK, Flather MD, et al.; Beta-Blockers in Heart Failure Collaborative Group. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. J Am Coll Cardiol. 2019;74(23):2893-904. doi:10.1016/j.jacc.2019.09.059. Erratum in: J Am Coll Cardiol. 2020;75(13):1615.

517

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/ HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012.

518

Ferrari R, Ford I, Greenlaw N, et al. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. Eur J Prev Cardiol. 2015;22(8):1056-65. doi:10.1177/2047487314547652.

519

Kontsevaya A, Sabgaida T, Ivanova A, et al. How has the management of acute coronary syndrome changed in the Russian Federation during the last 10 years? Health Policy. 2017;121(12):1274-9. doi:10.1016/j.healthpol.2017.09.018.

520

Мареев ВЮ, Беграмбекова ЮЛ, Мареев ЮВ и др. Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiia. 2022;62(5):4-8. doi:10.18087/CARDIO.2022.5.N2083.

Mareev VYu, Begrambekova YuL, Mareev YuV, et al. Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiia. 2022;62(5):4-8. (In Russ.) doi:10.18087/CARDIO.2022.5.N2083.

521

Арутюнов АГ, Драгунов ДО, Арутюнов ГП и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55(5):12-21.

Arutyunov AG, Dragunov DO, Arutyunov GP, et al. The first open study of acute decompensation syndrome of heart failure and concomitant diseases in the Russian Federation. The ORACLE-RF Independent Register. Kardiologiia. 2015;55(5):12-21. (In Russ.)

522

Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Int J Cardiol. 2003;88(2-3):207-14. doi:10.1016/S0167-5273(02)00401-1.

523

Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511-20. doi:10.1056/NEJMoa1602001.

524

Wyse DG, Waldo AL, DiMarco JP, et al. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med. 2002;347(23):1825-33. doi:10.1056/NEJMoa021328.

525

Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375.

526

Chaterjee S, Sardar P, Lichstein E, et al. Pharmacologic Rate versus Rhythm-Control Strategies in Atrial Fibrillation: An Updated Comprehensive Review and Meta-Analysis. Pacing Clin Electrophysiol. 2013;36(1):122-33. doi:10.1111/j.1540-8159.2012.03513.x.

527

Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77. doi:10.1056/NEJMoa0708789.

528

Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. doi:10.1056/NEJMOA2019422.

529

Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120(22):2170-6. doi:10.1161/CIRCULATIONAHA.109.853689.

530

Packer DL, Piccini JP, Monahan KH, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021;143(14):1377-90. doi:10.1161/CIRCULATIONAHA.120.050991.

531

Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted DeviceCLINICAL PERSPECTIVE. Circulation. 2016;133(17):1637-44. doi:10.1161/CIRCULATIONAHA.115.019406.

532

Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27. doi:10.1056/NEJMOA1707855.

533

Parkash R, Wells G, Rouleau J, et al. A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. Am Heart J. 2021;234:90-100. doi:10.1016/j.ahj.2021.01.012.

534

Marrouche NF, Brachmann J. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) — study design. Pacing Clin Electrophysiol. 2009;32(8):987-94. doi:10.1111/j.1540-8159.2009.02428.x.

535

Мареев В. Ю., Гиляревский С. Р., Мареев Ю. В. и др. Согласованное мнение экспертов по поводу роли дефицита железа у больных с хронической сердечной недостаточностью, а также о современных подходах к его коррекции. Кардиология. 2020;60(1):99-106. doi:10.18087/cardio.2020.1.n961.

Mareev VYu, Gilyarevskiy SR, Mareev YuV, et al. Position Paper. The role of iron deficiency in patients with chronic heart failure and current corrective approaches. Kardiologiia. 2020;60(1):99-106. (In Russ.) doi:10.18087/cardio.2020.1.n961.

536

Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial. JAMA — J Am Med Assoc. 2017;317(19):1958-66. doi:10.1001/jama.2017.5427.

537

Anker SD, Comin Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436-48. doi:10.1056/nejmoa0908355.

538

Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68. doi:10.1093/eurheartj/ehu385.

539

Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. In: Circulation. Vol 136. Lippincott Williams and Wilkins; 2017:1374-83. doi:10.1161/CIRCULATIONAHA.117.027497.

540

Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904. doi:10.1016/S0140-6736(20)32339-4.

541

Мареев Ю. В., Гиляревский С. Р., Беграмбекова Ю. Л. и др. Согласованное мнение экспертов по поводу лечения дефицита железа у стабильных и декомпенсированных больных хронической сердечной недостаточностью. Кардиология. 2021;61(4):73-8. doi:10.18087/cardio.2021.4.n1639.

Mareev YuV, Gilarevsky SR, Begrambekova YuL, et al. Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure. Kardiologiia. 2021;61(4):73-8. (In Russ.) doi:10.18087/cardio.2021.4.n1639.

542

Mullens W, Martens P, Testani JM, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(4):603-19. doi:10.1002/EJHF.2471.

543

Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail. 2011;4(1):18-26. doi:10.1161/CIRCHEARTFAILURE.109.932558.

544

Kittleson MM, Ruberg FL, Ambardekar A V, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076-1126. doi:10.1016/J.JACC.2022.11.022.

545

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/ HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2— evidence base and standardized methods of imaging. J Nucl Cardiol 2019 266. 2019;26(6):2065-123. doi:10.1007/S12350-019-01760-6.

546

Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/ HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2— Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2019;27(2):659-73. doi:10.1007/S12350-019-01761-5/METRICS.

547

Hanna M, Ruberg FL, Maurer MS, et al. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(22):2851-62. doi:10.1016/J.JACC.2020.04.022.

548

Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study. 2009;40(3):232-239. doi:10.1080/07853890701842988.

549

Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26(12):1221-7. doi:10.1093/EURHEARTJ/EHI143.

550

Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10(1). doi:10.1186/S13023-015-0253-6.

551

Germain DP, Arad M, Burlina A, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease — A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224-35. doi:10.1016/J.YMGME.2018.09.007.

552

Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693-718. doi:10.1164/rccm.200811-1757ST.

553

Cohen AJ, Brauer M, Burnett R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. The Lancet. 2017;389(10082),1907-18. doi:10.1016/S0140-6736(17)30505-6.

554

Vanfleteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir. Med. 2012;106(6):871-4. doi:10.1016/j.rmed.2012.01.008.

555

Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014;12:963-74. doi:10.2147/COPD.S67283.

556

Andreeva E, Pokhaznikova M, Lebedev A, et al. The prevalence of chronic obstructive pulmonary disease by the Global Lung Initiative equations in North-Western Russia. Respiration. 2016; 91(1):43-55. doi:10.1159/000442887.

557

Концевая А. В., Муканеева Д. К., Баланова Ю. А. и др. Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году. Пульмонология. 2019;29(2):159-66. doi:10.18093/0869-0189-2019-29-2-159-166.

Kontsevaya AV, Mukaneyeva DK, Balanova YuA, et al. Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016. PULMONOLOGIYA. 2019;29(2):159-66. (In Russ.) doi:10.18093/0869-0189-2019-29-2-159-166.

558

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.

559

Domej W, Oettl K, Renner W.Oxidative stress and free radicals in COPD — implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis. 2014;9:1207-24.

560

Wang LY, Zhu YN, Cui JJ, et al. Subclinical atherosclerosis risk markers in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med. 2017;123:18-27.

561

Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66:769-74.

562

Soumagne T, Roche N, Guillien A, et al. Cardiovascular Risk in COPD. Deciphering the Contribution of Tobacco Smoking. CHEST. 2020;157(4):834-45, doi:10.1016/j.chest.2019.11.002.

563

Thomsen, Dahl, Lange, et al.: Inflammation and Comorbidities in COPD. Am J Respir Crit Care Med. 2012;186(10):982-8.

564

Гайнитдинова В. В., Авдеев С. Н. Ремоделирование крупных периферических артерий у больных хронической обструктивной болезнью легких и при ее сочетании с артериальной гипертензией. Пульмонология. 2015;25(1):50-7. doi:10.18093/0869-0189-2015-25-1-50-57.

Gaynitdinova VV, Avdeev SN. Large peripheral vessel remodeling in patients with chronic obstructive pulmonary disease and in hypertension co-morbidity. PULMONOLOGIYA. 2015;25(1):50-7. (In Russ.) doi:10.18093/0869-0189-2015-25-1-50-57.

565

Miller BE, Tal-Singer R, Rennard SI, et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;193(6):607-13. doi:10.1164/rccm.201509-1722PP.

566

Метельская В. А., Гуманова Н. Г. Валидные кардиоспецифические биохимические маркеры. Часть I. Кардиоваскулярная терапия и профилактика. 2020;19(4): 2573. doi:10.15829/1728-8800-2020-2573.

Metelskaya VA, Gumanova NG. Valid cardiac biomarkers. Part I. Cardiovascular Therapy and Prevention. 2020;19(4):2573. (In Russ.) doi:10.15829/1728-8800-2020-2573.

567

Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive ulmonary disease (COPD). J Thorac Dis. 2014;6(11):1532-47. doi:10.3978/j.issn.2072-1439.2014.11.33.

568

Le TT, Qato DM, Magder L, et al. Prevalence and Newly Diagnosed Rates of Multimorbidity in Older Medicare Beneficiaries with COPD. COPD. 2021;18(5):541-8. doi:10.1080/15412555.2021.1968815.

569

Kahnert K, Lucke T, Huber RM, et al.; COSYCONET consortium. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS One. 2017;12(5):e0177501. doi:10.1371/journal.pone.0177501.

570

Курехян А. С., Смирнова М. И., Горбунов В. М. и др. Частота и характеристики фенотипов артериального давления у больных с артериальной гипертонией и хроническими болезнями органов дыхания (исследование данных амбулаторной практики кардиолога). Рациональная Фармакотерапия в Кардиологии. 2020;16(4):542-9. doi:10.20996/1819-6446-2020-08-20.

Kurekhyan AS, Smirnova MI, Gorbunov VM, et al. Prevalence and Characteristics of Blood Pressure Phenotypes in Patients with Hypertension and Chronic Respiratory Diseases (Study of Ambulatory Practice Data of a Cardiologist). Rational Pharmacotherapy in Cardiology. 2020;16(4):542-9. (In Russ.) doi:10.20996/1819-6446-2020-08-20.

571

Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-9. doi:10.1016/S2213-2600(15)00241-6.

572

Cao C, Wang R, Wang J, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7(8):e43892. doi:10.1371/journal.pone.0043892.

573

Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33-40. doi:10.1136/thoraxjnl-2014-205795.

574

Lu Y, Chang R, Yao J, et al. Effectiveness of long-term using statins in COPD — a network meta-analysis. Respir Res. 2019;20(1):17. doi:10.1186/s12931-019-0984-3.

575

Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013; 26(2):212-7.

576

Bonnet J, McPherson R, Tedgui A, et al. CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008; 30(12):2298-313.

577

Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 2002;106(16):2104-10.

578

Wang L, Mengjue L, Yanping T. Therapeutic effect of fluvastatin on pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chin J Gerontol. 2011;31(9):1666-7.

579

Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2005;25(11): 2335-42.

580

Dan C, Wang B.The clinical effect of atorvastatin in the treatment of chronic obstructive pulmonary disease complicated with pulmonary hypertension. Chin J of Clinical Rational Drug Use. 2016;9(2):1-3.

581

582

Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593-5. doi:10.1016/S2213-2600(15)00279-9.

583

Roversi S, Fabbri LM, Sin DD, et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016;194(11):1319-36. doi:10.1164/rccm.201604-0690SO.

584

Григорьева Н. Ю., Майорова М. В., Королёва М. Е., Самолюк М. О. Особенности формирования и развития сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких. Терапевтический архив. 2019;91(1):43-7. doi:10.26442/00403660.2019.01.000027.

Grigoryeva NY, Maiorova MV, Korolyova ME, Samolyuk MO. Comorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Terapevticheskii arkhiv. 2019;91(1):43-7. (In Russ.) doi:10.26442/00403660.2019.01.000027.

585

Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70. doi:10.1016/j.annepidem.2005.04.008.

586

Svendsen CD, Kuiper KKJ, Ostridge K, et al. Factors associated with coronary heart disease in COPD patients and controls. PLoS One. 2022;17(4):e0265682. doi:10.1371/journal.pone.0265682.

587

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? [published correction appears in Eur Respir Rev. 2018 Nov 21;27(150):]. Eur Respir Rev. 2018;27(149):180057. doi:10.1183/16000617.0057-2018.

588

Cui H, Miao DM, Wei ZM, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol. 2012;9(1):5-10. doi:10.3724/SP.J.1263.2012.00005.

589

Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956-62. doi:10.1136/thx.2009.128082.

590

Коломоец Н. М., Бакшеев В. И., Зарубина Е. Г., Увайсова К. У. Эффективность длительной терапии триметазидином у больных с ишемической болезнью сердца в сочетании с хронической обструктивной болезнью легких. Кардиология. 2008;(2):47-51.

Kolomoets NM, Baksheev VI, Zarubina EG, Uvaisova KU. Efficacy of long-term therapy with trimetazidine in patients with coronary heart disease in combination with chronic obstructive pulmonary disease. Kardiologiia. 2008;(2):47-51. (In Russ.)

591

Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454-75. doi:10.1183/09059180.00008612.

592

Man JP, Sin DD, Ignaszewski A, Man SFP. The complex relationship between ischemic heart disease and COPD exacerbations. Chest. 2012;141(4):837-8. doi:10.1378/chest.11-2483.

593

Павленко, В. И., Нарышкина С. В. Особенности проявления безболевой ишемии миокарда у больных хронической обструктивной болезнью легких. Кардиология. 2012;52(2):36-40. EDN TKMYXB.

Pavlenko VI, Naryshkina SV. Manifestations of painless myocardial ischemia in patients with chronic obstructive pulmonary disease. Kardiologiia. 2012;52(2):36-40. (In Russ.) EDN TKMYXB.

594

Павленко, В. И., Нарышкина, С. В. Особенности проявления безболевой ишемии миокарда и ее прогностическое значение при сочетанной кардиопульмональной патологии. Бюллетень физиологии и патологии дыхания, 2014;(51):44-7. EDN: RZAQNN

Pavlenko VI, Naryshkina SV. The behavior of silent myocardial ischemia and its predictive value under combined cardiopulmonary. Bulletin of Physiology and Pathology of Respiration, 2014;(51):44-7. (In Russ.) EDN: RZAQNN

595

Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162(4):237-51. doi:10.1016/j.trsl.2013.05.001.

596

Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39:51-8.

597

Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015;109(11):1371-80. doi:10.1016/j.rmed.2015.07.014.

598

Morgan AD, Sharma C, Rothnie KJ, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017;14(5):754-65. doi:10.1513/AnnalsATS.201611-932SR.

599

Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11(2):130-9. doi:10.1093/eurjhf/hfn013.

600

Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. Eur J Heart Fail. 2012;14(4):395-403. doi:10.1093/eurjhf/hfs009.

601

Braga JR, Tu JV, Austin PC, et al. Recurrent events analysis for examination of hospitalizations in heart failure: insights from the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) trial. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):18-26. doi:10.1093/ehjqcco/qcx015.

602

Abusaid GH, Barbagelata A, Tuero E, et al. Diastolic dysfunction and COPD exacerbation. Postgraduate medicine. 2009;121(4):76-81.

603

López-Sánchez, M., Muñoz-Esquerre M, Huertas D, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a low exercise capacity: a cross-sectional study. PloS one. 2013;8(6):e68034.

604

Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264(4):361-9. doi:10.1111/j.1365-2796.2008.01975.x.

605

Газизянова В. М., Булашова О. В., Хазова Е. В. и др. Особенности клинического фенотипа и прогноза хронической сердечной недостаточности в сочетании с хронической обструктивной болезнью легких. Кардиология. 2019;59(6S):51-60. doi:10.18087/cardio.2674.

Gazizyanova VM, Bulashova OV, Hazova EV, et al. Clinical features and prognosis in heart failure patients with chronic obstructive pulmonary diseases. Kardiologiia. 2019;59(6S):51-60. (In Russ.) doi:10.18087/cardio.2674.

606

Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: An ignored combination?. Eur J Heart Fail. 2006;8(7):706-11. doi:10.1016/j.ejheart.2006.01.010.

607

Matamis D, Tsagourias M, Papathanasiou A, et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. Journal of critical care. 2014;29(2):315-e7.

608

MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138-48. doi:10.1016/S2213-2600(15)00509-3.

609

Ahn Y-H, Lee KS, Park JH, et al. Independent Risk Factors for Mortality in Patients with Chronic Obstructive Pulmonary Disease Who Undergo Comprehensive Cardiac Evaluations. Respiration 2015;90:199-205. doi:10.1159/000437097.

610

Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol. 2015;199:264-73. doi:10.1016/j.ijcard.2015.06.096.

611

Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21(6):1012-6. doi:10.1183/09031936.03.00051502.

612

Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol 2017;69:699-705.

613

Konecny T, Somers KR, Park JY, et al. Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. Heart Rhythm. 2018;15:832-8.

614

van den Berg ME, Stricker BH, Brusselle GG, Lahousse L. Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review. Trends Cardiovasc Med. 2016;26:606-13.

615

Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18(19):2908-17.

616

Hayashi H, Miyamoto A, Kawaguchi T, et al. P-pulmonale and the development of atrial fibrillation. Circ J. 2014;78(2):329-37. doi:10.1253/circj.cj-13-0654.

617

McCord J, Borzak S. Multifocal Atrial Tachycardia. Chest. 1998;113(1):203-9. doi:10.1378/chest.113.1.203.

618

Chuchalin AG. Chronic obstructive pulmonary disease and co-morbidities. PULMONOLOGIYA. 2008;(2):5-14. (In Russ.) Чучалин А. Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Пульмонология. 2008;(2):5-14. doi:10.18093/0869-0189-2008-0-2-5-14.

Chuchalin AG. Chronic obstructive pulmonary disease and co-morbidities. PULMONOLOGIYA. 2008;(2):5-14. (In Russ.) doi:10.18093/0869-0189-2008-0-2-5-14.

619

Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114-6. doi:10.1136/thoraxjnl-2011-201275.

620

Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305-11.

621

Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-21. doi:10.1378/chest.125.6.2309.

622

Wise RA, Anzueto A, Cotton D, et al.; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-501. doi:10.1056/NEJMoa1303342.

623

Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine. 2008;359(15):1543-54.

624

Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11(1):149. doi:10.1186/1465-9921-11-149.

625

Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. The Lancet. 2003;361(9356):449-56.

626

Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal. 2003;21(1):74-81.

627

Calverley PM, Boonsawat, W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. European Respiratory Journal. 2003;22(6):912-9.

628

Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719-25.

629

Vestbo J, Anderson JA, Brook RD, et al.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26. doi:10.1016/S0140-6736(16)30069-1.

630

Members WC, January CT, Wann LS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199.

631

Ohta K, Fukuchi Y, Grouse L, et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory medicine. 2004;98(10):1016-24.

632

Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity: a prospective continuous electrocardiographic study. Chest. 1990;98(3):672-8.

633

Byrd JB, Newby DE, Anderson JA, et al. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J. 2018;39(33):3128-34. doi:10.1093/eurheartj/ehy451.

634

Askın M, Koc EM, Sozmen K, et al. Evaluation of Dipper and Non-dipper Blood Pressure Patterns and Quality of Life Among Patients with Chronic Obstructive Pulmonary Disease. Arq Bras Cardiol. 2021;116(2):295-302. English, Portuguese. doi:10.36660/abc.20190536.

635

Смирнова М.И., Горбунов В.М., Курехян А.С. и др. Различные виды вариабельности артериального давления у больных артериальной гипертонией и хроническими болезнями нижних дыхательных путей. Рациональная Фармакотерапия в Кардиологии. 2018;14(6):816-25. doi:10.20996/1819-6446-2018-14-6-816-825.

Smirnova MI, Gorbunov VM, Kurekhyan AS, et al. Different Types of Blood Pressure Variability in Hypertensive Patients with Chronic Lower Airway Diseases. Rational Pharmacotherapy in Cardiology. 2018;14(6):816-825. (In Russ.) doi:10.20996/1819-6446-2018-14-6-816-825.

636

Ambrosino P, Lupoli R, Cafaro G, et al. Subclinical carotid atherosclerosis in patients with chronic obstructive pulmonary disease: a meta-analysis of literature studies. Ann Med. 2017;49:513-24.

637

Chindhi S, Thakur S, Sarkar M, Negi PC. Subclinical atherosclerotic vascular disease in chronic obstructive pulmonary disease: Prospective hospital-based case control study. Lung India. 2015;32(2): 137-341.

638

Schneider С, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J.Epidemiol. 2010;25(4):253-60.

639

Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int. J. Chron. Obstruct Pulmon Dis. 2009;(4):337-49.

640

Gulsvik AK, Gulsvik A, Skovlund E, et al. The association between lung function and fatal stroke in a community followed for 4 decades. J. Epidemiol. Community Health. 2012;66(11):1030-6.

641

Hozawa A, Billings JL, Shahar E, et al. Lung function and ischemic stroke incidence: the atherosclerosis risk in communities study. Chest. 2006;130(6):1642-9.

642

Truelsen T, Prescott E, Lange P, et al. Lung function and risk of fatal and non-fatal stroke. The copenhagen city heart study. Int. J.Epidemiol. 2001;30(1):145-51.

643

Dodd JW, Chung AW, van den Broek MD, et al. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am.J. Respir. Crit. Care Med. 2012;186(3):240-5.

644

Шпрах В. В., Нечаева Ю. П. Распространенность и структура ранних форм хронической церебральной ишемии у больных хронической обструктивной болезнью легких. Сибирский медицинский журнал. 2007;4:54-7.

Shprach VV, Nechaeva Yu P. Prevalence and structure of early forms of chronic cerebral ischemia in patients with chronic obstructive pulmonary disease. Siberian Medical Journal. 2007;4:54-7. (In Russ.)

645

van Dijk EJ, Vermeer SE, de Groot JC, et al. Arterial oxygen saturation, COPD, and cerebral small vessel disease. J. Neurol. Neurosurg. Psychiatry. 2004;75(5):733-6.

646

Liao D, Higgins M, Bryan NR, et al. Lower pulmonary function and cerebral subclinical abnormalities detected by MRI: the atherosclerosis risk in communities study. Chest. 1999;116(1):150-6.

647

Jones HJ, Ibrahim AE, Hoskins C, Derodra J.K. Aortic aneurysm screening in general practice. Lancet. 1996;348:320.

648

van Laarhoven CJ, Borstlap AC, van Berge Henegouwen DP, et al. Chronic obstructive pulmonary disease and abdominal aortic aneurysms. Eur J Vasc Surg. 1993;7(4):386-90. doi:10.1016/s0950-821x(05)80254-3.

649

Lindholt JS, Heickendorff L, Antonsen S, et al. Natural history of abdominal aortic aneurysm with and without coexisting chronic obstructive pulmonary disease. J Vasc Surg. 1998;28:226-33.

650

Flessenkaemper IH, Loddenkemper R, Roll S, et al. Screening of COPD patients for abdominal aortic aneurysm. Int J Chron Obstruct Pulmon Dis. 2015;10:1085-91. doi:10.2147/COPD.S81439.

651

Xiong J, Wu Z, Chen C, Guo W. Chronic obstructive pulmonary disease effect on the prevalence and postoperative outcome of abdominal aortic aneurysms: A meta-analysis. Sci Rep. 2016;6:25003. doi:10.1038/srep25003.

652

Fowkes FG, Anandan CL, Lee AJ, et al. Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease. J Vasc Surg. 2006;43(3):474-80.

653

Akturk UA, Kocak ND, Akturk S, et al. What are the Prevalence of Abdominal Aortic Aneurysm in Patients with Chronic Obstructive Pulmonary Diseases and the Characteristics of These Patients? Eurasian J Med. 2017;49(1):36-9. doi:10.5152/eurasianjmed.2017.16156.

654

Ando K, Kaneko N, D o i T, Aoshima M, Takahashi K. Prevalence and risk factors of aortic aneurysm in patients with chronic obstructive pulmonary disease. J Thorac Dis. 2014;6(10):1388-95. doi:10.3978/j.issn.2072-1439.2014.10.01.

655

Houben-Wilke S, Jörres RA, Bals R, et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017;195(2):189-97. doi:10.1164/rccm.201602-0354OC.

656

Terzikhan N, Lahousse L, Verhamme KMC, et al. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Res. 2018;4(4):00086-2018. doi:10.1183/23120541.00086-2018.

657

Kaszuba M, Śliwka A, Piliński R, et al. The Comorbidity of Chronic Obstructive Pulmonary Disease and Peripheral Artery Disease — A Systematic Review. COPD. 2019;16(3-4):292-302. doi:10.1080/15412555.2019.1653271.

658

Tatò F.Durchblutungsstörungen der oberen Extremitäten [Upper extremity peripheral arterial disease]. Dtsch Med Wochenschr. 2020;145(20):1437-42. German. doi:10.1055/a-1068-4230.

659

Stepansky F, Hecht EM, Rivera R, et al. Dynamic MR angiography of upper extremity vascular disease: pictorial review. Radiographics. 2008;28(1):e28. doi:10.1148/radiol.e28.

660

Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135(3):786-93.

661

Gunen H, Gulbas G, In E, et al. Venous thromboemboli and exacerbations of COPD. Eur Respir J. 2010;35(6):1243-8.

662

Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA. 2021;325(1):59-68.

663

Tillie-Leblond I. Pulmonary Embolism in Patients with Unexplained Exacerbation of Chronic Obstructive Pulmonary Disease: Prevalence and Risk Factors. Annals of Internal Medicine. 2006;144(6):390. doi:10.7326/0003-4819-144-6-200603210-00005.

664

Castellana G, Intiglietta P, Dragonieri S, et al. Incidence of deep venous thrombosis in patients with both Pulmonary Embolism and COPD. Acta Biomed. 2021;92(3):e2021210. doi:10.23750/abm.v92i3.11258.

665

Bertoletti L, Quenet S, Laporte S, et al. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res. 2013;14:75.

666

Kahn S, Lim W, Dunn A, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Pracice Guidelines. Chest. 2012;141((2 Suppl)):e195S-226S.

667

Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis. 1985;131(6):835-9. doi:10.1164/arrd.1985.131.6.835.

668

Weitzenblum E, Krieger J, Apprill M, et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis. 1988;138(2):345-9. doi:10.1164/ajrccm/138.2.345.

669

Sharma B, Neilan TG, Kwong RY, et al. Evaluation of right ventricular remodeling using cardiac magnetic resonance imaging in co-existent chronic obstructive pulmonary disease and obstructive sleep apnea. COPD. 2013;10(1):4-10. doi:10.3109/15412555.2012.719050.

670

AlHafidh OZ, Sidhu JS, Virk J, et al. Incidence, Predictors, Causes, and Cost of 30-Day Hospital Readmission in Chronic Obstructive Pulmonary Disease Patients Undergoing Bronchoscopy. Cureus. 2020;12(6):e8607. doi:10.7759/cureus.8607.

671

Iyer KS, Newell JD Jr, Jin D, et al. Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. Am J Respir Crit Care Med. 2016;193(6):652-61. doi:10.1164/rccm.201506-1196OC.

672

Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005;60(7):605-9.

673

Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109-D116. doi:10.1016/j.jacc.2013.10.036.

674

Ewert R, Heine A, Bollmann T, et al. Right Heart Catheterization During Exercise in Patients with COPD-An Overview of Clinical Results and Methodological Aspects. COPD. 2018;15(6):588-99. doi:10.1080/15412555.2018.1545832.

675

Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292-301. doi:10.1183/09031936.00079512.

676

Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189-94. doi:10.1164/rccm.200401-006OC.

677

Cassady SJ, Reed RM. Pulmonary Hypertension in COPD: A Case Study and Review of the Literature. Medicina (Kaunas). 2019;55(8):432. doi:10.3390/medicina55080432.

678

Добнер С. Ю., Федосенко С. В., Родионов Е. О. и др. Рак легкого у больных ХОБЛ и факторы, ассоциированные со снижением их выживаемости. Бюллетень сибирской медицины. 2022;21(3):41-9. doi:10.20538/1682-0363-2022-3-41-49.

Dobner SYu, Fedosenko SV, Rodionov EO, et al. Lung cancer in patients with COPD and factors associated with reduced survival. Bulletin of Siberian Medicine. 2022;21(3):41-9. (In Russ.) doi:10.20538/1682-0363-2022-3-41-49.

679

Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011;81(4):265-84. doi:10.1159/000324601.

680

Forder A, Zhuang R, Souza VGP, et al. Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer. Int J Mol Sci. 2023;24(3):2859. doi:10.3390/ijms24032859.

681

Kondo R, Yoshida K, Eguchi T, et al. Clinical features of lung cancer smokers with light and mind chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases. European Journal of Cardio-thoracic Surgery. 2011;40(6):1439-43. doi:10.1016/j.ejcts.2011.03.017.

682

Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. Journal. 2009;34(2):380-6. doi:10.1183/09031936.00144208.

683

Murakami J, Ueda K, Sano F, et al. Pulmonary emphysema and tumor microenvironment in primary lung cancer. Journal of Surgical Research. 2016;200(2):690-7. doi:10.1016/j.jss.2015.09.004.

684

Tisi S, Dickson JL, Horst C, et al.; SUMMIT Consortium; Hurst JR, Janes SM. Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry. Eur Respir J. 2022;60(6):2200795. doi:10.1183/13993003.00795-2022.

685

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. doi:10.3322/caac.21660.

686

Takiguchi Y, Sekine I, Iwasawa S, et al. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol. 2014;5(4):660-6. doi:10.5306/wjco.v5.i4.660.

687

Hopkins RJ, Duan F, Gamble GD, et al. Chr15q25 Genetic Variant (Rs16969968) Independently Confers Risk of Lung Cancer, COPD and Smoking Intensity in a Prospective Study of High-Risk Smokers. Thorax. 2021;76:272-80. doi:10.1136/thoraxjnl-2020-214839.

688

Douglas NJ. Asthma and chronic obstructive pulmonary disease. In: Kryger M., Roth Th., Dement W., ed. Principles and practice of sleep medicine. 4-th ed. Philadelphia: Elsevier Saunders; 2005. 1122-35.

689

Gunduz C, Basoglu OK, Tasbakan MS. Prevalence of overlap syndrome in chronic obstructive pulmonary disease patients without sleep apnea symptoms. Clin. Respir. J. 2018;12(1):105-12. doi:10.1111/crj.12493.

690

Soler X, Gaio E, Powell FL, et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2015;12(8):1219-25. doi:10.1513/AnnalsATS.201407-336OC.

691

McNicholas WT. COPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management. Chest. 2017;152(6):1318-26. doi:10.1016/j.chest.2017.04.160.

692

Mermigkis C, Kopanakis A, Foldvary-Schaefer N, et al. Health-related quality of life in patients with obstructive sleep apnoea and chronic obstructive pulmonary disease (overlap syndrome). Int J Clin Pract. 2007;61(2):207-11. doi:10.1111/j.1742-1241.2006.01213.x.

693

Du W, Liu J, Zhou J, et al. Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005-2008 National Health and Nutrition Examination Survey. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13: 665-74. doi:10.2147/COPD.S148735.

694

Xie J, Li F, Wu X, Hou W. Prevalence of pulmonary embolism in patients with obstructive sleep apnea and chronic obstructive pulmonary disease: The overlap syndrome. Heart Lung. 2019;48(3):261-5. doi:10.1016/j.hrtlng.2018.11.001.

695

McNicholas W. T. Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease. J. Thorac. Dis. 2018;10(Suppl. 34):S4253-4261. doi:10.21037/jtd.2018.10.117.

696

Chaouat ARI, Weitzenblum E, Krieger J, et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. American journal of respiratory and critical care medicine. 1995;151(1):82-6.

697

Shepard JrJW, Garrison MW, Grither DA, et al. Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. The American journal of medicine. 1985;78(1):28-34.

698

Lacedonia D, Carpagnano GE, Aliani M, et al. Daytime PaO2 in OSAS, COPD and the combination of the two (overlap syndrome). Respir. Med. 2013;107(2):310-6. doi:10.1016/j.rmed.2012.10.012.

699

Bouloukaki I, Mermigkis C, Tzanakis N, et al. Evaluation of Inflammatory Markers in a Large Sample of Obstructive Sleep Apnea Patients without Comorbidities. Mediators Inflamm. 2017;2017:4573756. doi:10.1155/2017/4573756.

700

Domagała-Kulawik J, Osińska I, Piechuta A, et al. T, B, and NKT Cells in Systemic Inflammation in Obstructive Sleep Apnoea. Mediators Inflamm. 2015;2015:161579. doi:10.1155/2015/161579.

701

Baessler A, Nadeem R, Harvey M, et al. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers — a meta-analysis. J Inflamm (Lond). 2013;10:13. doi:10.1186/1476-9255-10-13.

702

Stanchina ML, Welicky LM, Donat W, et al. Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med. 2013;9(8):767-72. doi:10.5664/jcsm.2916.

703

Toraldo DM, De Benedetto M, Scoditti E, De Nuccio F. Obstructive sleep apnea syndrome: coagulation anomalies and treatment with continuous positive airway pressure. Sleep Breath. 2016;20(2):457-65. doi:10.1007/s11325-015-1227-6.

704

Singh G, Agarwal A, Zhang W, et al. Impact of PAP therapy on hospitalization rates in Medicare beneficiaries with COPD and coexisting OSA. Sleep Breath. 2019;23(1):193-200. doi:10.1007/ s11325-018-1680-0.

705

Цеймах И. Я., Шойхет Я. Н. Факторы дисфункции эндотелия сосудов и тромбогенного риска у больных хронической обструктивной болезнью легких в сочетании с синдромом обструктивного апноэ сна в период после обострения. Пульмонология. 2021;31(3):329-37. doi:10.18093/0869-0189-2021-31-3-329-337.

Tseymakh IYa, Shoykhet YN. Factors of vascular endothelial dysfunction and thrombogenic risk in patients with chronic obstructive pulmonary disease in combination with obstructive sleep apnea after an exacerbation. PULMONOLOGIYA. 2021;31(3):329-37. (In Russ.) doi:10.18093/0869-0189-2021-31-3-329-337.

706

Sherrill D, Guerra S, Bobadilla A, Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur. Respir. J. 2003;21(1):95-100.

707

Schneider A, Tilemann L, Schermer T, et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement — results of a prospective diagnostic study: FENO < or = 16 ppb better than FENO < or =12 ppb to rule out mild and moderate to severe asthma [added]. Respir. Res. 2009;10:15.

708

Cazzola M, Puxeddu E, Bettoncelli G, et al. The prevalence of asthma and COPD in Italy: a practicebased study. Respir. Med. 2011;105(3):386-91.

709

Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719-28. doi:10.1016/S2213-2600(15)00254-4.

710

Gelb AF, Christenson SA, Nadel JA. Understanding the pathophysiology of the asthma-chronic obstructive pulmonary disease overlap syndrome. Curr Opin Pulm Med. 2016;22(2):100-5. doi:10.1097/MCP.0000000000000236.

711

Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20:229. doi:10.1186/s12931-019-1198-4.

712

Ovcharenko SI, Leshchenko IV. Chronic obstructive pulmonary disease. M.: GEOTAR-Media. 2016, 189 p. (In Russ.) Овчаренко С. И., Лещенко И. В. Хроническая обструктивная болезнь лёгких. М.: ГОЭТАР-Медиа. 2016, 189 с.

Ovcharenko SI, Leshchenko IV. Chronic obstructive pulmonary disease. M.: GEOTAR-Media. 2016, 189 p. (In Russ.)

713

Cosentino J, Zhao H, Hardin M, et al; COPDGene Investigators. Analysis of asthma-chronic obstructive pulmonary disease overlap syndrome defined on the basis of bronchodilator response and degree of emphysema. Ann Am Thorac Soc. 2016;13:1483-9. doi:10.1513/AnnalsATS.201511-761OC.

714

Miravitlles M, Soler-Cataluna JJ, Calle M, еt al. Spanish COPD Guidelines (Ges EPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch. Broncopneumol. 2012;48(7):247-57.

715

Cebron Lipovec N, Beijers RJ, van den Borst B, et al. The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD. 2016; 13(3):399-406. doi:10.3109/15412555.2016.1140732.

716

Giri Ravindran S, Saha D, Iqbal I, et al. The Obesity Paradox in Chronic Heart Disease and Chronic Obstructive Pulmonary Disease. Cureus. 2022;14(6):e25674. doi:10.7759/cureus.25674.

717

Carbone S, Lavie CJ, Arena R. Obesity and Heart Failure: Focus on the Obesity Paradox. Mayo Clin Proc. 2017;92(2):266-79. doi:10.1016/j.mayocp.2016.11.001.

718

Elagizi A, Kachur S, Lavie CJ, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis. 2018;61(2):142-50. doi:10.1016/j.pcad.2018.07.003.

719

Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes Rev. 2016;17(10):989-1000. doi:10.1111/obr.12440.

720

Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099-107.

721

Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. European Respiratory Journal. 2008;31(1):204-12.

722

Мягкова М. А., Скрипникова И. А., Косматова О. В. и соавт. Ассоциации абсолютного риска остеопорозных переломов (FRAX®) и суммарного сердечно-сосудистого риска (SCORE) среди городского населения Российской Федерации. Кардиоваскулярная терапия и профилактика. 2019;18(5):108-16. doi:10.15829/1728-8800-2019-5-108-116.

Myagkova MA, Skripnikova IA, Kosmatova OV, et al. Associations of absolute risk of osteoporotic fractures (FRAX®) and total cardiovascular risk (SCORE) in urban population of the Russian Federation. Cardiovascular Therapy and Prevention. 2019;18(5):108-16. (In Russ.) doi:10.15829/1728-8800-2019-5-108-116.

723

Chen YW, Ramsook AH, Coxson HO, et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis. Chest. 2019;156(6):1092-110. doi:10.1016/j.chest.2019.06.036.

724

Jaramillo JD, Wilson C, Stinson DS, et al. Reduced Bone Density and Vertebral Fractures in Smokers Men and COPD Patients at Increased Risk [published correction appears in Ann Am Thorac Soc. 2015 Jul;12(7):1112. Stinson, Douglas J [corrected to Douglas S]]. Ann Am Thorac Soc. 2015;12(5):648-56. doi:10.1513/AnnalsATS.201412-591OC.

725

Li Y, Gao H, Zhao L, Wang J. Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation. Clin Respir J. 2022;16(7):487-96. doi:10.1111/crj.13514.

726

Finlea JD, Grossmann RE, Tangpricha V. Vitamin D and chronic lung diseases: a review of molecular mechanisms and clinical studies. Adv. Nutr. 2011:2:244-53.

727

Hughes DA, Norton R. Vitamin D and respiratory health. Clin. Exp. Immunol. 2009;158:20-5.

728

Wang YL, Kong H, Xie WP, Wang H. Association of vitamin D-binding protein variants with COPD: a meta-analysis. Genetics and Molecular Research. 2015;14:10774-85.

729

Hanson C, Rutten EP, Wouters EF, Rennard S. Diet and vitamin D as risk factors for lung impairment and COPD. Transl. Res. 2013;162:219-36.

730

Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with COPD. Ann. Med. 2013;45:91-6.

731

Berg I, Hanson C, Sayles H, et al. Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir. Med. 2013;107:1578-88.

732

Lee HM, Liu M, Lee K, et al. Does low vitamin D amplify the association of COPD with total and cardiovascular mortality? Clin. Cardiol. 2014;37:473-8.

733

Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in COPD: randomized trial. Ann. Intern. Med. 2012;156:105-14.

734

Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest. 2005;128:3792-8.

735

Болотова Е. В., Являнская В. В., Дудникова А. В. Предикторы развития больших кардиоваскулярных событий у больных хронической обструктивной болезнью легких в сочетании с ранними стадиями хронической болезни почек. Кардиология. 2019;59(3S):52-60. doi:10.18087/cardio.2539.

Bolotova EV, Yavlyanskaya VV, Dudnikova AV. Predictors for development of major cardiovascular events in elderly patients with severe and extremely severe chronic obstructive pulmonary disease in combination with early stages of chronic kidney disease. Kardiologiia. 2019;59(3S):52-60. (In Russ.) doi:10.18087/cardio.2539.

736

Zhu B, Zhu B, Xiao C, Zheng Z. Vitamin D deficiency is associated with the severity of COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:1907-16.

737

Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Archives of internal medicine. 2007;167(1):60-7.

738

Eisner MD, Blanc PD, Yelin EH, et al. Influence of anxiety on health outcomes in COPD. Thorax. 2010;65(3):229-34.

739

Hanania NA, Müllerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. American journal of respiratory and critical care medicine. 2011;183(5):604-11.

740

Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4):43S-56S.

741

Martínez-Gestoso S, García-Sanz MT, Carreira JM, et al. Impact of anxiety and depression on the prognosis of copd exacerbations [published correction appears in BMC Pulm Med. 2022;22(1):169. doi:10.1186/s12890-022-01934-y. Erratum in: BMC Pulm Med. 2022;22(1):213.

742

Sampaio MS, Vieira WA, Bernardino ÍM, et al. Chronic obstructive pulmonary disease as a risk factor for suicide: A systematic review and meta-analysis. Respir Med. 2019;151:11-8. doi:10.1016/j.rmed.2019.03.018.

743

Deng D, Zhou A, Chen P, Shuang Q. CODEXS: A New Multidimensional Index to Better Predict Frequent COPD Exacerbators with Inclusion of Depression Score. Int J Chron Obstruct Pulmon Dis. 2020;15:249-59. doi:10.2147/COPD.S237545.

744

Lecheler L, Richter M, Franzen DP, et al. The frequent and underrecognised co-occurrence of acute exacerbated COPD and depression warrants screening: a systematic review. Eur Respir Rev. 2017;26(144):170026. doi:10.1183/16000617.0026-2017.

745

Vikjord SAA, Brumpton BM, Mai XM, et al. The association of anxiety and depression with mortality in a COPD cohort. The HUNT study, Norway. Respir Med. 2020;171:106089. doi:10.1016/j.rmed.2020.106089.

746

Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults: accredited by NICE. Thorax. 2013;68(Suppl 2), ii1-ii30.

747

Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. Plos one. 2013;8(4):e60532. doi:10.1371/journal.pone.0060532.

748

Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(2):134-7. doi:10.1164/rccm.200902-0276OC.

749

van Beers M, Janssen DJ, Gosker HR, Schols AM. Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions. Expert review of respiratory medicine. 2018;12(12):1061-74.

750

Yohannes AM, Chen W, Moga AM, et al. Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: a systematic review and meta-analysis of observational studies. Journal of the American Medical Directors Association. 2017;18(5):451-e1.

751

Pierobon A, Ranzini L, Torlaschi V, et al. Screening for neuropsychological impairment in COPD patients undergoing rehabilitation. PLoS One. 2018;13(8):e0199736.

752

Cleutjens FA, Franssen FM, Spruit MA, et al. Domain-specific cognitive impairment in patients with COPD and control subjects. International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:1.

753

Cleutjens FA, Spruit MA, Ponds RW, et al. Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. Chronic respiratory disease. 2018;15(2): 91-102.

754

Rusanen M, Ngandu T, Laatikainen T, et al. Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. Current Alzheimer Research. 2013;10(5):549-55.

755

Xie F, Xie L. COPD and the risk of mild cognitive impairment and dementia: a cohort study based on the Chinese Longitudinal Health Longevity Survey. International journal of chronic obstructive pulmonary disease. 2019;14:403.

756

Torres-Sánchez I, Rodríguez-Alzueta E, Cabrera-Martos I, et al. Cognitive impairment in COPD: a systematic review. J Bras Pneumol. 2015;41(2):182-90. doi:10.1590/S1806-37132015000004424.

757

Higbee DH, Dodd JW. Cognitive impairment in COPD: an often overlooked co-morbidity. Expert Rev Respir Med. 2021;15(1):9-11. doi:10.1080/17476348.2020.1811090.

758

Baird C, Lovell J, Johnson M, et al. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. Respiratory medicine. 2017;129:130-9.

759

Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. J Am Geriatr Soc. 2012;60(10):1839-46. doi:10.1111/j.1532-5415.2012.04171.x.

760

Dodd JW, Charlton RA, van den Broek MD, Jones PW. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest. 2013;144(1):119-27. doi:10.1378/chest.12-2099.

761

Martinez CH, Richardson CR, Han MK, Cigolle CT. Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the health and retirement study. Annals of the American Thoracic Society. 2014;11(9):1362-70.

762

Antonelli-Incalzi R, Corsonello A, Pedone C, et al. Drawing impairment predicts mortality in severe COPD. Chest. 2006;130(6):1687-94. doi:10.1378/chest.130.6.1687.

763

Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J. 2006;27:390-6.

764

Cote C, Zilberberg M, Mody S, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. EurRespir J. 2007;29(5):923-9.

765

Portillo K, Belda J, Anton P, Casan P. High frequency of anemia in COPD patients admitted in a tertiary hospital. Rev Clin Esp. 2007;207:383-7.

766

John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: Comparison to other chronic diseases. Int J Cardiol. 2006;111(3):365-70

767

Alisamir M, Ebrahimi M, Rahim F. Anemia in chronic obstructive pulmonary disease: A systematic review. Respir Investig. 2022;60(4):510-21. doi:10.1016/j.resinv.2022.03.006.

768

Pancirov D, Radisic Biljak V, Stjepanovic G, et al. Hematological markers of anemia and C-reactive protein in patients with stable chronic obstructive pulmonary disease. Biochemia Medica. 2009;19(3):266-76.

769

Xu Y, Hu T, Ding H, Chen R. Effects of anemia on the survival of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14(12):1267-77. doi:10.1080/17476348.2020.1816468.

770

Fawzy A, Woo H, Balasubramanian A, et al. Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstr Pulm Dis. 2021;8(3):326-35. doi:10.15326/jcopdf.2021.0216.

771

Guo L, Chughtai AR, Jiang H, et al. Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease patients with low-risk pulmonary embolism. J Thorac Dis. 2016;8(11):3119-131. doi:10.21037/jtd.2016.11.31.

772

Haider MZ, Anwer F. Secondary Polycythemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

773

Shirai T, Mikamo M, Tsuchiya T, et al. Real-world effect of gastroesophageal reflux disease on cough-related quality of life and disease status in asthma and COPD. Allergology International. 2015;64(1):79-83.

774

Benson VS, Müllerová H, Vestbo J, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respiratory Medicine. 2015;109(9):1147-54.

775

Crowell MD, Zayat EN, Lacy BE, et al. The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose-response study. Chest. 2001;120(4):1184-9.

776

Broers C, Tack J, Pauwels A. Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease. Alimentary Pharmacology & Therapeutics. 2018;47(2):176-91.

777

Pacheco-Galván A, Hart SP, Morice AH. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. Archivos de bronconeumologia. 2011;47(4):195-203. doi:10.1016/j.arbres.2011.02.001.

778

Ingebrigtsen TS, Marott JL, Vestbo J, et al. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20(1):101-7. doi:10.1111/resp.12420.

779

Hurst JR, Vestbo J, Anzueto A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38. doi:10.1056/NEJMoa0909883.

780

Su VY, Liao HF, Perng DW, et al. Proton pump inhibitors use is associated with a lower risk of acute exacerbation and mortality in patients with coexistent COPD and GERD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:2907-15.

781

Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J. 2010;35(3):676-80. doi:10.1183/09031936.00120609.

782

Singh D. Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul). 2017;80(4):317-24. doi:10.4046/trd.2017.0080.

783

Schroeder JD, McKenzie AS, Zach JA, et al. Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease. AJR Am J Roentgenol. 2013;201(3):W460-W470. doi:10.2214/AJR.12.10102.

784

Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry [published correction appears in JAMA Intern Med. 2015;175(9):1588]. JAMA Intern Med. 2015;175(9):1539-49. doi:10.1001/jamainternmed.2015.2735.

785

Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;198(9):1130-9. doi:10.1164/rccm.201804-0621CI.

786

Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure — COPD or congestion? Int J Cardiol. 2013;168(3):1910-6. doi:10.1016/j.ijcard.2012.12.083.

787

Ford ES, Cunningham TJ, Mercado CI. Lung function and metabolic syndrome: Findings of National Health and Nutrition Examination Survey 2007–2010. J Diabetes. 2014;6(6):603-13. doi:10.1111/1753-0407.12136.

788

Lusuardi M, Garuti G, Massobrio M, et al. Heart and lungs in COPD. Close friends in real life-separate in daily medical practice? Monaldi Archives Chest Disease. 2008;69(1):11-7.

789

Sugawara H, Saito A, Yokoyama S, et al. Association between annual change in FEV1 and comorbidities or impulse oscillometry in chronic obstructive pulmonary disease. BMC Pulm Med. 2022;22(1):185. doi:10.1186/s12890-022-01980-6.

790

Zhai T, Li Y, Brown R, Lanuti M, Gainor JF, Christiani DC. Spirometry at diagnosis and overall survival in non-small cell lung cancer patients. Cancer Med. 2022;11(24):4796-805. doi:10.1002/cam4.4808.

791

Cooper BG. An update on contraindications for lung function testing. Thorax. 2011;66(8):714-23. doi:10.1136/thx.2010.139881.

792

Minasian AG, van den Elshout FJ, Dekhuijzen PR, et al. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med. 2014;2(1):12. doi:10.1186/s40247-014-0012-5.

793

Hublitz UF, Shapiro JH. Atypical pulmonary patterns of congestive failure in chronic lung disease. The influence of pre-existing disease on the appearance and distribution of pulmonary edema. Radiology. 1969;93(5):995-1006. doi:10.1148/93.5.995.

794

Aberle DR, Adams AM. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.

795

Sekine Y, Katsura H, Koh E, et al. Early detection of COPD is important for lung cancer surveillance. Eur Respir J. 2012;39(5):1230-40. doi:10.1183/09031936.00126011.

796

Wang Y, Midthun DE, Wampfler JA, et al. Trends in the Proportion of Patients with Lung Cancer Meeting Screening Criteria. J.Am. Med. Assoc. 2015;313:853-5. doi:10.1001/jama.2015.413.

797

Gottlieb M, Marsaa K, Godtfredsen NS, Mellemgaard A. Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer. Acta Oncol. 2015;54(5):767-71. doi:10.3109/0284186X.2014.1001496.

798

Iyer AS, Wells JM, Vishin S, et al. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest. 2014;145(4):824-32. doi:10.1378/chest.13-1422.

799

Nasir SA, Singh S, Fotedar M, et al. Echocardiographic Evaluation of Right Ventricular Function and its Role in the Prognosis of Chronic Obstructive Pulmonary Disease. J Cardiovasc Echogr. 2020;30(3):125-30. doi:10.4103/jcecho.jcecho_10_20.

800

Husebø GR, Gabazza EC, D’Alessandro Gabazza C, et al. Coagulation markers as predictors for clinical events in COPD. Respirology. 2021;26(4):342-51. doi:10.1111/resp.13971.

801

Sadeghi S, Emami Ardestani M, Raofi E, Jalaie Esfandabadi A. Diagnostic Value of D-dimer in Detecting Pulmonary Embolism in Patients with Acute COPD Exacerbation. Tanaffos. 2020;19(4):371-9.

802

COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12(6):1-75.

803

Celli B, Decramer M, Kesten S et al.; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948-55. doi:10.1164/rccm.200906-0876OC.

804

Tashkin DP, Leimer I, Metzdorf N, Decramer M. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respiratory research. 2015;16(1):1-7.

805

Martinez F, Rabe K, Ferguson G, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/ formoterol for chronic obstructive pulmonary disease. A randomized, doubleblind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2020;203(5):553-64.

806

Lipson DA, Crim C, Criner GJ, et al.; IMPACT investigators. Reduction in all-cause mortality with fluticasone furoate/ umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508-16.

807

Li C, Cheng W, Guo J, Guan W. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int J Chron Obstruct Pulmon Dis. 2019;14:799-808.

808

Löfdahl CG, Postma DS, Pride NB, et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29(6):1115-9. doi:10.1183/09031936.00128806.

809

Shin J, Yoon HY, Lee YM, et al. Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study. Sci Rep. 2020;10(1):18973. doi:10.1038/s41598-020-74854-8.

810

Liu J-C, Yang T-Y, Hsu Y-P, et al. Statins Dose-Dependently Exert a Chemopreventive Effect against Lung Cancer in COPD Patients: A Population-Based Cohort Study. Oncotarget. 2016;7:59618-29.

811

Raymakers AJN, Sadatsafavi M, Sin DD, et al. Inhaled Corticosteroids and the Risk of Lung Cancer in COPD: A Population-Based Cohort Study. Eur. Respir. J. 2019; 53:1801257.

812

Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2009;77(3):305-13.

813

Valerio G, Bracciale P, Grazia D’Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):15-21. doi:10.1177/1753465808103499.

814

Celli BR, Cote CG, Marin JM, et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obsructive pulmonary disease. N. Engl. J. Med. 2004;350(10):1005-12. doi:10.1056/NEJMoa021322.

815

Parikh MA, Aaron CP, Hoffman EA, et al. Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study. Ann Am Thorac Soc. 2017;14(5):649-58. doi:10.1513/AnnalsATS.201604-317OC.

816

Kristensen KE, Torp-Pedersen C, Gislason GH, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study. Arterioscler Thromb Vasc Biol. 2015;35(3):733-40. doi:10.1161/ATVBAHA.114.304428.

817

Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A metaanalysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med. 2013;107:1385-92.

818

Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-6. doi:10.1016/j.amjmed.2010.06.019.

819

Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375(17):1617-27. doi:10.1056/NEJMoa1604344.

820

Krammer F, Smith GJD, Fouchier RAM, et al. Influenza (Primer). Nature Reviews: Disease Primers. 2018;4:3. doi:10.1038/s41572-018-0002-y.

821

Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. MedRxiv; 2020. Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic obstructive pulmonary diseases (Miami, Fla.). 2020;7(2):73-5. doi:10.15326/jcopdf.7.2.2020.0149.

822

Wang L, He W, Yu X, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. Journal of Infection. 2020;80(6):639-45. doi:10.1016/j.jinf.2020.03.019.

823

Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur. Heart J. 2008;29:96-103. doi:10.1093/eurheartj/ehm516.

824

Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi:10.1093/ofid/ofu024

825

Soto-Gomez N, Anzueto A, Waterer GW, et al. Pneumonia: an arrhythmogenic disease? Am J Med. 2013;126(1):43-8. doi:10.1016/j.amjmed.2012.08.005.

826

Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. doi:10.1001/jama.2014.18229.

827

Corrales-Medina VF, Taljaard M, Yende S, et al. Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. Am Heart J. 2015;170(2):306-12. doi:10.1016/j.ahj.2015.04.028.

828

Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. MMWR. 2020;69(RR-3):77-83.

829

Nici L, Donner C, Wouters E, et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390-413.

830

Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest. 2007;131:4S-42S.

831

Puhan MA, Gimeno-Santos E, Scharplatz M, et al Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(10):CD005305.

832

Celli B. R. Pulmonary rehabilitation in patients with COPD. Am J Respir Crit Care Med. 1995;152:861-4.

833

Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:19-38.

834

Кубажи К., Соловьева А. В., Ракита Д. Р. Сравнительное исследование функции внешнего дыхания у больных ХОБЛ в сочетании с ИБС и артериальной гипертензией. Современные вопросы науки и образования. 2012;(2):77.

Kubazhi K, Solovyova AV, Rakita DR. Comparative study of the function of external respiration in patients with COPD in combination with coronary artery disease and hypertension. Modern issues of science and education. 2012;(2):77. (In Russ.)

835

Игнатова Г. Л., Антонов О. В., Родионова В. Н. Нарушение функции внешнего дыхания при сочетанном течении ХОБЛ и ИБС. Consilium Medicum. 2014;(11):28-32.

Ignatova GL, Antonov OV, Rodionova VN. Impaired respiratory function in the combined course of COPD and coronary heart disease. Consilium Medicum. 2014;(11):28-32. (In Russ.)

836

Adamson PD, Anderson JA, Brook RD, et al. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol. 2018;72(10):1126-37.

837

Høiseth AD, Neukamm A, Karlsson BD, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011;66(9):775-81. doi:10.1136/thx.2010.153122.

838

Kaszuba E, Odeberg H, Råstam L, Halling A. Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study. BMC Fam Pract. 2018;19(1):178. doi:10.1186/s12875-018-0865-8.

839

Desai R, Patel U, Singh S, et al. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: Insights from the National Inpatient Sample. Int J Cardiol. 2019;281:49-55. doi:10.1016/j.ijcard.2019.01.074.

840

Wang M, Lin EP, Huang LC, et al. Mortality of Cardiovascular Events in Patients With COPD and Preceding Hospitalization for Acute Exacerbation. Chest. 2020;158(3):973-85. doi:10.1016/j.chest.2020.02.046.

841

Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis. 1997;52(1):43-7.

842

Кароли Н. А., Ребров А. П. Предикторы риска смерти пациентов с ХОБЛ (по результатам проспективного динамического наблюдения). Пульмонология. 2007;(3):77-80. doi:10.18093/0869-0189-2007-0-3-77-80.

Karoli NA, Rebrov AP. Predicting risk factors of death in patients with COPD (based on results of a prospective observational study). PULMONOLOGIYA. 2007;(3):77-80. (In Russ.) doi:10.18093/0869-0189-2007-0-3-77-80.

843

Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-31. doi:10.1136/thx.2005.040527.

844

Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J Suppl. 2003;46:2s-4s. doi:10.1183/09031936.03.00000203.

845

Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in die prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998:157:1791-7.

846

Almagro P, Martinez-Camblor P, Soriano JB, et al: Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014;9(2):e89866. doi:10.1371/journal.pone.0089866/

847

Boulet LP, Reddel HK, Bateman E, et al. The Global Initiative for Asthma (GINA): 25 years later. Eur Respir J. 2019;54(2):1900598. doi:10.1183/13993003.00598-2019.

848

To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. doi:10.1186/1471-2458-12-204.

849

GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-96. doi:10.1016/S2213-2600(20)30105-3.

850

Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28(3):202-12. doi:10.1007/s12325-010-0108-4.

851

Weatherburn CJ, Guthrie B, Mercer SW, et al. Comorbidities in adults with asthma: Population-based cross-sectional analysis of 1.4 million adults in Scotland. Clinical and Experimental Allergy. 2017;47(10):1246-52. doi:10.1111/cea.12971.

852

Engelkes M, de Ridder MA, Svensson E, et al. Multinational cohort study of mortality in patients with asthma and severe asthma. Respir Med. 2020;165:105919. doi:10.1016/j.rmed.2020.105919.

853

Veenendaal M, Westerik JAM, van den Bemt L, et al. Age- and sex-specific prevalence of chronic comorbidity in adult patients with asthma: A reallife study. NPJ Primary Care Respiratory Medicine. 2019;29(1):14. doi:10.1038/s41533-019-0127-9.

854

Su X, Ren Y, Li M, et al. Prevalence of Comorbidities in Asthma and Nonasthma Patients: A Meta-analysis. Medicine (Baltimore). 2016;95(22):e3459. doi:10.1097/MD.0000000000003459.

855

Laidlaw TM, Mullol J, Woessner KM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133-41. doi:10.1016/j.jaip.2020.09.063.

856

Крюков А. И., Царапкин Г. Ю., Романенко С.Г. и др. Распространенность и структура заболеваний носа и околоносовых пазух среди взрослого населения мегаполиса. Российская ринология. 2017;25(1):3-6. doi:10.17116/rosrino20172513-6.

Kryukov AI, Zarapkin GYu, Romanenko SG, et al. The prevalence and structure of diseases of the nose and paranasal sinuses among the adult population of the metropolis. Russian rhinology. 2017;25(1):3-6. (In Russ.) doi:10.17116/rosrino20172513-6.

857

Massoth L, Anderson C, McKinney KA. Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management. Med Sci (Basel). 2019;7(4):53. doi:10.3390/medsci7040053.

858

Bousquet J, Schünemann HJ, Togias A, et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3. doi:10.1016/j.jaci.2019.06.049.

859

Astafieva NG, Baranov AA, Vishneva EA, et al. Allergic rhinitis. Russian Rhinology. 2020;28(4):24656. (In Russ.) Астафьева Н.Г., Баранов А. А., Вишнева Е. А. и др. Аллергический ринит. Российская ринология. 2020;28(4):246-56. doi:10.17116/rosrino202028041246

Astafieva NG, Baranov AA, Vishneva EA, et al. Allergic rhinitis. Russian Rhinology. 2020;28(4):24656. (In Russ.) doi:10.17116/rosrino202028041246

860

Хаитов М. Р., Намазова-Баранова Л. С., Ильина Н. И. и др. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский Аллергологический Журнал. 2020;17(1):7-22. doi:10.36691/RAJ.2020.17.1.001.

Khaitov M, Namazova-Baranova L, Ilyina N, et al. 2019 ARIA: care pathways for allergic rhinitis in Russia. Russian Journal of Allergy. 2020;17(1):7-22. (In Russ.) doi:10.36691/RAJ.2020.17.1.001.

861

Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;14(4):950-8. doi:10.1016/j.jaci.2017.03.050.

862

Ненашева Н. М. Т2-бронхиальная астма: характеристика эндотипа и биомаркеры. Пульмонология. 2019;29(2):216-28. doi:10.18093/0869-0189-2019-29-2-216-228.

Nenasheva NM. Т2-high and T2-low bronchial asthma, endotype characteristics and biomarkers. PULMONOLOGIYA. 2019;29(2):216-28. (In Russ.) doi:10.18093/0869-0189-2019-29-2-216-228.

863

Kim DH, Han K, Kim SW. Relationship Between Allergic Rhinitis and Mental Health in the General Korean Adult Population. Allergy Asthma Immunol Res. 2016;8(1):49-54. doi:10.4168/aair.2016.8.1.49.

864

Пискунов Г.З., Моисеева Ю.П. Полипозный риносинусит, 2-е изд., доп. М.: МЕДпрессинформ, 2021, 136 с.

Piskunov GZ, Moiseeva Yu P. Polypous rhinosinusitis, 2nd ed., additional M.: MEDpress inform, 2021, 136 p. (In Russ.)

865

Palmer JN, Messina JC, Biletch R, et al. A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis. Allergy Asthma Proc. 2019;40(1):48-56. doi:10.2500/aap.2019.40.4182.

866

Beule A. Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2015;14:Doc11. doi:10.3205/cto000126.

867

Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. J Allergy Clin Immunol. 2017;140(5):1230-9. doi:10.1016/j.jaci.2017.09.009.

868

Козлов В.С., Савлевич Е. Л. Полипозный риносинусит. Современные подходы к изучению патогенеза, диагностике и лечению. Вестник оториноларингологии. 2015;80(4):95-9. doi:10.17116/otorino201580495-99.

Kozlov VS, Savlevich EL. Polypous rhinosinusitis. Modern approaches to the study of pathogenesis, diagnosis and treatment. Bulletin of otorhinolaryngology. 2015;80(4):95-9. (In Russ.) doi:10.17116/otorino201580495-99.

869

Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131(5):1350-60. doi:10.1016/j.jaci.2013.02.002.

870

Wojas O, Arcimowicz M, Furmańczyk K, et al. The relationship between nasal polyps, bronchial asthma, allergic rhinitis, atopic dermatitis, and non-allergic rhinitis. Postepy Dermatol Alergol. 2021;38(4):650-6. doi:10.5114/ada.2020.94400.

871

Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676-81.e1. doi:10.1016/j.jaci.2014.08.020.

872

Княжеская Н. П. Аспириновая бронхиальная астма и антагонисты лейкотриенов. Русский медицинский журнал. 2000;12:505.

Knyazheskaya NP. Aspirin bronchial asthma and leukotriene antagonists. Russian Medical Journal. 2000;12:505. (In Russ.)

873

Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.J Eur Acad Dermatol Venereol. 2018;32(5):657-82.

874

Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388-98.

875

Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-82.

876

van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-9. doi:10.1016/j.jaci.2007.05.042.

877

Aw M, Penn J, Gauvreau GM, et al. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1-10. doi:10.1159/000502958.

878

Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss- of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-6. doi:10.1038/ng1767.

879

Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/ IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-37. doi:10.1080/1744666X.2017.1298443.

880

Muraro A, Werfel T, Hoffmann-Sommergruber K, et al.; EAACI Food Allergy and Anaphylaxis Guidelines Group. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69(8):1008-25.

881

Ebisawa M, Ito K, Fujisawa T; Committee for Japanese Pediatric Guideline for Food Allergy, The Japanese Society of Pediatric Allergy and Clinical Immunology; Japanese Society of Allergology. Japanese guidelines for food allergy 2020. Allergol Int. 2020;69(3):370-86. doi:10.1016/j.alit.2020.03.004.

882

Emons JAM, Gerth van Wijk R. Food Allergy and Asthma: Is There a Link?. Curr Treat Options Allergy. 2018;5(4):436-44. doi:10.1007/s40521-018-0185-1.

883

Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2010;126(4):798-806. doi:10.1016/j.jaci.2010.07.026.

884

Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319-32.e3. doi:10.1053/j.gastro.2017.06.067.

885

Hruz P, Straumann A, Bussmann C, et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol. 2011;128(6):1349-50.e1345. doi:10.1016/j.jaci.2011.09.01371-78.

886

Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009;7(10):1055-61. doi:10.1016/j.cgh.2009.06.023.

887

Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? Clin Rev Allergy Immunol. 2018;55(1):56-64. doi:10.1007/s12016-018-8670-7.

888

Shaheen NJ, Mukkada V, Eichinger CS, et al. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. Dis Esophagus. 2018;31(8):4-14.

889

Ивашкин В. Т., Маев И. В., Трухманов А. С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97. doi:10.22416/1382-4376-2020-30-4-70-97.

Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97. (In Russ.) doi:10.22416/1382-4376-2020-30-4-70-97.

890

Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 2015;149(7):1731-41.

891

El-Serag HB, Sweet S, Winchester CC., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-80.

892

Hom C, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. Drugs. 2013;73(12):1281-95.

893

Beituganova IM, Chuchalin AG. Reflux induced bronchial asthma. breast cancer. RMJ. 1998;17(6):1102-8. (In Russ.) Бейтуганова И. М., Чучалин А. Г. Рефлюксиндуцированная бронхиальная астма. РМЖ. 1998;17(6):1102-8.

Beituganova IM, Chuchalin AG. Reflux induced bronchial asthma. breast cancer. RMJ. 1998;17(6):1102-8. (In Russ.)

894

Плешко Р. И., Суходоло И. В., Огородова Л. М. Морфофункциональные аспекты сопряженности бронхиальной астмы и гастроэзофагеального рефлюкса. Бюллетень сибирской медицины. 2005;(4):54-9.

Pleshko RI, Sukhodolo IV, Ogorodova LM. Morphofunctional aspects of the conjugacy of bronchial asthma and gastroesophageal reflux. Bulletin of Siberian medicine. 2005;(4):54-9. (In Russ.)

895

Irani C, Adib S, Halaby G, Sibai A. Obesity/overweight and asthma control in LEBANESE adults: a cross-sectional study. BMC Public Health. 2019;19(1):769. doi:10.1186/s12889-019-7116-3.

896

Forte GC, Almeida JC, da Silva DTR, et al. Association between anthropometric markers and asthma control, quality of life and pulmonary function in adults with asthma. Journal of Human Nutrition and Dietetics. 2019;32(1):80-5. doi:10.1111/jhn.12584.

897

Rastogi D, Fraser S, Oh J, et al. Inflammation, metabolic dysregulation, and pulmonary function among obese urban adolescents with asthma. Am J Respir Crit Care Med. 2015;191:149-60.

898

Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest. 2013;143:406-14.

899

Al-Alwan A, Bates JH, Chapman D, et al. The non-allergic asthma of obesity: a matter of distal lung compliance. Am J Respir Crit Care Med. 2014;189:1494-502.

900

Sideleva O, Suratt BT, Black KE, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186:598-605.

901

Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4:574-84.

902

Shimobayashi M, Albert V, Woelnerhanssen B, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128:1538-50.

903

Tregoning JS, Mallia P. Modulating airway glucose to reduce respiratory infections. Expert Rev Respir Med. 2019;13:121-4.

904

Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev. 2012;(7):CD009339. doi:10.1002/14651858.

905

Moreira A., Bonini M., Garcia-Larsen V, et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy. 2013;68(4):425-39.

906

Pite H, Aguiar L, Morello J, et al. Metabolic Dysfunction and Asthma: Current Perspectives. J Asthma Allergy. 2020;13:237-47. doi:10.2147/JAA.S208823.

907

Brumpton BM, Camargo CA Jr, Romundstad PR, et al. Metabolic syndrome and incidence of asthma in adults: the HUNT study. Eur Respir J. 2013;42(6):1495-502. doi:10.1183/09031936.00046013.

908

Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145

909

Zou XZ, Gong ZC, Liu T, et al. Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/ TGF-β1/KLF6 signaling pathway in diabetic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;44:70-7. doi:10.1016/j.pupt.2017.03.012.

910

Klein OL, Krishnan JA, Glick S., et al. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Medicine. 2010;27(9):977-87. doi:10.1111/j.1464-5491.2010.03073.x.

911

Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir Med. 2012;106:249-56.

912

Боровков Н. Н., Добротина И. С., Бердникова Л. В. Особенности артериального давления по данным суточного мониторирования у больных артериальной гипертензией на фоне обострения бронхиальной астмы. Медицинский альманах. 2012;1:152-83.

Borovkov NN, Dobrotina IS, Berdnikova LV. Features of blood pressure according to daily monitoring data in patients with arterial hypertension against the background of exacerbation of bronchial asthma. Medical almanac. 2012;1:152-83. (In Russ.)

913

Гармазина М. В., Будневский А. В. Бронхиальная астма и гипертоническая болезнь: особенности клинико-психологического статуса и реабилитации пациентов с сочетанной патологией. Научно-медицинский вестник центрального Черноземья. 2008;32:63-9.

Karmazina MV, Budnevsky AV. Bronchial asthma and hypertension: features of the clinical and psychological status and rehabilitation of patients with combined pathology. Scientific and medical bulletin of the central Chernozem region. 2008;32:63-9. (In Russ.)

914

Урясьев O.M. Бронхиальная астма и заболевания сердечно-сосудистой системы. Земский врач. 2015;(4):5-14.

Uryagiev OM. Bronchial asthma and diseases of the cardiovascular system. Zemsky doctor. 2015;(4):5-14. (In Russ.)

915

Ушаков В. Ф. Исследование связи маркеров воспаления с уровнем артериального давления у больных бронхиальной астмой с пульмогенной артериальной гипертензией. Мед. наука и образование Урала. 2010;4(11):87-9.

Ushakov VF. Investigation of the relationship of markers of inflammation with blood pressure in patients with bronchial asthma with pulmogenic arterial hypertension. Medical science and education of the Urals. 2010;4(11):87-9. (In Russ.)

916

Moore WC, Hastie AT, Li X, et al. National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J. Allergy Clin. Immunol. 2014;133 (6):1557-63.e5. doi:10.1016/j.jaci.2013.10.011.

917

Bozek A, Rogala B, Bednarski P. Asthma, COPD and comorbidities in elderly people. J Asthma. 2016;53(9):943-7. doi:10.3109/02770903.2016.1170139.

918

Lee HM, Truong ST, Wong ND. Association of adult-onset asthma with specific cardiovascular conditions. Respir Med. 2012;106:948-53.

919

Демко И. В., Гордеева Н. В., Петрова М. М., Артюхов И. П. Клиника и лечение бронхиальной астмы, сочетающейся с патологией сердечно-сосудистой системы. Бюллетень сибирской медицины. 2007;6(2):90-7. doi:10.20538/1682-0363-2007-2-90-97.

Gordeyeva NV, Demko IV, Petrova MM, Artyukhov IP. Clinic and treatment of bronchial asthma, combined with cardiovascularpa thology. Bulletin of Siberian Medicine. 2007;6(2):90-7. (In Russ.) doi:10.20538/1682-0363-2007-2-90-97.

920

Onufrak SJ, Abramson JL, Austin HD, et al. Relation of Adult-Onset Asthma to Coronary Heart Disease and Stroke. Am J Cardiol 2008;101:1247-52.

921

Hua ML, Li L, Diao LL. Bronchial asthma and risk of 4 specific cardiovascular diseases and cardiovascular mortality: a meta-analysis of cohort studies. Eur Rev Med Pharmacol Sci. 2022;26(14):5081-91. doi:10.26355/eurrev_202207_29294.

922

Kim J, Purushottam B, Chae YK, et al. Relation Between Common Allergic Symptoms and Coronary Heart Disease Among NHANES III Participants. Am J Cardiol. 2010;7(106):984-7.

923

Rhee TM, Choi EK, Han KD, et al. Impact of the Combinations of Allergic Diseases on Myocardial Infarction and Mortality. J Allergy Clin Immunol Pract. 2021;9(2):872-80.e4. doi:10.1016/j.jaip.2020.09.008.

924

Gurgone D, McShane L, McSharry C, et al. Cytokines at the Interplay Between Asthma and Atherosclerosis? Front Pharmacol. 2020;11:166. doi:10.3389/fphar.2020.00166.

925

Fernández-Gallego N, Castillo-González R, Méndez-Barbero N, et al. The impact of type 2 immunity and allergic diseases in atherosclerosis. Allergy. 2022;77(11):3249-66. doi:10.1111/all.15426.

926

Warnier MJ, Rutten FH, Kors JA, et al. Cardiac arrhythmias in adult patients with asthma. J Asthma 2012;9(49):942-6.

927

Chan WL, Yang KP, Chao TF, et al. The association of asthma and atrial fibrillation--a nationwide population-based nested case-control study. Int J Cardiol. 2014;176(2):464-9. doi:10.1016/j.ijcard.2014.07.087.

928

Марченко В. Н., Трофимов В. И., Александрин В. А. и др. Нейровегетативная регуляция кардиореспираторной функциональной системы у больных бронхиальной астмой. Вестник современной клинической медицины. 2010;(3):26-9.

Marchenko VN, Trofimov VI, Alexandrin VA, et al. Neurovegetative regulation of the cardiorespiratory functional system in patients with bronchial asthma. Bulletin of Modern Clinical Medicine. 2010;(3):26-9. (In Russ.)

929

Rosero SZ, Zareba W, Moss AJ, et al. Asthma and the risk of cardiac events in the Long QT syndrome. Long QT Syndrome Investigative Group. Am J Cardiol. 1999;84(12):1406-11. doi:10.1016/s0002-9149(99)00586-x.

930

Belyalov FI. Treatment of diseases in conditions of comorbidity. M.: GEOTAR-Media, 2016, p. 544. (In Russ.) Белялов Ф. И. Лечение болезней в условиях коморбидности. M.: ГЭОТАР-Медиа, 2016, с. 544.

Belyalov FI. Treatment of diseases in conditions of comorbidity. M.: GEOTAR-Media, 2016, p. 544. (In Russ.)

931

Iribarren C, Tolstykh IV, Miller MK, et al. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol. 2012;176(11):1014-24. doi:10.1093/aje/kws181.

932

Ingebrigtsen TS, Marott JL, Vestbo J, et al. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res. 2020;7(1):e000470. doi:10.1136/bmjresp-2019-000470.

933

Демко И. В., Собко Е. А., Крапошина А. Ю. и др. Особенности ремоделирования правых и левых отделов сердца у больных бронхиальной астмой. Сибирское медицинское обозрение. 2016;(3):48-55.

Demko IV, Sobko EA, Kraposhina AYu, et al. Features of remodeling of the right and left parts of the heart in patients with bronchial asthma. Siberian Medical Review. 2016;(3):48-55. (In Russ.)

934

Синдром обструктивного апноэ сна: диагностика и консервативное лечение. Позиция невролога. Методические рекомендации. Под редакцией А. И. Крюкова. М., Департамент здравоохранения города Москвы. 2020. 25 с.

Obstructive sleep apnea syndrome: diagnosis and conservative treatment. The position of a neurologist. Methodological recommendations. Edited by A. I. Kryukov. M., Department of Health of the city of Moscow. 2020. 25 p. (In Russ.)

935

Kong DL, Qin Z, Shen H, et al. Association of Obstructive Sleep Apnea with Asthma: A Meta-Analysis. Sci Rep. 2017;7. doi:10.1038/S41598-017-04446-6.

936

Julien JY, Martin JG, Ernst P, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol. 2009;124:371-6. doi:10.1016/J.JACI.2009.05.016.

937

Dixon AE, Poynter ME. Mechanisms of Asthma in Obesity. Pleiotropic Aspects of Obesity Produce Distinct Asthma Phenotypes. Am J Respir Cell Mol Biol. 2016;54:601-8. doi:10.1165/RCMB.2016-0017PS.

938

Becerra MB, Becerra BJ, Teodorescu M. Healthcare burden of obstructive sleep apnea and obesity among asthma hospitalizations: Results from the U.S.-based Nationwide Inpatient Sample. Respir Med. 2016;117:230-6. doi:10.1016/J.RMED.2016.06.020.

939

Teodorescu M, Broytman O, Curran-Everett D, et al.; National Institutes of Health, National Heart, Lung and Blood Institute Severe Asthma Research Program (SARP) Investigators. Obstructive sleep apnea risk, asthma burden, and lower airway inflammation in adults in the Severe Asthma Research Program (SARP) II. J Allergy Clin Immunol Pract. 2015;3:566-75.e1.

940

ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812-8.

941

Wang Y, Liu K, Hu K, et al. Impact of obstructive sleep apnea on severe asthma exacerbations. Sleep Med. 2016;26:1-5.

942

Plojoux J, Charbonnier F, Janssens JP. Pneumologie: Asthme, mucoviscidose et pression positive nocturne [New treatments in respiratory medicine in 2018: asthma, cystic fibrosis and nocturnal positive pressure (CPAP or NIV)]. Rev Med Suisse. 2019;15(N° 632-633):96-100. French.

943

Мельниченко Г. А., Белая Ж. Е., Рожинская Л. Я. и соавт. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017;63(6):392-426. doi:10.14341/probl2017636392-426.

Mel’nichenko GA, Belaya ZhE, Rozhinskaya LYa, et al. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2017;63(6):392-426. (In Russ.) doi:10.14341/probl2017636392-426.

944

Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;2002(1):CD003537. doi:10.1002/14651858.CD003537.

945

Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004;169(1):83-8. doi:10.1164/rccm.200305-640OC.

946

Шапорова Н. Л., Трофимов В. Н. Вторичный остеопороз у пациентов с хронической обструктивной патологией легких. Медицинский совет. 2013;(11):54-7. doi:10.21518/2079-701X-2013-11-54-57.

Shaporova NL, Trofimov VN. Secondary osteoporosis in patients with chronic obstructive pulmonary pathology. Meditsinskiy sovet = Medical Council. 2013;(11):54-7. (In Russ.) doi:10.21518/2079-701X-2013-11-54-57.

947

Cassim R, Russell MA, Lodge CJ, et al. The role of circulating 25 hydroxyvitamin D in asthma: a systematic review. Allergy. 2015;70(4):339-54. doi:10.1111/all.12583.

948

Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017;5(11):881-90. doi:10.1016/S2213-2600(17)30306-5. Erratum in: Lancet Respir Med. 2018;6(6):e27.

949

Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, et al. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax. 2021;76(2):126-33. doi:10.1136/thoraxjnl-2019-213936.

950

Williamson A, Martineau AR, Sheikh A, et al. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2023;2(2):CD011511. doi:10.1002/14651858.CD011511.pub3.

951

Кривошеев В. В., Никитина Л. Ю., Козловский И. В. и др. Курение и витамин D. Наркология. 2023;22(8):40-9. doi:10.25557/1682-8313.2023.08.40-49.

Krivosheev VV, Nikitina LU, Kozlovsky IV, et al. Smoking and vitamin D. Narcology. 2023;22(8):40-9. (In Russ.) doi:10.25557/1682-8313.2023.08.40-49.

952

Сиволап Ю.П. Систематика и лечение тревожных расстройств. Журнал неврологии и психиатрии им. С. С. Корсакова. 2020;120(7):121-7. doi:10.17116/jnevro2020120071121.

Sivolap YuP. Systematics and treatment of anxiety disorders. S. S. Korsakov Journal of Neurology and Psychiatry 2020;120(7):1217. (In Russ.) doi:10.17116/jnevro2020120071121.

953

Ye G, Baldwin DS, Hou R. Anxiety in asthma: a systematic review and meta-analysis. Psychol Med. 2021;51(1):11-20. doi:10.1017/S0033291720005097.

954

Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the community. Arch Gen Psychiatry. 2003;60(11):1125-30. doi:10.1001/archpsyc.60.11.1125.

955

Brodskaya ON. Comorbid diseases in bronchial asthma. Practical pulmonology. 2017;(2):3-13. (In Russ.) Бродская О. Н. Коморбидные заболевания при бронхиальной астме. Практическая пульмонология. 2017;(2):3-13. EDN ZSHJAP.

Brodskaya ON. Comorbid diseases in bronchial asthma. Practical pulmonology. 2017;(2):3-13. (In Russ.) EDN ZSHJAP.

956

Боговин Л. В., Отраднова А. А., Монахова В. В., Шабанова А. С. Влияние тревожно-депрессивных расстройств на течение бронхиальной астмы. Бюллетень физиологии и патологии дыхания. 2014;(52):29-33.

Bogovin LV, Otradnova AA, Monakhova VV, Shabanova AS. The effect of anxiety and depressive disorders on the course of bronchial asthma. Bulletin of physiology and pathology of respiration. 2014;(52):29-33. (In Russ.)

957

Avdeev SN, Pozdnakova AA, Gaynitdinova VV, et al. Asthma in older adults with severe coronavirus disease 2019: Clinical outcomes and predictors of mortality. Ann Allergy Asthma Immunol. 2022;128(2):213-15. doi:10.1016/j.anai.2021.10.016.

958

Reed CE. Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol. 2010;126:681-7.

959

Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010;376:803-13.

960

Slavin RG, Haselkorn T, Lee JH, et al. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006;96:406-14.

961

Ивашкин В. Т., Маев И. В., Трухманов А. С. и др. Клинические рекомендации российской гастроэнтерологической ассоциации по диагностике и лечению эозинофильного эзофагита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(6):84-98. doi:10.22416/1382-4376-2018-28-6-84-98.

Ivashkin VT, Maev IV, Trukhmanov AS, et al. Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(6):84-98. (In Russ.) doi:10.22416/1382-4376-2018-28-6-84-98.

962

Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr Drugs. 2002;4(9):563-70.

963

Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755-67. doi:10.1080/17476348.2018.1506331.

964

Клевцова О. В., Краснова Ю. Н., Петухова Е. А. Нарушения функции внешнего дыхания у больных с острым коронарным синдромом и стабильной стенокардией. Сибирский медицинский журнал. 2009;90(7):41-3.

Klevtsova ОV, Кrasnova YN, Petukhova ЕА. Disorders of external respiration in patients with acute coronary syndrome and stable angina pectoris. Siberian Medical Journal. 2009;90(7):41-3. (In Russ.)

965

Остроумова О. Д., Голобородова И. В., Воеводина Н.Ю. и др. Бронхиальная астма и сердечно-сосудистые заболевания. Consilium Medicum. 2018;20(5):8-16. doi:10.26442/2075-1753_2018.5.8-16.

Ostroumova OD, Goloborodova IV, Voevodina NYu, et al. Asthma and cardiovascular disease. Consilium Medicum. 2018;20(5):8-16. (In Russ.) doi:10.26442/2075-1753_2018.5.8-16.

966

Cosman F, De Beur SJ, Leboff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-81. doi:10.1007/S00198-014-2794-2.

967

Paller AS, Bansal A, Simpson EL, et al. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119-31. doi:10.1007/s40257-019-00478-y.

968

Carr S, Chan ES, Watson W. Correction to: Eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2019;15:22. doi:10.1186/s13223-019-0336-3.

969

Loizou D, Enav B, Komlodi-Pasztor E, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS ONE. 2015;10(3):0113483.

970

Straumann A. Medical therapy in eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol. 2015;29(5):805-14.

971

Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500-7.

972

Chatila AT, Nguyen MTT, Krill T, et al. Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. Dis Mon. 2020;66(1):100848. doi:10.1016/j.disamonth.2019.02.001.

973

Scott HA, Gibson PG, Garg ML, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy. 2013;43(1):36-49. doi:10.1111/cea.12004.

974

Serrano-Pariente J, Plaza V, Soriano JB, et al.; CPASMA Trial Group. Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea. Allergy. 2017;72(5):802-12. doi:10.1111/all.13070.

975

Edgell H, Moore LE, Chung C, et al. Short-term cardiovascular and autonomic effects of inhaled salbutamol. Respir Physiol Neurobiol. 2016;231:14-20. doi:10.1016/j.resp.2016.05.014.

976

Olenchock BA, Fonarow GG, Pan W, et al.; Get With The Guidelines Steering Committee. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009;103(3):295-300. doi:10.1016/j.amjcard.2008.09.081.

977

Шульженко Л. В., Болотова Е. В. Эффективность и безопасность агонистов #b2-адренорецепторов ультрадлительного действия. Пульмонология. 2015;25(1):113-8. doi:10.18093/0869-0189-2015-25-1-113-118.

Shul’zhenko LV, Bolotova EV. Efficacy and safety of long-acting beta-2-agonists. PULMONOLOGIYA. 2015;25(1):113-8. (In Russ.) doi:10.18093/0869-0189-2015-25-1-113-118.

978

Агальцов М. В., Смирнова М. И. Бронхиальная астма и обструктивное апноэ сна — еще один фенотип астмы? Профилактическая медицина. 2023;26(6):124-9. doi:10.17116/profmed202326061124.

Agaltsov MV, Smirnova MI. Asthma and obstructive sleep apnea: is there another asthma phenotype? Russian Journal of Preventive Medicine and Public Health. 2023;26(6):1249. (In Russ.) doi:10.17116/profmed202326061124.

979

Cooley C, Park Y, Ajilore O, et al. Impact of interventions targeting anxiety and depression in adults with asthma. J Asthma. 2022;59(2):273-87. doi:10.1080/02770903.2020.1847927.

980

Физическая и реабилитационная медицина. Национальное руководство. Краткое издание. Под ред. Г.Н. Пономаренко. М.: ГЭОТАР-Медиа, 2017. 512 с.

Physical and rehabilitation medicine. National leadership. A short edition. Edited by G. N. Ponomarenko. M.: GEOTAR-Media, 2017. 512 p. (In Russ.)

981

Основы теории и практики медико-социальной реабилитации: руководство в 5 т. Под ред. А. И. Осадчих, С. Н. Пузина, Е. Е. Ачкасова. М.: Литтерра, 2018. Т. III. Реабилитационно-диагностические и медицинские аспекты реабилитологии. 576 с.

Fundamentals of the theory and practice of medical and social rehabilitation: a 5-volume manual. Edited by A. I. Osadchikh, S. N. Puzin, E. E. Achkasov. M.: Litterra, 2018. Vol. III. Rehabilitation, diagnostic and medical aspects of rehabilitation. 576 p. (In Russ.)

982

Rohrer V, Schmidt-Trucksass A. Impact of exercise, sport and rehabilitation therapy in asthma and COPD Ther Umsch. 2014;71(5):295-300.

983

Hennenberger PK, Liang X, Lilienberg L, et al. Occupational exposures associated with severe exacerbation of asthma. Int J Tuberc Lung Dis. 2015;19(2): 244-50.

984

Oland AA, Booster GD, Bender BG Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children. World Allergy Organ J. 2017;10(1):35.

985

Aarniala BS, Poussa T, Kvarnström J et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000;320:827-32.

986

Hasegawa K, Tsugawa Y, Lopez BL, et al. Body mass index and risk of hospitalization among adults presenting with asthma exacerbation to the emergency department. Ann Am Thorac Soc. 2014;11(9):1439-44.

987

Lim A, Stewart K, Konig K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45:931-45.

988

Eftekhari P, Forder PM, Majeed T, et al. Impact of asthma on mortality in older women: an Australian cohort study of 10,413 women. Respir Med. 2016;119:102-8.

989

Backman H, Hedman L, Stridsman C, et al. A population-based cohort of adults with asthma: mortality and participation in a long-term follow-up. Eur Clin Respir. J 2017;4:1334508.

990

Choi H, Lee H, Ryu J, et al. Bronchiectasis and increased mor tality in patients with cor ticosteroid-dependent severe asthma: a nationwide population study. Ther Adv Respir Dis. 2020;14:1753466620963030. doi:10.1177/1753466620963030.

991

Soto-Campos JG, Plaza V, Soriano JB, et al.; Grupo Emergente de Asma (GEA) del Área de Asma de la SEPAR. “Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study”. BMC Pulm Med. 2013;13:73. doi:10.1186/1471-2466-13-73.

992

Zhang P, Lopez R, Attaway AH, et al. Diabetes Mellitus Is Associated with Worse Outcome in Patients Hospitalized for Asthma. J Allergy Clin Immunol Pract. 2021;9(4):1562-9.e1. doi:10.1016/j.jaip.2020.10.054.

993

Жадова Т. А., Заикина М. В., Карпунина Н. С., Агафонов А. В. Анализ случаев смерти больных бронхиальной астмой в Пермском крае. Вестник современной клинической медицины. 2016;9(3):39-42. doi: 10.20969/VSKM.2016.9(3).39-42. EDN VZSZAP.

Zhadova TA, Zaikina MV, Karpunina NS, Agafonov AV. Analysis of deaths patients with bronchial asthma in the Perm region. The Bulletin of Contemporary Clinical Medicine. 2016;9(3):39-42. (In Russ.) EDN VZSZAP.

994

Gayle AV, Minelli C, Quint JK. Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. BMC Pulm Med. 2022;22(1):28. doi:10.1186/s12890-022-01823-4.

995

Levy ML. National Review of Asthma Deaths (NRAD). British Journal of General Practice. 2014;64(628):564. doi:10.3399/bjgp14X682237.

996

Lee H, Ryu J, Nam E, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019;54(5):1900804. doi:10.1183/13993003.00804-2019.

997

Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-12.

998

Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156:1738-45.

999

Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:1391-6.

1000

Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-6.

1001

Hu Y, Kung J, Galatis D, Banh HL. Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2022;25:193-200. doi:10.18433/jpps32738.

1002

Chang YL, Ko HK, Lu MS, et al. Independent risk factors for death in patients admitted for asthma exacerbation in Taiwan. NPJ Prim Care Respir Med. 2020;30(1):7. doi:10.1038/s41533-020-0164-4.

1003

Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am CollCardiol. 2017;69(7):841-58. doi:10.1016/j.jacc.2016.11.069.

1004

Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nature Reviews Disease Primers. 2015;1:1-20. doi:10.1038/nrdp.2015.15.

1005

Castro-Grattoni AL, Alvarez-Buvé R, Torres M, et al. Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea. Chest. 2016;149(6):1400-8. doi:10.1016/j.chest.2015.11.010.

1006

Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015;20:27-45. doi:10.1016/j.smrv.2014.07.003.

1007

Vgontzas AN, Gaines J, Ryan S, et al. CrossTalk proposal: Metabolic syndrome causes sleep apnoea. J Physiol. 2016;594(17):4687-90. doi:10.1113/JP272114.

1008

Elmasry A, Lindberg E, Hedner J, et al. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. EurRespir J. 2002;19:511-7. doi:10.1183/09031936.02.00106402.

1009

Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-98. doi:10.1016/S2213-2600(19)30198-5.

1010

Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310-8. doi:10.1016/S2213-2600(15)00043-0.

1011

McNicholas WT. Obstructive sleep apnoea and comorbidity — an overview of the association and impact of continuous positive airway pressure therapy. Expert Rev Respir Med. 2019;13(3):251-61. doi:10.1080/17476348.2019.1575204.

1012

Gleeson M, McNicholas WT. Bidirectional relationships of comorbidity with obstructive sleep apnoea. EurRespirRev. 2022;31:210-56. doi:10.1183/16000617.0256-2021.

1013

Crinion SJ, Ryan S, McNicholas WT. Obstructive sleep apnea as a cause of nocturnal nondipping blood pressure: recent evidence regarding clinical importance and underlying mechanisms. EurRespir J. 2017;49(1):1601818. doi:10.1183/13993003.01818-2016.

1014

Murphy AM, Thomas A, Crinion SJ, et al. Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. EurRespir J. 2017;49(4):1601731. doi:10.1183/13993003.01731-2016.

1015

Sjostrom C, Lindberg E, Elmasry A, et al. Prevalence of sleep apnoea and snoring in hypertensive men: a population based study. Thorax. 2002;57:602-7. doi:10.1136/thorax.57.7.602.

1016

Baguet JP, Levy P, Barone-Rochette G, et al. Masked hypertension in obstructive sleep apnea syndrome. J Hypertens. 2008;26:885-92. doi:10.1097/HJH.0b013e3282f55049.

1017

Gonçalves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest. 2007;132:1858-62. doi:10.1378/chest.07-1170.

1018

Vgontzas AN, Li Y, He F, et al. Mild-to-moderate sleep apnea is associated with incident hypertension: age effect. Sleep. 2019;42(4):zsy265. doi:10.1093/sleep/zsy265.

1019

Mokhlesi B, Finn LA, Hagen EW, et al. Obstructive Sleep Apnea during REM Sleep and Hypertension. Results of the Wisconsin Sleep Cohort. Am J Respir Crit Care Med. 2014;190:1158-67. doi:10.1164/rccm.201406-1136OC.

1020

Marrone O, Bonsignore MR. Blood-pressure variability in patients with obstructive sleep apnea: current perspectives. Nat Sci Sleep. 2018;10:229-42. doi:10.2147/NSS.S148543.

1021

Xia W, Huang Y, Peng B, et al. Relationship between obstructive sleep apnoea syndrome and essential hypertension: a dose-response meta-analysis. Sleep Med. 2018;47:11-8. doi:10.1016/j.sleep.2018.03.016.

1022

Lombardi C, Pengo MF, Parati G. Systemic hypertension in obstructive sleep apnea. J Thorac Dis. 2018;10(Suppl 34):S4231-S4243. doi:10.21037/jtd.2018.12.57.

1023

Khurshid K, Yabes J, Weiss PM, et al. Effect of antihypertensive medications on the severity of obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med. 2016;12:1143-51. doi:10.5664/jcsm.6054.

1024

Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med. 2007;167(8):757-64. doi:10.1001/archinte.167.8.757.

1025

Iftikhar IH, Valentine CW, Bittencourt LR, et al. Effects ofcontinuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens. 2014;32:2341-50. doi:10.1097/HJH.0000000000000372.

1026

Revol B, Jullian-Desayes I, Bailly S, et al. What is the best treatment strategy for obstructive sleep apnoea related hypertension? Hypertens Res. 2018;41(12):1070-2. doi:10.1038/s41440-018-0114-5.

1027

Patil SP, Ayappa IA, Caples SM, et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019;15(2):335-43. doi:10.5664/jcsm.7640.

1028

Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med. 1999;160:1101-6. doi:10.1164/ajrccm.160.4.9903020.

1029

Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure. A contemporary study of prevalence in and characteristics of 700 patients. EurJHeartFail. 2007;9:251-7. doi:10.1016/J.EJHEART.2006.08.003.

1030

Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352-60.doi:10.1161/CIRCULATIONAHA.109.901801.

1031

McNicholas WT. Obstructive Sleep Apnoea: Focus on Pathophysiology. Adv Exp Med Biol. 2022;1384:31-42. doi:10.1007/978-3-031-06413-5_3.

1032

Nicholl DD, Hanly PJ, Poulin MJ, et al. Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med. 2014;190(5):572-80. doi:10.1164/rccm.201403-0526OC.

1033

Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med. 2006;166(16):1716-22. doi:10.1001/archinte.166.16.1716.

1034

Khayat R, Jarjoura D, Porter K, et al. Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. Eur Heart J. 2015;36(23):1463-9. doi:10.1093/eurheartj/ehu522.

1035

White LH, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. J Physiol. 2013;591(5):1179-93. doi:10.1113/jphysiol.2012.245159.

1036

Kasai T, Arcand J, Allard JP, et al. Relationship between sodium intake and sleep apnea in patients with heart failure. J Am Coll Cardiol. 2011;58(19):1970-4. doi:10.1016/j.jacc.2011.08.012.

1037

Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med.2003;348(13):1233-41. doi:10.1056/NEJMoa022479.

1038

Lévy P, Ryan S, Oldenburg O, Parati G. Sleep apnoea and the heart. Eur Respir Rev. 2013;22(129):333-52. doi:10.1183/09059180.00004513.

1039

McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016;375(10):919-31. doi:10.1056/NEJMoa1606599.

1040

Fiori CZ, Martinez D, Montanari CC, et al. Diuretic or sodium-restricted diet for obstructive sleep apnea-a randomized trial. Sleep. 2018;41(4). doi:10.1093/sleep/zsy016.

1041

Stanchina ML, Ellison K, Malhotra A, et al. The impact of cardiac resynchronization therapy on obstructive sleep apnea in heart failure patients: a pilot study. Chest. 2007;132(2):433-9. doi:10.1378/chest.06-2509.

1042

Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108(1):47-51. doi:10.1016/j.amjcard.2011.02.343.

1043

Linz D, McEvoy RD, Cowie MR, et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: A Review. JAMA Cardiol. 2018;3(6):532-40. doi:10.1001/jamacardio.2018.0095.

1044

Агальцов М. В., Драпкина О. М., Давтян К. В. и др. Распространенность нарушений дыхания во сне у пациентов с фибрилляцией предсердий после перенесенного катетерного лечения. Рациональная Фармакотерапия в Кардиологии. 2019;15(1):36-42. doi:10.20996/1819-6446-2019-15-1-36-42.

Agaltsov MV, Drapkina OM, Davtyan KV, Arutyunyan GG. The prevalence of sleep breathing disorders in patients with atrial fibrillation undergoing catheter treatment. Rational Pharmacotherapy in Cardiology. 2019;15(1):36-42. (In Russ.) doi:10.20996/1819-6446-2019-15-1-36-42.

1045

Parati G, Lombardi C, Hedner J, et al. EU COST Action B26members. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J. 2013;41:523-38. doi:10.1183/09031936.00226711.

1046

Drager LF, Bortolotto LA, Pedrosa RP et al. Left atrial diameter is independently associated with arterial stiffness in patients with obstructive sleep apnea: potential implications for atrial fibrillation. Int J Cardiol. 2010;144:257-9. doi:10.1016/j.ijcard.2009.01.018.

1047

Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107:2589-94. doi:10.1161/01.CIR.0000068337.25994.21.

1048

Raghuram A, Clay R, Kumbam A et al A systematic review of the association between obstructive sleep apnea and ventricular arrhythmias. J Clin Sleep Med. 2014;10(10):1155-60. doi:10.5664/jcsm.4126.

1049

Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol. 2013;62:610-6. doi:10.1016/j.jacc.2013.04.080.

1050

Martins EF, Martinez D, da Silva FABS, et al. Disrupted day-night pattern of cardiovasculardeath in obstructive sleep apnea. Sleep Med. 2017;38:144-50. doi:10.1016/j.sleep.2017.06.027.

1051

Bassetti CLA, Randerath W, Vignatelli L, et al. EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke. Eur J Neurol. 2020;27(7):1117-6. doi:10.1111/ene.14201.

1052

Li M, Hou WS, Zhang XW, Tang ZY. Obstructive sleep apnea and risk of stroke: a meta-analysis of prospective studies. Int J Cardiol. 2014;172(2):466-9. doi:10.1016/j.ijcard.2013.12.230.

1053

Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2010;182(2):269-77. doi:10.1164/rccm.200911-1746OC.

1054

Arzt M, Young T, Finn L, et al. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005;172(11):1447-51. doi:10.1164/rccm.200505-702OC.

1055

Young T.Rationale, design and findings from the Wisconsin Sleep Cohort Study: Toward understanding the total societal burden of sleep disordered breathing. Sleep Med Clin. 2009;4(1):37-46. doi:10.1016/j.jsmc.2008.11.003

1056

Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med. 2010;6(2):131-7.

1057

Seiler A, Camilo M, Korostovtseva L, et al. Prevalence of sleep-disordered breathing after stroke and TIA: A meta-analysis. Neurology. 2019;92(7):e648-e654. doi:10.1212/WNL.0000000000006904.

1058

Menon D, Sukumaran S, Varma R, et al. Impact of obstructive sleep apnea on neurological recovery after ischemic stroke: a prospective study. Acta Neurol Scand. 2017;136:419-26.

1059

Kaneko Y, Hajek VE, Zivanovic V, et al. Relationship of sleep apnea to functional capacity and length of hospitalization following stroke. Sleep. 2003;26:293-7.

1060

Sahlin C, Sandberg O, Gustafson Y, et al. Obstructive sleep apnea is a risk factor for death in patients with stroke: a 10-year follow-up. Arch Intern Med. 2008;168:297-301.

1061

Haba-Rubio J, Vujica J, Franc Y, et al. Effect of CPAP treatment of sleep apnea on clinical prognosis after ischemic stroke: an observational study. J Clin Sleep Med. 2019;15:839-47.

1062

Parra O, Sánchez-Armengol Á, Capote F, et al. Efficacy of continuous positive airway pressure treatment on 5-year survival in patients with ischaemic stroke and obstructive sleep apnea: a randomized controlled trial. J Sleep Res. 2015;24:47-53.

1063

Li J, McEvoy RD, Zheng D, et al. Self-reported snoring patterns predict stroke events in high-risk patients with OSA: post hoc analyses of the SAVE study. Chest. 2020;158:2146-54.

1064

Brill AK, Horvath T, Seiler A, et al. CPAP as treatment of sleep apnea after stroke: a meta-analysis of randomized trials. Neurology. 2018;90:e1222-e1230.

1065

Bravata DM, Sico J, Vaz Fragoso CA, et al. Diagnosing and treating sleep apnea in patients with acute cerebrovascular disease. J Am Heart Assoc. 2018;7:e008841.

1066

Tuomilehto H, Seppä J, Uusitupa M. Obesity and obstructive of the association between obstructive sleep apnea — Clinical significance of weight loss. Sleep Med Rev. 2013;17:321-9.

1067

Resta O, Foschino-Barbaro MP, Legari G, et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord. 2001;25:669-75.

1068

Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnoea. Eur Respir J. 1995;8(7):1161-78. doi:10.1183/09031936.95.08071161.

1069

Fritscher LG, Mottin CC, Canani S, et al. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg. 2007;17:95-9.

1070

Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight loss on obstructive sleep apnea severity. ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med. 2021;203:221-9.

1071

Borel AL, Leblanc X, Almeras N, et al. Sleep apnoea attenuates the effects of a lifestyle intervention programme in men with visceral obesity. Thorax. 2012;67:735-41.

1072

Redenius R, Murphy C, O’Neill E, et al. Does CPAP lead to change in BMI? J Clin Sleep Med. 2008;4:205-9.

1073

Drager LF, Togeiro SM, Polotsky VY, et al. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62:569-76.

1074

Reutrakul S, Mokhlesi B. Obstructive sleep apnea and diabetes: a state of the art review. Chest. 2017;152:1070-86.

1075

Tahrani AA. Obstructive sleep apnoea in diabetes: does it matter? Diabetes and Vascular Disease Research. 2017;14:454-62. doi:10.1177/1479164117714397.

1076

Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012;3:126. doi:10.3389/fneur.2012.00126.

1077

Amin A, Ali A, Altaf QA, et al. Prevalence and associations of obstructive sleep apnea in south asians and white Europeans with type 2 diabetes: a cross-sectional study. Journal of Clinical Sleep Medicine. 2017;13:583-9. doi:10.5664/jcsm.6548.

1078

West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax. 2006;61:945-50. doi:10.1136/thx.2005.057745.

1079

Kent BD, Grote L, Ryan S, et al. Diabetes mellitus prevalence and control in sleep-disordered breathing: the European Sleep Apnea Cohort (ESADA) Study. Chest .2014;146:982-90.

1080

Kent BD, Grote L, Bonsignore MR, et al. Sleep apnoea severity independently predicts glycaemic health in nondiabetic subjects: the ESADA study. Eur Respir J. 2014;44:130-9.

1081

Lindberg E, Theorell-Haglöw J, Svensson M, et al. Sleep apnea and glucose metabolism: a long-term follow-up in a community-based sample. Chest. 2012;142(4):935-42. doi:10.1378/chest.11-1844.

1082

Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med. 2014;190(2):218-25. doi:10.1164/rccm.201312-2209OC.

1083

Subramanian A, Adderley NJ, Tracy A, et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care. 2019;42:954-63.

1084

Chirinos JA, Gurubhagavatula I, Teff K, et al. CPAP, weight loss or both for obstructive sleep apnea. N Engl J Med. 2014;370:2265-75.

1085

Ioachimescu OC, Anthony J, Constantin T, et al. VAMONOS (Veterans Affairs’ Metabolism, Obstructed and Non-Obstructed Sleep) study: effects of CPAP Therapy on glucose metabolism in patients with obstructive sleep apnea. J Clin Sleep Med. 2017;13:455-66.

1086

Pochetti P, Azzolina D, Ragnoli B, et al. Interrelationship among obstructive sleep apnea, renal function and survival: a cohort study. Int J Environ Res Public Health. 2020;17:4922.

1087

Hanly P. Sleep apnea and daytime sleepiness in end-stage renal disease. Semin Dial. 2004;17:109-14.

1088

Nicholl DDM, Ahmed SB, Loewen AHS, et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012;141:1422-30.

1089

Abuyassin B, Sharma K, Ayas NT, et al. Obstructive sleep apnea and kidney disease: a potential bidirectional relationship? J Clin Sleep Med. 2015;11:915-924.

1090

Lyons OD, Inami T, Perger E, et al. The effect of fluid overload on sleep apnoea severity in haemodialysis patients. Eur Respir J. 2017;49:1601789.

1091

Ahmed SB, Ronksley PE, Hemmelgarn BR, et al. Nocturnal hypoxia and loss of kidney function. PLoS One. 2011;6:e19029.

1092

Canales MT, Hagen EW, Barnet JH, et al. Sleep apnea and kidney function trajectory: results From a 20-year longitudinal study of healthy middle-aged adults. Sleep. 2017;41:zsx181.

1093

Chu H, Shih CJ, Ou SM, et al. Association of sleep apnoea with chronic kidney disease in a large cohort from Taiwan. Respirology. 2016;21:754-60.

1094

Lyons OD, Chan CT, Yadollahi A, et al. Effect of ultrafiltration on sleep apnea and sleep structure in patients with end-stage renal disease. Am J Respir Crit Care Med. 2015;191:1287-94.

1095

Beecroft JM, Zaltzman J, Prasad R, et al. Impact of kidney transplantation on sleep apnoea in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22:3028-33.

1096

Marrone O, Cibella F, Pépin JL, et al. Fixed but not autoadjusting positive airway pressure attenuates the time-dependent decline in glomerular filtration rate in patients with OSA. Chest. 2018;154:326-34.

1097

Koga S, Ikeda S, Yasunaga T, et al. Effects of nasal continuous positive airway pressure on the glomerular filtration rate in patients with obstructive sleep apnea syndrome. Intern Med. 2013;52:345-9.

1098

Rimke AN, Ahmed SB, Turin TC, et al. Effect of CPAP therapy on kidney function in patients with chronic kidney disease: a pilot randomized controlled trial. Chest. 2021;159:2008-19.

1099

Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med. 2003;167:7-14.

1100

Steveling EH, Clarenbach CF, Miedinger D, et al. Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2014;88:451-7.

1101

Greenberg-Dotan S, Reuveni H, Tal A, et al. Increased prevalence of obstructive lung disease in patients with obstructive sleep apnea. Sleep Breath. 2014;18:69-75.

1102

Zhao YY, Blackwell T, Ensrud KE, et al. Sleep apnea and obstructive airway disease in older men: outcomes of sleep disorders in older men study. Sleep. 2016;39:1343-51.

1103

Wang Y, Hu K, Liu K, et al. Obstructive sleep apnea exacerbates airway inflammation in patients with chronic obstructive pulmonary disease. Sleep Med. 2015;16:1123-30.

1104

Tuleta I, Stöckigt F, Juergens UR, et al. Intermittent hypoxia contributes to the lung damage by increased oxidative stress, inflammation, and disbalance in rotease/antiprotease system. Lung. 2016;194:1015-20.

1105

Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. Am J Respir Crit Care Med. 2010;182:325-31.

1106

Machado M-CL, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J. 2010;35:132-7.

1107

Bixler EO, Gaines J, Vgontzas AN. Obstructive sleep apnoea and depression: is there an association? Eur Respir J. 2017;49:1700858.

1108

Jehan S, Auguste E, Pandi-Perumal SR, et al. Depression, obstructive sleep apnea and psychosocial health. Sleep Med Disord. 2017;1:000012.

1109

Ong JC, Gress JL, San Pedro-Salcedo MG, et al. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J Psychosom Res. 2009;67:135–41.

1110

Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23:2324-32.

1111

Povitz M, Bolo CE, Heitman SJ, et al. Effect of treatment of obstructive sleep apnea on depressive symptoms: systematic review and meta-analysis. PLoS Med 2014; 11: e1001762.

1112

Edwards C, Mukherjee S, Simpson L, et al. Depressive symptoms before and after treatment of obstructive sleep apnea in men and women. J Clin Sleep Med. 2015;11:1029-38.

1113

Abdel Fattah MR, Jung SW, Greenspan MA, et al. Efficacy of antidepressants in the treatment of obstructive sleep apnea compared to placebo. A systematic review with meta-analyses. Sleep Breath. 2020;24:443-53.

1114

Randerath W, Bassetti CL, Bonsignore MR, et al. Challenges and perspectives in obstructive sleep apnoea: Report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society. Eur Respir J. 2018;52(3):1702616. doi:10.1183/13993003.02616-2017.

1115

Андреев Д. Н., Заборовский А. В., Трухманов А. С. и соавт. Эволюция представлений о функциональных заболеваниях желудочно-кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):4-11.

Andreev DN, Zaborovsky AV, Trukhmanov AS, et al. The evolution of ideas about functional diseases of the gastrointestinal tract in the light of the Roman criteria of the IV revision (2016). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):4-11. (In Russ.)

1116

Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014.

1117

Ивашкин В. Т., Маев И. В., Шептулин А. А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1): 50-61.

Ivashkin VT, Maev IV, Sheptulin AA, et al. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of functional dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50-61. (In Russ.)

1118

Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430-40. doi:10.1136/gutjnl-2016-313589.

1119

Chan F.K.L., Lau J. Y.W. Peptic ulcer disease. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia: Saunders Elsevier; 2015. Chap 14.

1120

Vasilenko VH, Grebenev AL, Sheptulin AA. Peptic ulcer disease. Moscow: Medicine, 1987. (In Russ.) Василенко В. Х., Гребенев А. Л., Шептулин А. А. Язвенная болезнь. М: Медицина, 1987.

Vasilenko VH, Grebenev AL, Sheptulin AA. Peptic ulcer disease. Moscow: Medicine, 1987. (In Russ.)

1121

Ивашкин В. Т., Маев И. В., Царьков П. В. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70.

Ivashkin VT, Mayev IV, Tsarkov PV, et al. Diagnosis and treatment of peptic ulcer disease in adults (Clinical recommendations of the Russian Gastroenterological Association, the Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. (In Russ.)

1122

Hawkey C.J., Wight N. J. Clinicia manual on NSAIDS and gastrointestinal complications. London: Life Science Communications, 2001.

1123

Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016:S0016-5085(16)00223-7. doi:10.1053/j.gastro.2016.02.032.

1124

Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации "Эндоскопическое общество РЭНДО" по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70-99. doi:10.22416/1382-4376-2021-31-4-70-99.

Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99. (In Russ.) doi:10.22416/1382-4376-2021-31-4-70-99.

1125

Шептулин А. А., Кайбышева В. О. Функциональная изжога и гиперчувствительность пищевода к рефлюксу. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):13-8. doi:10.22416/1382-4376-2017-27-2-13-18.

Sheptulin AA, Kaybysheva VO. Functional heartburn and reflux hypersensitivity syndrome (according to the Rome-IV functional esophageal disease diagnostic criteria). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):13-8. (In Russ.) doi:10.22416/1382-4376-2017-27-2-13-18.

1126

Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology. 2016:S0016-5085(16)00178-5. doi:10.1053/j.gastro.2016.02.012.

1127

Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70.

Ivashkin VT, Mayev IV, Lapina TL, et al. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of Helicobacter pylori infection in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.)

1128

Malfertheiner P, Megraud F, Rokkas T, et al; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. doi:10.1136/gutjnl-2022-327745.

1129

Ивашкин В. Т., Маев И. В., Абдулганиева Д. И. и др. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(2):65-91. doi:10.22416/1382-4376-2021-31-2-65-91.

Ivashkin VT, Maev IV, Abdulganieva DI, et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(2):65-91. (In Russ.) doi:10.22416/1382-4376-2021-31-2-65-91.

1130

Gesualdo M, Scicchitano P, Carbonara S, et al. The association between cardiac and gastrointestinal disorders: causal or casual link? J Cardiovasc Med (Hagerstown). 2016;17(5):330-8. doi:10.2459/JCM.0000000000000351.

1131

Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50:2021-8.

1132

Mohamed A, Ochoa Crespo D, Kaur G, et al. Gastroesophageal Reflux and Its Association With Atrial Fibrillation: A Traditional Review. Cureus. 2020;12(9):e10387. doi:10.7759/cureus.10387.

1133

Maruyama T., Fukata M., Akashi K. Association of atrial fibrillation and gastroesophageal reflux disease: natural and therapeutic linkage of the two common diseases. J Arrhythm. 2018;35:43-51. doi:10.1002/joa3.12125.

1134

Шавкута Г. В., Черкасов М. Ф., Пахомова В. М. и др. Желудок в грудной клетке, или что нам известно о гигантских грыжах пищеводного отверстия диафрагмы. Южно-Российский журнал терапевтической практики. 2021;2(1):115-20. doi:10.21886/2712-8156-2021-2-1-115-120.

Shavkuta GV, Cherkasov MF, Pakhomova VM, et al. Stomach in the chest or what we know about giant hiatal hernias. South Russian Journal of Therapeutic Practice. 2021;2(1):115-20. (In Russ.) doi:10.21886/2712-8156-2021-2-1-115-120.

1135

Xu L, Zhang Y, Xie J, et al. Association between gastroesophageal reflux disease and atrial fibrillation: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2019;111:874-9. doi:10.17235/reed.2019.5389/2017.

1136

Симаненков В. И., Маев И. В., Ткачева О. Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20 (1):2758. doi:10.15829/1728-8800-2021-2758.

Simanenkov VI, Maev IV, Tkacheva ON, et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi:10.15829/1728-8800-2021-2758.

1137

Jeremic N, Petkovic A, Srejovic I, et al. Effects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015;30:266-75. doi:10.5935/1678-9741.20150020.

1138

Saeed M, Bhandohal JS, Visco F, et al. Gastrocardiac syndrome: a forgotten entity. Am J Emerg Med. 2018;36:1525. doi:10.1016/j.ajem.2018.05.002.

1139

Qureshi K, Naeem N, Saleem S, et al. Recurrent Episodes of Paroxysmal Supraventricular Tachycardia Triggered by Dyspepsia: A Rare Case of Gastrocardiac Syndrome. Cureus. 2021;13(9):e17966. doi:10.7759/cureus.17966.

1140

Еремина Е. Ю., Зверева С. И., Козлова Л. С. Показатели вариабельности сердечного ритма у пациентов с гастроэзофагеальной рефлюксной болезнью. Экспериментальная и клиническая гастроэнтерология. 2018;(9):10-7. doi:10.31146/1682-8658-ecg-157-9-10-17.

Eremina EYu, Zvereva SI, Kozlova LS. Parameters of heart rate variability in patients with gastroesophageal reflux disease. Experimental and Clinical Gastroenterology. 2018;157(9): 10-7. (In Russ.) doi:10.31146/1682-8658-ecg-157-9-10-17.

1141

Kountouras J, Polyzos SA, Katsinelos P, et al. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-8. doi:10.1016/j.ijcard.2016.11.265.

1142

Zuin M, Rigatelli G, Del Favero G, et al. Coronary artery disease and Helicobacter pylori infection: Should we consider eradication therapy as cardiovascular prevention strategy? Int J Cardiol. 2016;223:711-2. doi:10.1016/j.ijcard.2016.08.320.

1143

Ивашкин В. Т., Шептулин А. А., Маев И. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;6:89-94.

Ivashkin VT, Sheptulin AA, Maev IV, et al. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of erosive ulcerative lesions of the stomach and duodenum caused by nonsteroidal antiinflammatory drugs. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;6:89-94. (In Russ.)

1144

Tai FWD, McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med (Lond). 2021;21(2):131-4. doi:10.7861/clinmed.2021-0039.

1145

Guo CG, Leung WK. Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract. Gut Liver. 2020;14(2):179-89. doi:10.5009/gnl19201.

1146

Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28(5):527-32. doi:10.1136/gut.28.5.527.

1147

Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-8.

1148

Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121-32. doi:10.1016/j.bpg.2009.11.005.

1149

Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021;85:1-13. doi:10.1016/j.ejim.2020.11.014.

1150

Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38. doi:10.1038/ajg.2009.115.

1151

Ивашкин В. Т., Маев И. В., Шелыгин Ю. А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95. doi:10.22416/1382-4376-2021-31-5-74-95.

Ivashkin VT, Maev IV, Shelygin YuA, et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95. (In Russ.) doi:10.22416/1382-4376-2021-31-5-74-95.

1152

Голованова Е. В. Функциональные гастроинтестинальные расстройства: подходы к коррекции психосоматических нарушений. РМЖ. 2019;5:24-9.

Golovanova EV. Functional gastrointestinal disorders: approaches to the correction of psychosomatic disorders. RMJ. 2019;5:24-9. (In Russ.)

1153

Мехтиев С. Н., Мехтиева О. А., Берко О. М. Синдром перекреста функциональных гастроинтестинальных расстройств: общие механизмы патогенеза как ключ к рациональной терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):95-103. doi:10.22416/1382-4376-2022-32-4-95-103.

Mekhdiyev SN, Mekhdieva OA, Berko OM. Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):95-103. (In Russ.) doi:10.22416/1382-4376-2022-32-4-95-103.

1154

Шептулин А. А., Кардашева С.С., Курбатова А. А. Сочетание функциональной диспепсии и синдрома раздраженного кишечника: случайная комбинация или закономерная связь? Клиническая медицина. 2020;98(4):251-5. doi:10.30629/0023-2149-2020-98-4-251-255.

Sheptulin AA, Kardasheva SS, Kurbatova AA. The overlap of functional dyspepsia and irritable bowel syndrome: a random combination or appropriate relationship? Clinical Medicine (Russian Journal). 2020;98(4):251-5. (In Russ.) doi:10.30629/0023-2149-2020-98-4-251-255.

1155

Лазебник Л. Б., Голованова Е. В., Волель Б. А. и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского Научного Медицинского Общества Терапевтов и Научного Общества Гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;192(8): 5-117. doi:10.31146/1682-8658-ecg-192-8-5-117.

Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;(8):5-117. (In Russ.) doi:10.31146/1682-8658-ecg-192-8-5-117.

1156

Топчий Н.В., Топорков А. С. Оптимизация применения нестероидных противовоспалительных препаратов в общемедицинской практике. РМЖ. 2011;2:98.

Topchiy NV, Toporkov AS. Optimization of the use of nonsteroidal anti-inflammatory drugs in general medical practice. RMJ. 2011;2:98. (In Russ.)

1157

Балабанцева А. П., Каратеев А. Е. Частота и клинико-эндоскопические особенности сочетанных НПВП-индуцированных гастроинтестинальных повреждений. Современная ревматология. 2018;12(4):95-100.

Balabantseva AP, Karateev AE. Frequency and clinical and endoscopic features of combined NSAID-induced gastrointestinal injuries. Modern rheumatology. 2018;12(4):95-100. (In Russ.)

1158

Каратеев А. Е., Гонтаренко Н. В., Цурган АВ. Коморбидная патология пищеварительной системы у больных ревматическими заболеваниями: не только НПВП-гастропатия. Научно-практическая ревматология. 2016;54(4):382.

Karateev AE, Gontarenko NV, Tsurkan AV. Comorbid pathology of the digestive system in patients with rheumatic diseases: not only NSAID-gastropathy. Scientific and practical rheumatology. 2016;54(4):382. (In Russ.)

1159

Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol. 2008;43(4):490-6. doi:10.1080/00365520701794121.

1160

Драпкина О.М., Корнеева О.Н. Поражения тонкой кишки при применении нестероидных противовоспалительных препаратов и антитромбоцитарной терапии. Подходы к профилактике и лечению. Терапевтический архив. 2016;88(12):133-9. doi:10.17116/terarkh20168812133-139.

Drapkina OM, Korneeva ON. Small bowel injuries due to nonsteroidal anti-inflammatory drugs and antiplatelet therapy. Approaches to prevention and treatment. Terapevticheskii arkhiv. 2016;88(12):133-9. (In Russ.) doi:10.17116/terarkh20168812133-139.

1161

Абдулганиева Д. И., Мясоутова Л. И. Влияние нестероидных противовоспалительных препаратов на слизистую оболочку желудочно-кишечного тракта: взгляд клинициста. Практическая медицина. 2008:25;17-9.

Abdulganieva DI, Myasoutova LI. The effect of nonsteroidal anti-inflammatory drugs on the mucous membrane of the gastrointestinal tract: a clinician’s view. Practical medicine. 2008:25;17-9. (In Russ.) Абдулганиева Д. И., Мясоутова Л. И. Влияние нестероидных противовоспалительных препаратов на слизистую оболочку желудочно-кишечного тракта: взгляд клинициста. Практическая медицина. 2008:25;17-9.

1162

Князев О. В., Шкурко Т. В., Каграманова А. В. др. Эпидемиология воспалительных заболеваний кишечника. Современное состояние проблемы (обзор литературы). Доказательная гастроэнтерология. 2020;9(2):66-73. doi:10.17116/dokgastro2020902166.

Kniazev OV, Shkurko TV, Kagramanova AV, et al. Epidemiology of inflammatory bowel disease. State of the problem (review). Russian Journal of Evidence-Based Gastroenterology. 2020;9(2):6673. (In Russ.) doi:10.17116/dokgastro2020902166.

1163

Шелыгин Ю. А., Ивашкин В. Т., Белоусова Е. А. и др. Клинические рекомендации. Язвенный колит (К51), взрослые. Колопроктология. 2023:22(1);10-44. doi:10.33878/2073-7556-2023-22-1-10-44.

Shelygin YuA, Ivashkin VT, Belousova EA, et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10-44. (In Russ.) doi:10.33878/2073-7556-2023-22-1-10-44.

1164

Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. doi:10.33878/2073-7556-2020-19-2-8-38.

Crohn’s disease. Clinical recommendations (preliminary version). Koloproktologia. 2020;19(2):8-38. (In Russ.) Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. doi:10.33878/2073-7556-2020-19-2-8-38.

1165

Сказываева Е. В., Бакулин И. Г., Авалуева Е. Б., Скалинская М. И. Первичный склерозирующий холангит и воспалительные заболевания кишечника: современные представления. Фарматека. 2018;9:10-17. doi:10.18565/pharmateca.2018.9.10-7.

Skazyvaeva EV, Bakulin IG, Avalueva EB, Skalinskaya MI. Primary sclerosing cholangitis and inflammatory bowel diseases: modern views. Pharmateca. 2018;9:10-7. (In Russ.) doi:10.18565/pharmateca.2018.9.10-7.

1166

Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102. doi:10.22416/1382-4376-2016-4-71-102.

Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71-102. (In Russ.) doi:10.22416/1382-4376-2016-4-71-102.

1167

Sarcognato S, Sacchi D, Grillo F, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021;113(3):170-84. doi:10.32074/1591-951X-245.

1168

Mertz A, Nguyen NA, Katsanos KH, Kwok RM. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019;32(2):124-33. doi:10.20524/aog.2019.0344.

1169

Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225-46. doi:10.1177/030006059702500501.

1170

Sajid MS, Hebbar M, Baig MK, et al. Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials. J Neurogastroenterol Motil. 2016;22(3):412-22. doi:10.5056/jnm16004.

1171

Ивашкин В. Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-40. doi:10.22416/1382-4376-2022-32-4-104-140.

Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-40. (In Russ.) doi:10.22416/1382-4376-2022-32-4-104-140.

1172

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi:10.1016/j.jhep.2015.11.004.

1173

Glass LM, Hunt CM, Fuchs M, Su GL. Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? Fed Pract. 2019;36(2):64-71.

1174

Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv. Ther. 2019;36:1574-94.

1175

Eguchi Y, Hyogo H, Ono M, et al.; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586-95. doi:10.1007/s00535-012-0533-z.

1176

Younossi Z, Aggarwal P, Shrestha I, et al. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4(9):100525. doi:10.1016/j.jhepr.2022.100525.

1177

Ивашкин В. Т., Драпкина О. М., Маев И. В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;(6):31-41.

Ivashkin VT, Drapkina OM, Mayev IV, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31-41. (In Russ.)

1178

Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31-55. doi:10.1016/j.immuni.2021.12.013.

1179

Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23. doi:10.1053/jhep.2003.50161. Erratum in: Hepatology. 2003;38(2):536.

1180

Shay JES, Singh A. The Effect of Obesity on Gastrointestinal Disease. Gastroenterol Clin North Am. 2023;52(2):403-15. doi:10.1016/j.gtc.2023.03.008.

1181

Pastori D, Loffredo L, Perri L, et al. Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. Am J Cardiol. 2015;115(10):1402-6. doi:10.1016/j.amjcard.2015.02.032.

1182

Peng H, Wang S, Wang M, et al. Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism. 2022;133:155220. doi:10.1016/j.metabol.2022.155220.

1183

Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016;22(16):4079-90. doi:10.3748/wjg.v22.i16.4079.

1184

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. doi:10.1097/HEP.0000000000000323.

1185

Liang Y, Chen H, Liu Y, et al. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. J Clin Endocrinol Metab. 2022;107(1):88-97. doi:10.1210/clinem/dgab641.

1186

Park J, Lee EY, Li J, et al. NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea. Dig Dis. 2021;39(6):634-45. doi:10.1159/000514953.

1187

Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557-65. doi:10.1002/hep.29085.

1188

Cai X, Zheng S, Liu Y, et al. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int. 2020;40(7):1594-600. doi:10.1111/liv.14461.

1189

Jamialahmadi O, Tavaglione F, Rawshani A, et al. Fatty liver disease, heart rate and cardiac remodelling: Evidence from the UK Biobank. Liver Int. 2023;43(6):1247-55. doi:10.1111/liv.15556.

1190

Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 2021;3(4):100305. doi:10.1016/j.jhepr.2021.100305.

1191

Rosato V, Masarone M, Dallio M, et al. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health. 2019;16(18):3415. doi:10.3390/ijerph16183415.

1192

Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021y;70(5):962-9. doi:10.1136/gutjnl-2020-322572.

1193

Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851-64. doi:10.1053/j.gastro.2020.01.052.

1194

Yi M, Peng W, Feng X, et al. Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses. Aliment Pharmacol Ther. 2022;56(7):1119-30. doi:10.1111/apt.17165.

1195

Yamazaki H, Tsuboya T, Tsuji K, et al. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes Care. 2015;38:1673-9.

1196

Chang Y, Noh YH, Suh BS, et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. J Clin Med. 2018;7(11):458. doi:10.3390/jcm7110458.

1197

Cortés VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity. Obes. Rev. 2020;21(4):e12983. doi:10.1111/obr.12983.

1198

Lyu J, Lin Q, Fang Z, et al. Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022;13:1032557. doi:10.3389/fendo.2022.1032557.

1199

Konyn P, Alshuwaykh O, Dennis BB, et al. Gallstone Disease and Its Association With Nonalcoholic Fatty Liver Disease, All-Cause and Cause-Specific Mortality. Clin Gastroenterol Hepatol. 2023;21(4):940-8.e2. doi:10.1016/j.cgh.2022.04.043.

1200

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl.) 2013;3:1-150. doi:10.1038/kisup.2012.48.

1201

Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012;56(1):225-33. doi:10.1016/j.jhep.2011.04.022.

1202

Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg. 2013;23(11):1815-25. doi:10.1007/s11695-013-0981-4.

1203

Drapkina OM, Elkina AYu, Sheptulina AF, Kiselev AR. Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives. Int. J. Mol. Sci.2023;24:8445.

1204

Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2012;97(6):2033-8. doi:10.1210/jc.2011-3010.

1205

Kim G, Kim KJ, Rhee Y, Lim SK. Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PloS One. 2017;12:e0182202.

1206

Purnak T, Beyazit Y, Ozaslan E, et al. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien. Klin. Wochenschr. 2012;124:526-31.

1207

Mózes FE, Lee JA, Selvaraj EA, et al.; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-19. doi:10.1136/gutjnl-2021-324243.

1208

Rinella ME, Lazarus JV, Ratziu V, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133. doi:10.1016/j.aohep.2023.101133.

1209

Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1-203. doi:10.4158/EP161365.GL.

1210

Кушунина Д. В., Калинина А. М., Дроздова Л. Ю. Выявление рака молочной железы в рамках диспансеризации: практика регионов. Профилактическая медицина. 2019;22(4):3742. doi:10.17116/profmed20192204137.

Kushunina DV, Kalinina AM, Drozdova LIu. Breast cancer screening: regional practices. Russian Journal of Preventive Medicine and Public Health. 2019;22(4):3742. (In Russ.) doi:10.17116/profmed20192204137.

1211

Brunetto MR, Salvati A, Petralli G, Bonino F. Nutritional intervention in the management of non-alcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 2023;62-63:101830.

1212

Loomba R, Abdelmalek MF, Armstrong MJ, et al.; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-22. doi:10.1016/S2468-1253(23)00068-7.

1213

Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-24. doi:10.1056/NEJMoa2028395.

1214

Перепеч Н. Б., Михайлова И. Е. Ингибиторы натрий-глюкозного котранспортера 2 типа: успешная погоня за двумя зайцами. Российский кардиологический журнал. 2021;26(2S):4534. doi:10.15829/1560-4071-2021-4534.

Perepech NB, Mikhailova IE. Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology. 2021;26(2S):4534. (In Russ.) doi:10.15829/1560-4071-2021-4534.

1215

Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812-21. doi:10.1111/dom.13584.

1216

Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019;42(5):931-7. doi:10.2337/dc18-1569.

1217

Roderburg C, Krieg S, Krieg A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023;28(1):153. doi:10.1186/s40001-023-01114-6.

1218

Ивашкин В. Т., Кригер А. Г., Охлобыстин А. В. и др. Клинические рекомендации Российского общества хирургов, Российской гастроэнтерологической ассоциации, Ассоциации хирургов-гепатологов и Эндоскопического общества "РЭндО" по диагностике и лечению хронического панкреатита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(2):99-156. doi:10.22416/1382-4376-2022-32-2-99-156.

Ivashkin VT, Kriger AG, Okhlobystin AV, et al. Clinical Guidelines of the Russian Society of Surgeons, the Russian Gastroenterological Association, the Association of Surgeons-Hepatologists and the Endoscopic Society “REndO” on Diagnostics and Treatment of Chronic Pancreatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):99-156. (In Russ.) doi:10.22416/1382-4376-2022-32-2-99-156.

1219

Gardner TB, Adler DG, Forsmark CE, et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322-39. doi:10.14309/ajg.0000000000000535.

1220

Mayev IV, Kucheryavy YuA. Diseases of the pancreas. Moscow: GEOTAR-Media, 2009. 736 p. (In Russ.) Маев И. В., Кучерявый Ю. А. Болезни поджелудочной железы. Москва: ГЭОТАР-Медиа, 2009. 736 с. ISBN: 978-5-9704-1002-8.

1221

DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol. 2010;26(5):490-8. doi:10.1097/MOG.0b013e32833d11b2

1222

Jupp J, Fine D, Johnson CD. The epidemiology and socioeconomic impact of chronic pancreatitis. Best Pract Res Clin Gastroenterol. 2010;24(3):219-31. doi:10.1016/j.bpg.2010.03.005.

1223

Shimizu K, Shiratori K. Chronic pancreatitis. 1. Its epidemiology and symptoms. Nihon Naika Gakkai Zasshi. 2010;99(1):36-40. Japanese. doi:10.2169/naika.99.36.

1224

Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi:10.1016/j.bpg.2007.10.007.

1225

Xiao AY, Tan ML, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016;1(1):45-55. doi:10.1016/S2468-1253(16)30004-8.

1226

Костюченко А. Л., Филин В. И. Неотложная панкреатология. СПб: Деан, 2000. 480 с.

Kostyuchenko AL, Filin VI. Emergency pancreatology. St. Petersburg: Dean, 2000. 480 p. (In Russ.)

1227

Маев И.В., Казюлин А. Н., Кучерявый Ю. А. Хронический панкреатит. М.: Медицина, 2005. 504 с.

Mayev IV, Kazyulin AN, Kucheryavy YuA. Chronic pancreatitis. M.: Medicine, 2005. 504 p. (In Russ.)

1228

Губергриц Н. Б., Христич Т. Н. Клиническая панкреатология. Донецк: Лебедь, 2000. 416 с.

Gubergritz NB, Hristich TN. Clinical pancreatology. Donetsk: Lebed, 2000. 416 p. (In Russ.)

1229

Передерий В. Г., Ткач С.М., Парунян Л.М. Частота и возможные причины экзокринной недостаточности поджелудочной железы при сахарном диабете. Украинский терапевт. 2004:2;12-6.

Perederii VG, Tkach SM, Paronian LM. Frequency and possible causes of exocrine pancreatic insufficiency in diabetes mellitus. Ukrainian Therapist. 2004:2;12-6. (In Russ.)

1230

Büchler MW, Uhl W, Malfertheiner P, et al. Diseases of the pancreas — Basel; Freiburg; Paris: Karger, 2004;212.

1231

Хатьков И. Е., Маев И. В., Абдулхаков С. Р. и соавт. Российский консенсус по диагностике и лечению хронического панкреатита. Терапевтический архив. 2017;89(2):105-13. doi:10.17116/terarkh2017892105-113.

Khatkov IE, Maev IV, Abdulkhakov SR, et al. The Russian consensus on the diagnosis and treatment of chronic pancreatitis. Terapevticheskii arkhiv. 2017;89(2):105-13. (In Russ.) doi:10.17116/terarkh2017892105-113.

1232

Andersen DK, Korc M, Petersen GM, et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017;66(5):1103-10. doi:10.2337/db16-1477.

1233

Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) — are we neglecting an important disease?. Eur J Intern Med. 2013;24(3):203-6. doi:10.1016/j.ejim.2012.12.017.

1234

Тарасова Ж. С., Бордин Д. С., Килейников Д. В., Кучерявый Ю. А. Панкреатогенный сахарный диабет: взгляд эндокринолога и гастроэнтеролога. Эффективная фармакотерапия. 2020;16(15):92-100. doi:10.33978/2307-3586-2020-16-15-92-100.

Tarasova JS, Bordin DS, Kileynikov DV, Kucheryavy Yu A. Pancreatogenic Diabetes Mellitus: Endocrinologist’s and Gastroenterologist’s Point of View. Effective pharmacotherapy. 2020;16(15):92-100. (In Russ.) doi:10.33978/2307-3586-2020-16-15-92-100.

1235

Quilliot D, Dousset B, Guerci B, et al. Evidence that diabetes mellitus favors impaired metabolism of zinc, copper and selenium in chronic pancreatitis. Pancreas. 2001;22:299-306.

1236

Кучерявый Ю. А., Оганесян Т. С. Аутоиммунный панкреатит: алгоритмы диагностики и подходы к лечению. Клинические перспективы гастроэнтерологии и гепатологии. 2010;6:3-10.

Kucheryavy YuA, Oganesyan TS. Autoimmune pancreatitis: diagnostic algorithms and treatment approaches. Clinical perspectives of gastroenterology and hepatology. 2010;6:3-10. (In Russ.)

1237

Маев И. В., Кучерявый Ю. А., Оганесян Т. С. Аутоиммунный панкреатит: Учебное пособие для системы последипломного образования врачей по специальности гастроэнтерология. М.: ФГУ "ФИРО" Минобрнауки РФ, 2011. 80 с.

Mayev IV, Kucheryavy YuA, Oganesyan TS. Autoimmune pancreatitis: A textbook for the system of postgraduate education of doctors in the specialty gastroenterology. Moscow: Federal State University “FIRO” Ministry of Education and Science of the Russian Federation, 2011. 80 p. (In Russ.)

1238

Охлобыстин А. В. Аутоиммунный панкреатит: новые представления патогенезе, диагностике и лечении. Доказательная гастроэнтерология. 2013;1:22-7.

Okhlobystin AV. Autoimmune pancreatitis: new concepts of pathogenesis, diagnosis and treatment. Evidence-based gastroenterology. 2013;1:22-7. (In Russ.)

1239

Okazaki K, Uchida K, Ikeura T, Takaoka M. Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system. J Gastroenterol. 2013;48(3):303-14.

1240

Culver EL, Sadler R, Simpson D, et al. Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. The American journal of gastroenterology. 2016;111(5):733. doi:10.1038/ajg.2016.40.

1241

Detlefsen S, Lohr JM, Drewes AM, et al. Current concepts in the diagnosis and treatment of type 1 and type 2 autoimmune pancreatitis. Recent patents on inflammation & allergy drug discovery. 2011;5(2):136-49. doi:10.2174/187221311795399228.

1242

Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139(1):140-8; quiz e12-3. doi:10.1053/j.gastro.2010.03.054.

1243

Negrelli R, Boninsegna E, Avesani G, et al. Type 1 and Type 2 Autoimmune Pancreatitis: Distinctive Clinical and Pathological Features, But Are There Any Differences at Magnetic Resonance? Experience From a Referral Center. Pancreas. 2018;47(9):1115-22. doi:10.1097/mpa.0000000000001142.

1244

Deshpande V, Gupta R, Sainani N, et al. Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance. The American journal of surgical pathology. 2011;35(1):26-35. doi:10.1097/PAS.0b013e3182027717

1245

Negrelli R, Manfredi R, Pedrinolla B, et al. Pancreatic duct abnormalities in focal autoimmune pancreatitis: MR/MRCP imaging findings. European radiology. 2015;25(2):359-67. doi:10.1007/s00330-014-3371-y.

1246

Manfredi R, Frulloni L, Mantovani W, et al. Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology. 2011;260(2):428-36. doi:10.1148/radiol.11101729.

1247

Zhao Z, Wang Y, Guan Z, et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases. Clinical and experimental rheumatology. 2016;34(1):119-25. doi:10.1097/RLU.0000000000001208.

1248

Kim HJ, Kim YK, Jeong WK, et al. Pancreatic duct "Icicle sign" on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. European radiology. 2015;25(6):1551-60. doi:10.1007/s00330-014-3548-4.

1249

Furuhashi N, Suzuki K, Sakurai Y, et al. Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT. European radiology. 2015;25(5):1366-74. doi:10.1007/s00330-014-3512-3.

1250

Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol. 2009;7(10):1097-103.

1251

Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56(12):1719-24. doi:10.1136/gut.2006.115246.

1252

Lohr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European gastroenterology journal. 2017;5(2):153-99. doi:10.1177/2050640616684695.

1253

Vujasinovic M, Hedstrom A, Maisonneuve P, et al. Zinc deficiency in patients with chronic pancreatitis. World journal of gastroenterology: WJG. 2019;25(5):600-7. doi:10.3748/wjg.v25.i5.600.

1254

Lindkvist B, Dominguez-Munoz JE, Luaces-Regueira M, et al. Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis. Pancreatology. 2012;12(4):305-10. doi:10.1016/j.pan.2012.04.006.

1255

Martinez-Moneo E, Stigliano S, Hedstrom A, et al. Deficiency of fat-soluble vitamins in chronic pancreatitis: A systematic review and meta-analysis. Pancreatology. 2016;16(6):988-94. doi:10.1016/j.pan.2016.09.008.

1256

Duggan SN, Smyth ND, O’Sullivan M, et al. The prevalence of malnutrition and fat-soluble vitamin deficiencies in chronic pancreatitis. Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition. 2014;29(3):348-54. doi:10.1177/0884533614528361.

1257

Duggan SN, Smyth ND, Murphy A, et al. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2014;12(2):219-28. doi:10.1016/j.cgh.2013.06.016.

1258

Dujsikova H, Dite P, Tomandl J, et al. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. Pancreatology. 2008;8(6):583-6. doi:10.1159/000159845.

1259

Frulloni L, Scattolini C, Falconi M, et al. et al. Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. The American journal of gastroenterology. 2009;104(9):2288-94. doi:10.1038/ajg.2009.327.

1260

Church NI, Pereira SP, Deheragoda MG, et al. et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. The American journal of gastroenterology. 2007;102(11):2417-25. doi:10.1111/j.1572-0241.2007.01531.x.

1261

Czako L, Gyokeres T, Topa L, et al. Autoimmune pancreatitis in Hungary: a multicenter nationwide study. Pancreatology. 2011;11(2):261-7. doi:10.1159/000327092.

1262

Vujasinovic M, Valente R, Maier P, et al. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatology. 2018;18(8):900-4. doi:10.1016/j.pan.2018.09.003.

1263

Lopez-Serrano A, Crespo J, Pascual I, et al. Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-centre study. Pancreatology. 2016;16(3):382-90. doi:10.1016/j.pan.2016.02.006.

1264

Ito T, Kawa S, Matsumoto A, et al. Risk Factors for Pancreatic Stone Formation in Type 1 Autoimmune Pancreatitis: A Long-term Japanese Multicenter Analysis of 624 Patients. Pancreas. 2019;48(1):49-54. doi:10.1097/mpa.0000000000001210.

1265

Maruyama M, Arakura N, Ozaki Y, et al. Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients. International journal of rheumatology. 2013;2013:272595. doi:10.1155/2013/272595.

1266

Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771-6. doi:10.1136/gutjnl-2012-30361.

1267

Kloppel G, Luttges J, Lohr M, et al. Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas. 2003;27(1):14-9. doi:10.1097/00006676-200307000-00002.

1268

Tacelli M, Celsa C, Magro B, et al. Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Metaanalysis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2019;17(6):1061-72.e8. doi:10.1016/j.cgh.2018.09.051.

1269

Ito T, Ishiguro H, Ohara H, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol. 2016;51(2):85-92. doi:10.1007/s00535-015-1149-x.

1270

Prados-Torres A. Multimorbidity Patterns in Primary Care: Interactions among Chronic Diseases Using Factor Analysis. PLoS ONE. 2012;(7):e3219.

1271

Bartkiene E, Steibliene V, Adomaitiene V, et al. Factors Affecting Consumer Food Preferences: Food Taste and Depression-Based Evoked Emotional Expressions with the Use of Face Reading Technology. Biomed Res Int. 2019;2019:2097415. doi:10.1155/2019/2097415.

1272

Bansal S, Zilberman D. Macrorelationship between Average Life Expectancy and Prevalence of Obesity: Theory and Evidence from Global Data. Agricultural Economics. 2020;51:403-27. doi:10.1111/agec.12562.

1273

Захарова А. В., Лукина Ю. В., Воронина В. П. и др. "Портрет" больного ожирением по результатам амбулаторного регистра пациентов с сердечно-сосудистыми заболеваниями "Профиль", Кардиоваскулярная терапия и профилактика. 2016;15(4):44-9. doi:10.15829/1728-8800-2016-4-44-49.

Zakharova AV, Lukina YuV, Voronina VP, et al. An obese patient “portrait” by the results of outpatient cardiovascular registry “PROFILE”. Cardiovascular Therapy and Prevention. 2016;15(4):44-9. (In Russ.) doi:10.15829/1728-8800-2016-4-44-49.

1274

Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. DMSO. 2020;13:3611-6. doi:10.2147/DMSO.S275898.

1275

Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell metabolism. 2016;23:591-601.

1276

Мустафина С.В., Малютина С.К., Рымар О.Д. и др. Эпидемиология ожирения и развитие нарушений углеводного обмена по данным проспективного исследования в Сибири. Ожирение и метаболизм. 2015;12(4):14-28. doi:10.14341/omet2015414-28.

Mustafina VS, Malyutina SK, Rymar OD, et al. The epidemiology of obesity and the development of disorders of glucose metabolism according to a prospective study in Siberia. Obesity and metabolism. 2015;12(4):14-28. (In Russ.) doi:10.14341/omet2015414-28.

1277

Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P. Obesity and diabetes-Not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7):e3042. doi:10.1002/dmrr.3042.

1278

Kannel WB. The Relation of Adiposity to Blood Pressure and Development of Hypertension. Ann Intern Med. 1967;67(1):48. doi:10.7326/0003-4819-67-1-48.

1279

Шальнова С.А., Деев А. Д., Баланова Ю.А. и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика. 2017;16(4):4-10. doi:10.15829/1728-8800-2017-4-4-10.

Shalnova SA, Deev AD, Balanova YuA, et al. Twenty years trends of obesity and arterial hypertension and their association in Russia. Cardiovascular Therapy and Prevention. 2017;16(4):4-10. (In Russ.) doi:10.15829/1728-8800-2017-4-4-10.

1280

Shariq OA, McKenzie TJ. Obesity-Related Hypertension: A Review of Pathophysiology, Management, and the Role of Metabolic Surgery. Gland Surg. 2020;9:80-93. doi:10.21037/gs.2019.12.03.

1281

Fan J, Song Y, Chen Y, et al. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: A meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761-8. doi:10.1016/j.ijcard.2013.07.230.

1282

Wing RR, Lang W, Wadden TA, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care. 2011;34(7):1481-6. doi:10.2337/dc10-2415.

1283

Klop B. Elte JW. Castro Cabezas, M. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013;5:1218-40.

1284

Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Obesity and lipotoxicity. 2017;960:1-17. doi:10.1007/978-3-319-48382-5_1.

1285

Karason, K., Jamaly, S. Heart Failure Development in Obesity: Mechanistic Pathways. European Heart Journal. 2020;41:3485. doi:10.1093/eurheartj/ehaa422.

1286

Mahajan R, Stokes M, Elliott A. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis. Heart. 2020;106:58-68.

1287

Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The Role of Obesity in Atrial Fibrillation. European heart journal. 2016;37:1565-72.

1288

Munger, T.M., Dong, Y.-X., Masaki, M., et al Electrophysiological and Hemodynamic Characteristics Associated with Obesity in Patients with Atrial Fibrillation. Journal of the American College of Cardiology 2012;60:851-60.

1289

Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20(5):437-44. doi:10.1097/MOH.0b013e3283634443.

1290

Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas. 2016;89:22-8. doi:10.1016/j.maturitas.2016.04.006.

1291

Vranić L, Mikolašević I, Milić S. Vitamin D Deficiency: Consequence or Cause of Obesity? Medicina (Kaunas). 2019;55(9):541. doi:10.3390/medicina55090541.

1292

Pasquali R, Gambineri A, Pagotto U. Review article: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG An Int J Obstet Gynaecol. 2006;113(10):1148-59. doi:10.1111/j.1471-0528.2006.00990.x

1293

Kuchenbecker WKH, Groen H, Zijlstra TM, et al. The Subcutaneous Abdominal Fat and Not the Intraabdominal Fat Compartment Is Associated with Anovulation in Women with Obesity and Infertility. J Clin Endocrinol Metab. 2010;95(5):2107-112. doi:10.1210/jc.2009-1915.

1294

Norman JE. The adverse effects of obesity on reproduction. Reproduction. 2010;140(3):343-5. doi:10.1530/REP-10-0297.

1295

Liu Y, Hu X, Xiong M, et al. Association of BMI with erectile dysfunction: A cross-sectional study of men from an andrology clinic. Front Endocrinol (Lausanne). 2023;14:1135024. doi:10.3389/fendo.2023.1135024.

1296

Lazo M, Clark J. The Epidemiology of Non-alcoholic Fatty Liver Disease: A Global Perspective. Semin Liver Dis. 2008;28(04):339-50. doi:10.1055/s-0028-1091978.

1297

Anderson EL, Howe LD, Jones HE, et al. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(10): e0140908. doi:10.1371/journal.pone.0140908.

1298

Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-5. doi:10.1007/s11894-009-0008-4.

1299

Zitt E, Fischer A, Lhotta K, et al. Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. Sci Rep. 2020;10(1):7578. doi:10.1038/s41598-020-64587-z.

1300

GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100): 1345-422. doi:10.1016/S0140-6736(17)32366-8. Erratum in: Lancet. 2017;390(10104):1736. Erratum in: Lancet. 2017;390(10106):e38.

1301

Chen J-H, Pan W-H, Hsu C-C, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: A prospective study. Arthritis Care Res (Hoboken). 2013;65(1):133-40. doi:10.1002/acr.21824.

1302

Juraschek SP, Miller ER, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010. Arthritis Care Res (Hoboken). 2013;65(1):127-32. doi:10.1002/acr.21791.

1303

Xia Y, Wu Q, Wang H, et al. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology. 2020;59(7):1529-38. doi:10.1093/rheumatology/kez476.

1304

Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: Umbrella review of the literature. BMJ. 2017;356:477.

1305

Pati S, Irfan W, Jameel A, et al. Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. Cancers (Basel). 2023;15(2):485. doi:10.3390/cancers15020485.

1306

Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284:3015-21.

1307

Pillar G, Shehadeh N. Abdominal fat and sleep apnea: The chicken or the egg? Diabetes Care. 2008;31 (Suppl. S2):S303-S309.

1308

Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol. 2013;177:1006-14.

1309

Gorbunova MV, Babak SL, Malyavin AG. Rational antihypertensive therapy in patients with obstructive sleep apnea. The Russian Archives of Internal Medicine. 2019;9(2):85-92. (In Russ.) doi:10.20514/2226-6704-2019-9-2-85-92.

1310

Duarte RLM, Magalhaes-da-Silveira FJ, Gozal D. Predictive Factors for Obstructive Sleep Apnea Diagnosis in Bariatric Surgery Candidates with or Without Chronic Insomnia Complaints. Obesity Surgery 2022;32:33-41. doi:10.1007/S11695-021-05748-5.

1311

Чижова О. Ю. Значение обструктивных апноэ сна в развитии метаболического синдрома и ожирения. Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. 2019;11:49-52. doi:10.17816/mechnikov201911249-52.

Chizhova OY. The importance of obstructive sleep apnea in the development of metabolic syndrome and obesity. HERALD of North-Western State Medical University named after I. I. Mechnikov. 2019;11(2):49-52. (In Russ.) doi:10.17816/mechnikov201911249-52.

1312

Дедов И. И., Шестакова М. В., Мельниченко Г. А. и др. Междисциплинарные клинические рекомендации "Лечение ожирения и коморбидных заболеваний". Ожирение и метаболизм. 2021;18(1):5-99. doi:10.14341/omet12714.

Dedov II, Shestakova MV, Melnichenko GA, et al. Interdisciplinary clinical practice guidelines "management of obesity and its comorbidities". Obesity and metabolism. 2021;18(1):5-99. (In Russ.) doi:10.14341/omet12714.

1313

Елиашевич С. О., Худяков М.Б., Сенько О.В. и др. Особенности питания и распределения жировой ткани у лиц группы низкого сердечно-сосудистого риска в зависимости от наличия абдоминального ожирения. Вопросы питания. 2023;92(1):74-84. doi:10.33029/0042-8833-2023-92-1-74-84.

Eliashevich SO, Khudyakov MB, Senko OV, et al. Nutrition and adipose tissue distribution in low cardiovascular risk individuals, depending on the central obesity. Voprosy pitaniia [Problems of Nutrition]. 2023;92(1):74-84. (In Russ.) doi:10.33029/0042-8833-2023-92-1-74-84.

1314

Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1):40-66. doi:10.1159/000496183.

1315

Елиашевич С. О., Дадаева В. А., Драпкина О. М. Снижение и "удержание" массы тела — известное неравенство в рамках профилактики хронических неинфекционных заболеваний. Профилактическая медицина. 2022;25(3):8591. doi:10.17116/profmed20222503185.

Eliashevich SO, Dadaeva VA, Drapkina OM. Losing and "maintaining" body weight is a well-known inequity in the prevention of chronic noncommunicable diseases. Russian Journal of Preventive Medicine and Public Health. 2022;25(3):8591. (In Russ.) doi:10.17116/profmed20222503185.

1316

Yumuk V, Tsigos C, Fried M, et al. Obesity Management Task Force of the European Association for the Study of Obesity European guidelines for obesity management in adults. Obes Facts.2015;8(6):402-24.

1317

Волкова Л. Ю., Елиашевич С. О., Шепель Р. Н., и др. Структурированный подход к изменению модели питания у взрослых пациентов с ожирением при оказании первичной медико-санитарной помощи. Профилактическая медицина. 2023;26(2):949. doi:10.17116/profmed20232602194.

Volkova LYu, Eliashevich SO, Shepel RN, et al. A structured approach to dietary modification in adult obese patients in primary care. Russian Journal of Preventive Medicine and Public Health. 2023;26(2):949. (In Russ.) doi:10.17116/profmed20232602194.

1318

Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients., Diabetes Care. 2004;27(1):155-61.

1319

Dedov II, Melnichenko GA, Troshina EA, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11(4):335-43.

1320

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892.

1321

Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation, Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2020;28:460-95.

1322

Pescatello LS, Buchner DM, Jakicic JM, et al. for the 2018 Physical activity guidelines advisory committee. Physical Activity to Prevent and Treat Hypertension: A Systematic Review. Med. Sci. Sports Exerc. 2019;51(6):1314-23.

1323

Ahima RS. Connecting Obesity, Aging and Diabetes. Nat Med. 2009;15:996-7. doi:10.1038/nm0909-996.

1324

Canizares M, Hogg-Johnson S, Gignac MAM, et al. Increasing Trajectories of Multimorbidity Over Time: Birth Cohort Differences and the Role of Changes in Obesity and Income. J Gerontol B Psychol Sci Soc Sci. 2018;73(7):1303-14. doi:10.1093/geronb/gbx004.

1325

Mujica-Mota RE, Roberts M, Abel G, et al. Common patterns of morbidity and multi-morbidity and their impact on health-related quality of life: evidence from a national survey. Qual Life Res. 2015;24(4):909-18. doi:10.1007/s11136-014-0820-7.

1326

Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):377-88. doi:10.1097/01.med.0000433067.01671.f5.

1327

Kushner RF, Ryan DH. Assessment and lifestyle Management of Patients with Obesity: clinical recommendations from systematic reviews. JAMA. 2014;312(9):943-52. doi:10.1001/jama.2014.10432.

1328

Charisse Madlock-Brown, Rebecca B. Reynolds. Identifying obesity-related multimorbidity combinations in the United States. Clinical Obesity. 2019;e12336. doi:10.1111/cob.12336.

1329

Воевода М. И., Галстян Г. Р., Шестакова М. В. и др. Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений. Российский кардиологический журнал.2019;(4):83-91. doi:10.15829/1560-4071-2019-4-83-91.

Barbarash OL, Voyevoda MI, Galstyan GR, et al. Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology. 2019;(4):83-91. (In Russ.) doi:10.15829/1560-4071-2019-4-83-91.

1330

American Diabetes Association Professional Practice Committee; 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S17-S38. doi:10.2337/DC22-S002.

1331

Hostalek U. Global epidemiology of prediabetes — present and future perspectives. Clin Diabetes Endocrinol. 2019;5(1):1-5. doi:10.1186/s40842-019-0080-0.

1332

Lailler G, Fuentes S, Kab S, et al. Prevalence and risk factors associated with prediabetes and undiagnosed diabetes in France: The national CONSTANCES cohort. Diabetes Epidemiology and Management. 2023;10:100121. doi:10.1016/j.deman.2022.100121.

1333

Hauguel-Moreau M, Hergault H, Cazabat L, et al. Prevalence of prediabetes and undiagnosed diabetes in a large urban middle-aged population: the CARVAR 92 cohort. Cardiovasc Diabetol. 2023;22(1):31. doi:10.1186/s12933-023-01761-3.

1334

Mainous AG, Tanner RJ, Baker R, et al. Prevalence of prediabetes in England from 2003 to 2011: Population-based, cross-sectional study. BMJ Open. 2014;4(6). doi:10.1136/bmjopen-2014-005002.

1335

Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013-2018. JAMA. 2021;326(24):2498-506. doi:10.1001/JAMA.2021.22208.

1336

Satman I, Bayirlioglu S, Okumus F, et al.; TURDEP-II Study Group. Estimates and Forecasts on the Burden of Prediabetes and Diabetes in Adult and Elderly Population in Turkiye. Eur J Epidemiol. 2023;38(3):313-23. doi:10.1007/s10654-022-00960-8.

1337

Rooney MR, Fang M, Ogurtsova K, et al. Global Prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388-94. doi:10.2337/dc22-2376.

1338

Tabák AG, Herder C, Rathmann W, et al. Prediabetes: A high-risk state for diabetes development. Lancet. 2012;379(9833). doi:10.1016/S0140-6736(12)60283-9.

1339

Драпкина О.М., Дроздова Л.Ю., Шепель Р.Н. и др. Анализ распространенности предиабета и реальная клиническая практика назначения медикаментозной терапии пациентам с предиабетом. Профилактическая медицина. 2022;25(12):96-105. doi:10.17116/profmed20222512196.

Drapkina OM, Drozdova LYu, Shepel RN, et al. Analysis of prediabetes prevalence and real-world practice in prescribing drug therapy to prediabetic patients. Russian Journal of Preventive Medicine and Public Health. 2022;25(12):96105. (In Russ.) doi:10.17116/profmed20222512196.

1340

Beulens JWJ, Rutters F, Rydén L, et al. Risk and management of pre-diabetes. Eur J Prev Cardiol. 2019;26(2_suppl). doi:10.1177/2047487319880041.

1341

Lindström J, Tuomilehto J. The Diabetes Risk ScoreA practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31. doi:10.2337/DIACARE.26.3.725.

1342

Дедов И. И., Шестакова М. В., Майоров А. Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144. doi:10.14341/DM221S1.

Dedov II, Shestakova MV, Mayorov AYu, et al. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov. 9th edition. Diabetes mellitus. 2019;22(1 S 1):1-144. (In Russ.) doi:10.14341/DM221S1.

1343

Мустафина С. В., Рымар О. Д., Сазонова О. В. и др. Валидизация финской шкалы риска "FINDRISC" на европеоидной популяции Сибири. Сахарный диабет. 2016;19(2):113-8. doi:10.14341/DM7630-5736.

Mustafina SV, Rymar OD, Sazonova OV, et al. Validation of the Finnish risk scale "FINDRISCUS" on the Caucasian population of Siberia. Diabetes mellitus. 2016;19(2):113-8. (In Russ.) doi:10.14341/DM7630-5736.

1344

Евстифеева С. Е., Шальнова С.А., Деев А. Д. и др. Риск сахарного диабета и его ассоциации с социально-демографическими и поведенческими факторами риска в российской популяции: данные исследования ЭССЕ-РФ. Российский кардиологический журнал. 2017;(9):13-20. doi:10.15829/1560-4071-2017-9-13-20.

Evstifeeva SE, Shalnova SА, Deev АD, et al. Diabetes risk and associations with demographic and behavioral factors in Russian population: data from the ESSE-RF study. Russian Journal of Cardiology. 2017;(9):13-20. (In Russ.) doi:10.15829/1560-4071-2017-9-13-20.

1345

Riise HKR, Graue M, Igland J, et al. Prevalence of increased risk of type 2 diabetes in general practice: a cross-sectional study in Norway. BMC Prim Care. 2023;24(1):151. doi:10.1186/s12875-023-02100-x.

1346

Nieto-Martinez R, Barengo NC, Restrepo M, et al. Large scale application of the Finnish diabetes risk score in Latin American and Caribbean populations: a descriptive study. Front Endocrinol (Lausanne). 2023;14:1188784. doi:10.3389/FENDO.2023.1188784/BIBTEX.

1347

Elshebiny A, Alrashed A, Albuwaydi Z, et al. An Assessment of the 10-Year Risk of Developing Type 2 Diabetes Among Saudi Adults Based on the Finnish Diabetes Risk Score. Cureus. 2022;14(11):e32034. doi:10.7759/cureus.32034.

1348

Sezer Ö, Lafçi NÖ, Korkmaz S, Daǧdeviren HN. Prediction of a 10-year risk of type 2 diabetes mellitus in the Turkish population A cross-sectional study. Med (United States). 2021;100(44). doi:10.1097/MD.0000000000027721.

1349

Ford JH, Lage MJ, Boye KS, et al. Five-year morbidity and mortality rates in a U.S. population with obesity with and without prediabetes. J Diabetes Complications. 2023;37(5). doi:10.1016/j.jdiacomp.2023.108454.

1350

Veronese N, Noale M, Sinclair A, et al. Risk of progression to diabetes and mortality in older people with prediabetes: The English longitudinal study on ageing. Age Ageing. 2022;51(2). doi:10.1093/ageing/afab222.

1351

Zhang X, Wu H, Fan B, et al. The role of age on the risk relationship between prediabetes and major morbidities and mortality: Analysis of the Hong Kong diabetes surveillance database of 2 million Chinese adults. Lancet Reg Health West Pac. 2022,22;30:100599. doi:10.1016/j.lanwpc.2022.100599.

1352

Breyer MK, Ofenheimer A, Altziebler J, et al. Marked differences in prediabetes- and diabetes-associated comorbidities between men and women — Epidemiological results from a general population-based cohort aged 6-80 years — The LEAD (Lung, hEart, sociAl, boDy) study. Eur J Clin Invest. 2020;50(3):e13207. doi:10.1111/eci.13207.

1353

Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65(2). doi:10.1007/s00125-021-05592-3.

1354

Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297.

1355

Khan MAB, Hashim MJ, King JK, et al. Epidemiology of Type 2 Diabetes — Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107-11. doi:10.2991/jegh.k.191028.001.

1356

Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.

1357

Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 10-й выпуск (дополненный). М.; 2021. doi:10.14341/DM12802.

Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I. I. Dedov, M. V. Shestakova, A. Y. Mayorov. 10th edition (expanded). M.; 2021. (In Russ.) doi:10.14341/DM12802.

1358

Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3-16. doi:10.1007/s00125-018-4711-2.

1359

Magliano DJ, Islam RM, Barr ELM, et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ. 2019;366:l5003.

1360

Muschik D, Tetzlaff J, Lange K, et al. Change in life expectancy with type 2 diabetes: a study using claims data from lower Saxony, Germany. Popul Health Metr. 2017;15(1):5. doi:10.1186/s12963-017-0124-6.

1361

Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51(12):2187-96. doi:10.1007/s00125-008-1156-z.

1362

Gregg EW, Zhuo X, Cheng YJ, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol. 2014;2(11):867-74. doi:10.1016/S2213-8587(14)70161-5.

1363

Cosentino F, Grant PJ, Aboyans V, et al. 2019 Рекомендации ЕSC/EASD по сахарному диабету, предиабету и сердечно-сосудистым заболеваниям. Российский кардиологический журнал. 2020;25(4):3839. doi:10.15829/1560-4071-2020-3839.

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russian Journal of Cardiology. 2020;25(4):3839. (In Russ.) doi:10.15829/1560-4071-2020-3839.

1364

Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension. 2021;78(5):1197-205. doi:10.1161/HYPERTENSIONAHA.121.17981.

1365

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2016 Executive summary. Endocrine Pract. 2016; 22(1):84-113.

1366

ElSayed NA, Aleppo G, Aroda VR, et al., American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes — 2023. Diabetes Care 2023;46(Suppl. 1):S158-S190.

1367

Кобалава Ж. Д., Колесник Э. Л., Троицкая Е. А. Современные европейские рекомендации по артериальной гипертонии: обновленные позиции и нерешенные вопросы. Клиническая фармакология и терапия. 2019;28(2):7-18. doi:10.32756/0869-5490-2019-2-7-18.

Kobalava JD, Kolesnik EL, Troitskaya EA. Modern European recommendations on arterial hypertension: updated positions and unresolved issues. Clinical pharmacology and therapy. 2019;28(2):7-18. (In Russ.) doi:10.32756/0869-5490-2019-2-7-18.

1368

Друк И.В., Нечаева Г.И. Сахарный диабет 2 типа для кардиологов. Под ред. М.Н. Мамедова. М.: МИА, 2017, 208 с.

Druk IV, Nechaeva GI. Type 2 diabetes mellitus for cardiologists. Edited by M. N. Mamedov. M.: MIA, 2017, 208 p. (In Russ.)

1369

Dunlay SM, Givertz MM, Aguilar D, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Heart Failure Society of America. Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. J Card Fail. 2019;25(8):584-619. doi:10.1016/j.cardfail.2019.05.007.

1370

Williams JG, Morris AI, Hayter RC, Ogilvie CM. Respiratory responses of diabetics to hypoxia, hypercapnia, and exercise. Thorax. 1984;39(7):529-34.

1371

Fontaine-Delaruelle C, Viart-Ferber C, Luyton C, Couraud S. Lung function in patients with diabetes mellitus. Rev Pneumol Clin. 2016;72(1):10-6.

1372

Nakajima K, Kubouchi Y, Muneyuki T, et al possible association between suspected restrictive pattern as assessed by ordinary pulmonary function test and the metabolic syndrome. Chest. 2008;134(4):712-8.

1373

Park SS, Perez Perez JL, Perez Gandara B, Agudelo CW, Rodriguez Ortega R, Ahmed H, Garcia-Arcos I, McCarthy C, Geraghty P. Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD? Medicina (Kaunas). 2022;58(8):1030. doi:10.3390/medicina58081030.

1374

Khateeb J, Fuchs E, Khamaisi M. Diabetes and Lung Disease: A Neglected Relationship. Rev Diabet Stud. 2019;15:1-15. doi:10.1900/RDS.2019.15.1.

1375

Tanase DM, Gosav EM, Costea CF, et al The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020:3920196. doi:10.1155/2020/3920196.

1376

Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab. 2021;23(5):1069-83. doi:10.1111/dom.14322.

1377

Киселева Е. В., Демидова Т. Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития. Ожирение и метаболизм. 2021;18(3):313-9. doi:10.14341/omet12758.

Kiseleva EV, Demidova TY. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021;18(3):313-9. (In Russ.) doi:10.14341/omet12758.

1378

Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother. 2021;55(1):65-79. doi:10.1177/1060028020935105.

1379

Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic Hypogonadism in Men With Diabesity. Diabetes Care. 2018;41(7):1516-25. doi:10.2337/dc17-2510.

1380

Pelusi C. The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis. Front Endocrinol (Lausanne). 2022;13:821113. doi:10.3389/fendo.2022.821113.

1381

Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022;38(2):e3494. doi:10.1002/dmrr.3494.

1382

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736-88.

1383

Sacerdote C, Ricceri F. Epidemiological dimensions of the association between type 2 diabetes and cancer: a review of observational studies. Diabetes Res Clin Pract. 2018;143:369-77.

1384

Suh S, Kim KW. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes Metab J. 2019;43(6):733-43. doi:10.4093/dmj.2019.0177.

1385

Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. J Clin Oncol. 2016;34:4261-9.

1386

Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5:10147.

1387

Петунина Н. А., Трухин И. В., Трухина Л. В. и др. Сердечная недостаточность и сахарный диабет: взгляд на коморбидность. Сахарный диабет. 2019;22(1):79-87. doi:10.14341/DM9784.

Petunina NA, Trukhin IV, Trukhina LV, et al. Heart failure and diabetes mellitus: a look at comorbidity. Diabetes mellitus. 2019;22(1):79-87. (In Russ.) doi:10.14341/DM9784.

1388

Potere N, Del Buono MG, Vecchié A, et al. Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiol Angiol. 2022;70(3):344-56. doi:10.23736/S2724-5683.22.05967-1.

1389

Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. Am J Med. 2017;130(6S):S40-S50. doi:10.1016/j.amjmed.2017.04.010.

1390

Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg) 2021;25(5):10-82. (In Russ.) Клинические рекомендации. Хроническая болезнь почек. Нефрология. 2021;25(5):10-82. doi:10.36485/1561-6274-2021-25-5-10-82.

1391

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008.

1392

Kanis JA. Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3-44.

1393

Лесняк О. М., Баранова И. А., Белова К. Ю. и др. Остеопороз в Российской Федерации: эпидемиология, медико-социальные и экономические аспекты проблемы (обзор литературы). Травматология и ортопедия России. 2018;24(1):155-68.

Lesnyak OM, Baranova IA, Belova KYu, et al. Osteoporosis in the Russian Federation: epidemiology, medical, social and economic aspects of the problem (literature review). Traumatology and orthopedics of Russia. 2018;24(1):155-68. (In Russ.)

1394

Aparicio HJ, Benjamin EJ, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update A Report from the American Heart Association. Circulation. 2021;143(8):e254-e743. doi:10.1161/CIR.0000000000000950.

1395

Von der Recke P, Hansen M. A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. American Journal of Medicine. 1999;106(3):273-8.

1396

Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcified Tissue International. 2001;68(5):271-6.

1397

Sennerby U, Melhus H, Gedeborg R, et al. Cardiovascular diseases and risk of hip fracture. JAMA. 2009;302(15):1666-73. doi:10.1001/jama.2009.1463.

1398

Varma R, Aronow WS, Basis Y, et al. Relation of bone mineral density to frequency of coronary heart disease. Am J Cardiol. 2008;101:1103-4.

1399

Gupta G, Aronow WS. Atherosclerotic vascular disease may be associated with osteoporosis or osteopenia in postmenopausal women: a preliminary study. Arch Gerontol Geriatr. 2006;43: 285-8.

1400

Tankó LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. Journal of Bone and Mineral Research. 2005;11:1912-20.

1401

Veronese N, Stubbs B, Crepaldi G, et al. Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis. J.Bone Miner Res. 2017;32(5):1126-35.

1402

Uyl D, den Nurmohamed MT, Tuyl LHD, et al. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; A systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Research and Therapy. 2011;13(1):R5.

1403

Szulc P. Abdominal aortic calcification: A reappraisal of epidemiological and pathophysiological data. Bone. 2016;84: 25-37.

1404

Galliera E, Locati M, Mantovani A, Corsi MM. Chemokines and bone remodeling. Int J Immunopathol Pharmacol. 2008;21(3):485-91. doi:10.1177/039463200802100301.

1405

Qiao JH, Mishra V, Fishbein MC, et al. Multinucleated giant cells in atherosclerotic plaques of human carotid arteries: Identification of osteoclast-like cells and their specific proteins in artery wall. Experimental and Molecular Pathology. 2015;99(3):654-62.

1406

Lampropoulos CE, Papaioannou I, D’Cruz DP. Osteoporosis — A risk factor for cardiovascular disease? Nature Reviews Rheumatology. 2012;8(10):587-98.

1407

Wade MJ. Epistasis, complex traits, and mapping genes. Genetica. 2001;112:59-69.

1408

Колчина М.А., Скрипникова И.А., Мешков А. Н. и др. Ассоциации костной массы и полигенного риска остеопороза с показателями состояния артериальной стенки. Остеопороз и остеопатии. 2022;25(2):21-30.

Kolchina MA, Skripnikova IA, Meshkov AN, et al. Associations of bone mass and polygenic risk of osteoporosis with indicators of arterial wall condition. Osteoporosis and osteopathies. 2022;25(2):21-30. (In Russ.)

1409

Pijnenburg L, Salem J-E, Lebrun-Vignes B, et al. Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study. Europ J Endocrin. 2021;184:437-44.

1410

D’Silva КМ, Cromer SJ, Elaine WYu, et al. Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study. J Bone Miner Res. 2021;36(1):52-60.

1411

Бубнова М. Г., Аронов Д. М. Кардиореабилитация: этапы, принципы и международная классификация функционирования (МКФ). Профилактическая медицина 2020;23(5):40-9.

Bubnova MG, Aronov DM. Cardiorehabilitation: stages, principles and international classification of functioning (ICF). Preventive Medicine 2020;23(5):40-9. (In Russ.)

1412

Graat-Verboom L, Wouters EF, Smeenk FW, et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209-18. doi:10.1183/09031936.50130408.

1413

Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med. 2015 2;9:5-21. doi:10.4137/CCRPM. S22803.

1414

Zhang P, Pan L. et al. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. National Library of Vtdicine.2013;10(6):650-6.

1415

Ionescu A.A., Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:46:64s-75s.

1416

Руководство для врачей "Остеопороз" под редакцией проф. О.М. Лесняк, 2-ое издание, переработанное и дополненное. ГЭОТАР-Медиа. 2023. с 416-7.

The guide for doctors "Osteoporosis" edited by Prof. O.M. Lesnyak, 2nd edition, revised and supplemented. GEOTAR Media. 2023. р. 416-7. (In Russ.)

1417

Tariq MH, Sulaiman SA. Prevalence of Osteopenia and Osteoporosis among Chronic Kidney Disease Patients: A Systematic Review. The Open Urology & Nephrology Journal. 2020;3:5-123.

1418

West SL, Lok CE, Langsetmo L, et al. Done mineral density predicts fractures in chronic kidney disease. J Bone Miner. Res. 2015;30(5):913-9 .

1419

Mazurenko SO, Mazurenko OG, Enkin AA, et al. Use of dual energy X-ray absorptiometry for assessment of fracture risk in dialysis patietns. Biomedical Engineering. 2017;51(1):20-3.

1420

Prasad B, Ferguson T, Tangri N, et al. Association of one mineral density with fractures across the spectrum of cronic kidney disease: The Regina CKD-MBD study. Can. J.Kidney Health. Dis. 2019.6:1-10.

1421

Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder. Guideline Update what’s changed and why it matters. Kidney Int. 2017;92(1):26-36.

1422

Kidney Disease: Improving Global Outcomes KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Miner and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.

1423

Vrancken I. Off label prescription of medication. Eur. J. Health. Law. 2015;22(2):165-86.

1424

Ко GJ, Obi Y, Tortorici AR, et al. Dietary protein intake and chronic kidney disease. Curr. Opin.Clin.Nutr. Metab. Care. 2017;20(1):77-85.

1425

Крутько Д. М., Мазуренко С. О., Старосельский К. М. и др. Влияние нутритивного статуса на прогноз пациентов, получающих лечение гемодиализом. Нефрология. 2019;23(4):33-51.

Krutko DM, Mazurenko SO, Staroselsky KM, et al. The effect of nutritional status on the prognosis of patients receiving hemodialysis treatment. Nephrology. 2019;23(4):33-51. (In Russ.)

1426

Тargher G, Lonardo A, Rossini M.Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest. 2015;38:817-25.

1427

Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabet Med. 2015;32:1134-42.

1428

Schwait AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int. 2003;73(6):515-9.

1429

Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2009;84(1):45-55. doi:10.1007/s00223-008-9195-5.

1430

Koromani F, Oei L, Shevroja E, et al. Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care. 2020;43(1):137-44.

1431

Ferrari SL, Abrahamsen B, Napoli N, et al.; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29(12):2585-96. doi:10.1007/s00198-018-4650-2.

1432

Caffarelli C, Pitinca MDT, Refaie AA, et al. Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes. Aging Clin and experiment. Res. 2022;34:121-7.

1433

Yamamoto M, Yamaguchi T, Yamauchi M, et al. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702-9. doi:10.1359/jbmr.081207.

1434

Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014;63(12):1480-90. doi:10.1016/j.metabol.2014.09.002.

1435

Yang S, Leslie WD, Morin SN, et al. Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study. Diabetes Obes Metab. 2016;18(9):875-81.

1436

Ferrari S, Eastell R, Napoli N, et al. Denosumab in post-menopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. 2020;134:115268.

1437

Schwartz AV. Efficacy of osteoporosis Therapies in Diabetic Patients. Calcif. Tisue Int. 2017;100(2):165-73.

1438

Hu F, Jiang C, Shen J, Tang P, Wang Y. Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury. 2012;43:676-85.

1439

Алексеева Л. И., Баранова И. А., Белосельский Н. Н. и др. Руководство по остеопорозу. Москва: ООО “Издательство "БИНОМ. Лаборатория знаний”, 2003. 524 с. ISBN: 5-9777-4056-7. EDN MWBRKM.

Alekseeva LI, Baranova IA, Beloselsky NN, et al. A guide to osteoporosis. Moscow: BINOM Publishing House, LLC. Laboratory of Knowledge”, 2003. 524 p. (In Russ.) ISBN: 5-9777-4056-7. EDN MWBRKM.

1440

Adami G, Fassio A, Rossini M, et al Osteoporosis in Rheuma tic Diseases. Int J Mol Sci. 2019;20(23):5867. doi:10.3390/ijms20235867.

1441

Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43(3):522-30. doi:10.1002/1529-0131(200003)43.

1442

Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis. 2004;63(12):1576-80. doi:10.1136/ard.2003.016253.

1443

Mori Y, Kuwahara Y, Chiba S, et al. Bone Mineral Density of Postmenopausal Women with Rheumatoid Arthritis Depends on Disease Duration Regardless of Treatment. J. Bone Miner. Metab. 2017;35:52-7. doi:10.1007/s00774-015-0716-9.

1444

Таскина Е. А., Алексеева Л. И., Дыдыкина И. С. и др. Факторы риска развития остеопороза у больных ревматоидным артритом (предварительные результаты по материалам многоцентровой программы "Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение"). Научно-практическая ревматология. 2014;52(4):393-7. doi:10.14412/1995-4484-2014-393-397.

Taskina EA, Alekseeva LI, Dydykina IS, et al. Risk factors for osteoporosis in patients with rheumatoid arthritis (preliminary results based on the materials of the multicenter program "Osteoporosis in rheumatoid arthritis: diagnosis, risk factors, fractures, treatment"). Scientific and practical rheumatology. 2014;52(4):393-7. (In Russ.) doi:10.14412/1995-4484-2014-393-397.

1445

Подворотова M.M., Дыдыкина И. С., Таскина E. A. и др. Факторы риска переломов у больных ревматоидным артритом (предварительные результаты по материалам многоцентровой программы "Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение"). Научно-практическая ревматология. 2013;51(2):154-8. doi:10.14412/1995-4484-2013-643.

Podvorotova MM, Dydykina IS, Taskina EA, et al. Risk factors for fractures in patients with rheumatoid arthritis (preliminary results based on the materials of the multicenter program "Osteoporosis in rheumatoid arthritis: diagnosis, risk factors, fractures, treatment"). Scientific and practical rheumatology. 2013;51(2):154-8. (In Russ.) doi:10.14412/1995-4484-2013-643.

1446

Добровольская О. В., Ефремова А. О., Демин Н. В., Торопцова Н. В. Минеральная плотность костной ткани и риск переломов у больных ревматическими заболеваниями. Медицинский совет. 2020;(8):120-7. doi:10.21518/2079-701X-2020-8-120-127.

Dobrovolskaya OV, Efremova AO, Demin NV, Toroptsova NV. Bone mineral density and fracture risk in patients with rheumatic diseases. Meditsinskiy sovet = Medical Council. 2020;(8):120-7. (In Russ.) doi:10.21518/2079-701X-2020-8-120-127.

1447

Xue AL, Wu SY, Jiang L, et al. Bone Fracture Risk in Patients with Rheumatoid Arthritis: A meta-Analysis. Medicine. 2017;96:e6983. doi:10.1097/MD.0000000000006983.

1448

Balasubramanian A., Wade SW, Adler RA, et al. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients with Selected Conditions. J. Bone Miner. Res. 2018;33:1881-8. doi:10.1002/jbmr.3523.

1449

Hauser B, Harre U. The Role of Autoantibodies in Bone Metabolism and Bone Loss. Calcif Tissue Int. 2018;102(5):522-32. doi:10.1007/s00223-017-0370-4.

1450

Orsolini G, Caimmi C, Viapiana O, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int. 2017;101:17-23.

1451

Llorente I, Merino L, Ortiz AM, et al. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int. 2017;37:799-806.

1452

Bugatti S, Bogliolo L, Vitolo B, et al Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18:226.

1453

Hauser B, Riches PL, Gilchrist T, et al. Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1631-2.

1454

Briot K, Durnez A, Paternotte S, et al. Bone Oedema on MRI is Highly Associated with Low Bone Mineral Density in Patients with Early Inflammatory Back Pain: Results from the DESIR Cohort. Ann. Rheum. Dis. 2013;72:1914-9. doi:10.1136/annrheumdis-2012-201845.

1455

Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754-66. doi:10.1016/j.bone.2006.03.017.

1456

Rossini M, Viapiana O, Idolazzi L, et al. Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis. Calcif. Tissue Int. 2016;98:438-45. doi:10.1007/s00223-015-0093-3.

1457

Ramirez J, Nieto-Gonzalez JC, Curbelo Rodriguez R, et al Prevalence and Risk Factors for Osteoporosis and Fractures in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. Semin. Arthritis Rheum. 2018;48:44-52. doi:10.1016/j.semarthrit.2017.12.001.

1458

Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases -- a case-control study with 53,108 patients with fracture. J Rheumatol. 2010;37(11):2247-50. doi:10.3899/jrheum.100363.

1459

Montala N, Juanola X, Collantes E, et al Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol. 2011;38(5):893-7. doi:10.3899/jrheum.100851.

1460

Tsur AM, David P, Watad A, et al. Ankylosing spondylitis and the risk of hip fractures: a matched cohort study. J Gen Intern Med. 2022;37(13):3283-8. doi:10.1007/s11606-021-07241-2.

1461

Добровольская О. В., Торопцова Н. В., Логинова Е. Ю., Коротаева Т. В. Системный остеопороз и псориатический артрит: современные представления о состоянии проблемы. Научно-практическая ревматология. 2017;55(5):566-71. doi:10.14412/1995-4484-2017-566-571.

Dobrovolskaya OV, Toroptsova NV, Loginova EYu, Korotaeva TV. Systemic osteoporosis and psoriatic arthritis: modern ideas about the state of the problem. Scientific and practical rheumatology. 2017;55(5):566-71. (In Russ.) doi:10.14412/1995-4484-2017-566-571.

1462

Wang Y, Song Z-B, Deng X-R, et al Risk factors associated with osteoporosis and fracture in psoriatic arthritis. 2021;134(21):2564-72. doi:0.1097/CM9.0000000000001810.

1463

Chen TL, Lu JW, Huang YW, et al. Bone Mineral Density, Osteoporosis, and Fracture Risk in Adult Patients with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Observational Studies.J Clin Med. 2020;9(11):3712. doi:10.3390/jcm9113712.

1464

Edens C, Robinson AB. Systemic lupus erythematosus, bone health, and osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity 2015;22(6):422-31. doi:10.1097/MED.0000000000000197.

1465

Шкиреева С. Ю., Лесняк О. М., Зоткин Е. Г. Бессимптомные компрессионные переломы позвонков у женщин в постменопаузе с системной красной волчанкой. Научно-практическая ревматология. 2017;55(1):26-31. doi:10.14412/1995-4484-2017-26-31.

Kireeva SYu, Lesnyak OM, Zotkin EG. Asymptomatic compression fractures of the vertebrae in postmenopausal women with systemic lupus erythematosus. Scientific and practical rheumatology. 2017;55(1):26-31. (In Russ.) doi:10.14412/1995-4484-2017-26-31.

1466

Tedeschi SK, Kim SC, Guan H, et al Comparative Fracture Risks Among United States Medicaid Enrollees with and Those without Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1141-6. doi:10.1002/art.40818.

1467

Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224-30.

1468

Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106-12. doi:10.1191/0961203305lu2039oa.

1469

Guo Q, Fan P, Luo J, et al. Assessment of bone mineral density and bone metabolism in young male adults recently diagnosed with systemic lupus erythematosus in China. Lupus. 2017;26(3):289-93. doi:10.1177/0961203316664596.

1470

Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995;8(3):137-45. doi:10.1002/art.1790080305.

1471

Zhu TY, Griffith JF, Au SK, et al. Bone mineral density change in systemic lupus erythematosus: a 5-year follow-up study. J Rheumatol. 2014;41(10):1990-7. doi:10.3899/jrheum.131190.

1472

Jacobs J, Korswagen LA, Schilder AM, et al. Six year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int. 2013;24(6):1827-33. doi:10.1007/s00198-012-2157-9.

1473

Almehed K, Forsblad d’Elia H, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients: extended report. Rheumatology. 2007;46:1185-90. doi:10.1093/rheumatology/ kem105.

1474

Bultink IEM. Bone Disease in Connective Tissue Disease/ Systemic Lupus Erythematosus. Calcif Tissue Int. 2018;102(5):575-91. doi:10.1007/s00223-017-0322-z.

1475

Ефремова А. О., Торопцова Н. В., Добровольская О. В. и др. Риск переломов и потребность в антиостеопоротическом лечении у больных системной склеродермией. Современная ревматология. 2021;15(1):32-7. doi:10.14412/1996-7012-2021-1-32-37

Efremova AO, Toroptsova NV, Dobrovolskaya OV, et al. The risk of fractures and the need for anti-osteoporotic treatment in patients with systemic sclerosis. Sovremennaya Revmatologiy a=Modern Rheumatology Journal. 2021;15(1):32-7. (In Russ.) doi:10.14412/1996-7012-2021-1-32-37

1476

Caimmi C, Caramaschi P, Barausse G, et al. Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis. Calcif. Tissue Int. 2016;99:23-9. doi:10.1007/s00223-016-0119-5.

1477

Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2007;21(5):885-906. doi:10.1016/j.berh.2007.06.002.

1478

Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679-87.e1. doi:10.1016/j.amjmed.2011.09.033.

1479

Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603. doi:10.1161/CIR.0000000000000485.

1480

Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217-26. doi:10.1111/j.1755-5922.2011.00277.x.

1481

Елисеев М. С., Денисов И. С., Маркелова Е. И. и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного наблюдения. Терапевтический архив. 2017;89(5):10-9. doi:10.17116/terarkh201789510-19.

Eliseev MS, Denisov IS, Markelova EI, et al. Independent risk factors for severe cardiovascular events in male patients with gout: Results of a 7-year prospective study. Terapevticheskii arkhiv. 2017;89(5):10-9. (In Russ.) doi:10.17116/terarkh201789510-19.

1482

Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. doi:10.1002/art.22014.

1483

Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxf). 2010;49(1):141-6. doi:10.1093/rheumatology/kep364.

1484

Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheum Dis. 2015;74(4):631-4. doi:10.1136/annrheumdis-2014-206432.

1485

Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022;8(2):229-39. doi:10.1016/j.ekir.2022.11.016.

1486

Nasonov EL, Eliseev MS. The role of interleukin 1 in the development of human diseases. Scientific and practical rheumatology. 2016;54(1):60-77. (In Russ.) Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi:10.14412/1995-4484-2016-60-77.

Nasonov EL, Eliseev MS. The role of interleukin 1 in the development of human diseases. Scientific and practical rheumatology. 2016;54(1):60-77. (In Russ.) doi:10.14412/1995-4484-2016-60-77.

1487

Kotur-Stevuljevic J, Memon L, Stefanovic A, et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem. 2007;40(3-4):181-7. doi:10.1016/j.clinbiochem.2006.09.007.

1488

Tsutsumi Z, Moriwaki Y, Takahashi S, et al. Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta. 2004;339:117-22. doi:10.1016/j.cccn.2003.09.019.

1489

Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-7. doi:10.1136/annrheumdis-2014-205252.

1490

Chang K, Yokose C, Tenner C, et al. Association between gout and aortic stenosis. Am J Med. 2017;130(2):230.e1-8. doi:10.1016/j.amjmed.2016.09.005.

1491

Kuo CF, Luo SF. Gout: Risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017;13(4):200-1. doi:10.1038/nrrheum.2017.27.

1492

Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):S11-S16. doi:10.1016/j.semarthrit.2020.04.008.

1493

Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826-31. doi:10.1038/ni.3790.

1494

Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi:10.1186/s13075-015-0610-9.

1495

Jaffe DH, Klein AB, Benis A, et al. Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatol. 2019;3:11. doi:10.1186/s41927-019-0060-0.

1496

Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi:10.1002/art.22466.

1497

Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-79. doi:10.1136/annrheumdis-2021-221733.

1498

Елисеев М. С., Новикова А. М., Желябина О. В. и др. Оценка сердечно-сосудистого риска у пациентов с микрокристаллическими артритами и ревматоидным артритом с помощью шкал ATP III и Reynolds Risk Score. Научно-практическая ревматология. 2020;58(5):512-9. doi:10.47360/1995-4484-2020-512-519.

Eliseev MS, Novikova AM, Zhelyabina OV, et al. Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Rheumatology Science and Practice. 2020;58(5):512-9. (In Russ.) doi:10.47360/1995-4484-2020-512-519.

1499

Andrés M, Bernal JA, Sivera F, et al. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76(7):1263-8. doi:10.1136/annrheumdis-2016-210357.

1500

Dalbeth N, Stamp LK, Taylor WJ. What is remission in gout and how should we measure it? Rheumatology (Oxford). 2021;60(3):1007-9. doi:10.1093/rheumatology/keaa853.

1501

Hochberg M. C. Mortality in osteoarthritis. Clin. exp. Rheum. 2008;26 (5 Suppl. 51):120-4.

1502

Swain S, Sarmanova A, Coupland C, et al. Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2020;72:991-1000.

1503

Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-99.

1504

Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. The Lancet. 2020;396(10264):1711-2. doi:10.1016/s0140-6736(20)32230-3.

1505

Toivanen AT, Heliövaara M, Impivaara O, et al. Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis — a population-based study with a follow-up of 22 years. Rheumatology (Oxford). 2010;49(2):308-14. doi:10.1093/rheumatology/kep388.

1506

Reyes C, Leyland KM, Peat G, et al. Association Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand Osteoarthritis: A Population-Based Cohort Study. Arthritis Rheumatol. 2016;68(8):1869-75. doi:10.1002/art.39707.

1507

Стребкова Е. А., Соловьева И. В., Шарапова Е. П. и др. Оценка влияния медикаментозной терапии ожирения на клинические проявления остеоартроза коленных суставов у женщин с избыточной массой тела. Научно-практическая ревматология. 2015;53(4):391-6.

Strebkova EA, Solovyova IV, Sharapova EP, et al. Evaluation of the effect of drug therapy for obesity on the clinical manifestations of osteoarthritis of the knee joints in overweight women. Scientific and practical rheumatology. 2015;53(4):391-6. (In Russ.)

1508

Tanamas SK. Association of weight gain with incident knee pain, stiffness, and functional difﬁculties: a longitudinal study. Arthritis care and research. 2013;65(1):34-43.

1509

Courties A, Berenbaum F, Sellam J. The Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated Osteoarthritis. Joint Bone Spine. 2019;86(6):725-30. doi:10.1016/j.jbspin.2018.12.005.

1510

Azamar-Llamas D, Hernández-Molina G, Ramos-Ávalos B, Furuzawa-Carballeda J. Adipokine Contribution to the Pathogenesis of Osteoarthritis. Mediators Inflamm. 2017;2017:5468023. doi:10.1155/2017/5468023.

1511

Ku JH, Lee CK, Joo BS, et al. Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clinical Rheumatology. 2009;28(12):1431-5.

1512

Karvonen-Gutierrez CA, Harlow SD, Mancuso P, et al. Association of leptin levels with radiographic knee osteoarthritis among a cohort of midlife women. Arthritis Care and Research. 2013;65(6):936-44.

1513

van Caam A, Thijssen E, van der Kraan PM. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. Rheumatology. 2014;54(4):588-600.

1514

Runhaar J, van Middelkoop M, Reijman M, et al. Malalignment: a possible target for prevention of incident knee osteoarthritis in overweight and obese women. Rheumatology. 2014;53(9):1618-24.

1515

Stenholm S, Alley D, Bandinelli S, et al. The effect of obesity combined with low muscle strength on decline in mobility in older persons: results from the InCHIANTI study. Int J Obes (Lond). 2009;33(6):635-44.

1516

Marshall DA, Liu X, Barnabe C, et al. Existing comorbidities in people with osteoarthritis: a retrospective analysis of a population-based cohort in Alberta, Canada. BMJ Open. 2019;9(11):e033334. doi:10.1136/bmjopen-2019-033334.

1517

Yoshimura N, Muraki S, Oka H, et al. Accumulation Of Metabolic Risk Factors Such As Overweight, Hypertension, Dyslipidaemia, And Impaired Glucose Tolerance Raises The Risk Of Occurrence And Progression Of Knee Osteoarthritis: A 3-Year Follow-Up Of The Road Study. Osteoarthritis Cartilage. 2012;20(11):1217-26. doi:10.1016/j.joca.2012.06.006.

1518

Ding X, Zeng C, Wei J, et al. The associations of serum uric acid level and hyperuricemia with knee osteoarthritis. Rheumatol Int. 2016;36(4):567-73.

1519

Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol. 1995;22(6):1118-23.

1520

Dellisola A, Allan R, Smith S, et al. Identification Of Clinical Phenotypes In Knee Osteoarthritis: A Systematic Review Of The Literature. Bmc Musculoskelet Disord. 2016;17(1):425.

1521

Стребкова Е. А., Алексеева Л. И. Остеоартроз и метаболический синдром. Фарматека. 2015;(17):15-19.

Strebkova EA, Alekseeva LI. Osteoarthritis and metabolic syndrome. Pharmateca. 2015;(17):15-19. (In Russ.)

1522

Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505-14. doi:10.1002/art.1780340502.

1523

Драпкина О. М., Самородская И. В., Старинская М. А. и др. Ожирение: оценка и тактика ведения пациентов. М.: ФГБУ "НМИЦ ТПМ" Минздрава России; ООО "Силицея-Полиграф". 2021. с. 174.

Drapkina OM, Samorodskaya IV, Starinskaya MA, et al. Obesity: assessment and tactics of patient management. Moscow: FSBI "NMIC TPM" Ministry of Health of the Russian Federation; LLC "Silicea-Polygraph". 2021. p. 174. (In Russ.)

1524

Hochberg MC, Martel-Pelletier J, Monfort J, et al.; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75(1):37-44. doi:10.1136/annrheumdis-2014-206792.

1525

Pelletier J, Raynauld J, Paiement P, et al. In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms [abstract]. Arthritis Rheumatol. 2019;71 (suppl 10). ACR 2019.

1526

Yang W, Sun C, He SQ, et al. The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis — a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021;36(7):2085-93.

1527

Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9.

1528

Mazzucchelli R, Rodríguez-Martín S, García-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS One. 2021;16(7):e0253932.

1529

Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Клинические рекомендации Рациональное использование нестероидных противовоспалительных препаратов. Научно-практическая ревматология. 2018;56:1-29.

Karateev AE, Nasonov EL, Ivashkin VT, et al. Clinical recommendations Rational use of nonsteroidal antiinflammatory drugs. Scientific and practical rheumatology. 2018;56:1-29. (In Russ.)

1530

Галушко Е. А., Большакова Т. В., Виноградова И. Б. и др. Cтруктура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;1:11-7.

Galushko EA, Bolshakova TV, Vinogradova IB, et al. The structure of rheumatic diseases among the adult population of Russia according to epidemiological research (preliminary results). Scientific and practical rheumatology. 2009;1:11-7. (In Russ.)

1531

Van Dijk GM, Veenhof C, Schellevis F, et al. Comorbidity limitations in activities and pain in patients with osteoarthritis of the hip and knee. BMC Musculoskeletal disorders. 2008;9:95-103.

1532

Алексеева Л.И., Зайцева Е. М. Роль субхондральной кости при остеоартрозе. Научно-практическая ревматология. 2009; 47(4):41-8.

Alekseeva LI, Zaitseva EM. The role of the subchondral bone in osteoarthritis. Scientific and practical rheumatology. 2009; 47(4):41-8. (In Russ.)

1533

Lajeunesse D. The role of bone in treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12 Suppl A:S34-8.

1534

Ding C, Cicuttini F, Boon C, et al. Knee and hip radiographic osteoarthritis predict total hip bone loss in older adults: a prospective study. J Bone Miner Res. 2010;25(4):858-65. doi:10.1359/jbmr.091012.

1535

Bettica P, Cline G, Hart DJ, et al. Evidence for increased bone resoption in patients with progressive knee osteoarthritis. Arthritis Rheum. 2002;46(12):3178-84.

1536

Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050-5.

1537

Ding M, Odgaard A, Hvid I. Changes in the three-dimensional microstructure of human tibial cancellous bone in early osteoarthritis. J Bone Joint Surg Br. 2003;85:906-12.

1538

Carbone LD, Nevitt MC, Wildy K. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 2004;50(11):3516-25.

1539

Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of asteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50(4):1193-206.

1540

Rizzoli R, Larochc M, Kreig MA, et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis Rheumatology Int. 2010;30:1341-8.

1541

Salis Z, Sainsbury A, Keen H, et al. Weight loss is associated with reduced risk of knee and hip replacement: A survival analysis using Osteoarthritis Initiative data. Int J Obes (Lond). 2022;46(4):874-84.

1542

Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: a narrative review. Am J Geriatr Pharmacother. 2011;9(6):378-91. doi:10.1016/j.amjopharm.2011.10.002.

1543

Low LF, Yap M, Brodaty H. A systematic review of different models of home and community care services for older persons. BMC Health Serv Res. 2011;11(1):93. doi:10.1186/1472-6963-11-93.

1544

Kirkwood TB. A systematic look at an old problem. Nature. 2008;451(7179):644-7. doi:10.1038/451644a.

1545

Steves CJ, Spector TD, Jackson SH. Ageing, genes, environment and epigenetics: what twin studies tell us now, and in the future. Age Ageing. 2012;41(5):581-6. doi:10.1093/ageing/afs097.

1546

Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487-92.

1547

Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009; 5(4):210-20.

1548

Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430-9. doi:10.1016/j.arr.2011.03.003.

1549

Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):35763. doi:10.1370/afm.983.

1550

Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008;8:221. doi:10.1186/1471-2458-8-221.

1551

Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. European Heart Journal. 2014;35(26):1726-31. doi:10.1093/eurheartj/ehu197.

1552

Australian Institute of Health and Welfare (AIHW): Chronic diseases and associated risk factors in Australia. 2006. Canberra, ACT; 2006. р. 96. ISBN: 978 1 74024 619 4.

1553

Olshansky SJ, Goldman DP, Zheng Y, Rowe JW. Aging in America in the twenty-first century: demographic forecasts from the MacArthur Foundation Research Network on an aging society. The Milbank Quarterly. 2009;87(4):842-62.

1554

Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-78.

1555

Held FP, Blyth F, Gnjidic D, et al. Association Rules Analysis of Comorbidity and Multimorbidity: The Concord Health and Aging in Men Project. J Gerontol A Biol Sci Med Sci. 2016;71(5):625-31. doi:10.1093/gerona/glv181.

1556

Vetrano DL, Foebel AD, Marengoni A, et al. Chronic diseases and geriatric syndromes: The different weight of comorbidity. Eur J Intern Med. 2016;27:62-7.

1557

Franck L, Molyneux N, Parkinson L. Systematic review of interventions addressing social isolation and depression in aged care clients. Qual Life Res. 2016;25(6):1395-407. doi:10.1007/s11136-015-1197-y.

1558

Molinari E, Spatola C, Pietrabissa G, et al. The Role of Psychogeriatrics in Healthy Living and Active Ageing. Stud Health Technol Inform. 2014;203:122-33.

1559

Jonsson R, Sixt E, Landahl S, Rosenhall U. Prevalence of dizziness and vertigo in an urban elderly population. J Vestib Russ. 2004;14(1):47-52.

1560

Barin K., Dodson E. Dizziness in the elderly. Otolaringoe Clin North Am. 2011;44(2):437-54. doi:10.1016/j.otc.2011.01.013.

1561

Замерград М. В. Нарушения равновесия у пожилых. Неврология, нейропсихиатрия, психосоматика. 2012;4(1):101-5. doi:10.14412/2074-2711-2012-371.

Zamergrad MV. Imbalances in the elderly. Neurology, neuropsychiatry, psychosomatics. 2012;4(1):101-5. (In Russ.) doi:10.14412/2074-2711-2012-371.

1562

Wright JM, Beaudart C, Zaaria M, et al. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169548. doi:10.1371/journal.pone.0169548

1563

von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129-33. doi:10.1007/s13539-010-0014-2.

1564

Chen L, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300-7.e2. doi:10.1016/j.jamda.2019.12.012.

1565

Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016;57:58-67. doi: 10.1016/j.ejca.2015.12.030.

1566

Collamati A, Marzetti E, Calvani R, et al Sarcopenia in heart failure: mechanisms and therapeutic strategies. J GeriatrCardiol. 2016;13(7):615-24. doi:10.11909/j.issn.1671-5411.2016.07.004.

1567

Hirai K, Ookawara S, Morishita Y. Sarcopenia and Physical Inactivity in Patients With Chronic Kidney Disease. Nephrourol Mon. 2016;26;8(3):e37443. doi:10.5812/numonthly.37443.

1568

Nichols S, O’Doherty A, Taylor C, et al. Low skeletal muscle mass is associated with low aerobic capacity and increased mortality risk in patients with coronary heart disease — a CARE CR study. Clin Physiol Funct Imaging. 2019;39(1):93-102. doi:10.1111/cpf.12539.

1569

Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008;18(5):388-95. doi:10.1016/j.numecd.2007.10.002.

1570

Гасанов М. З. Молекулярные аспекты патогенеза саркопении при хронической болезни почек: интегративная роль mTOR. Нефрология. 2018;22(5):9-16. doi:10.24884/1561-6274-2018-22-5-9-16.

Gasanov MZ. molecular aspects of sarcopenia pathogenesis in chronoc kidney disease: integrated role of mTOR. Nephrology (Saint-Petersburg). 2018;22(5):9-16. (In Russ.) doi:10.24884/1561-6274-2018-22-5-9-16.

1571

Гасанов М. З. Саркопения у пациентов с хронической болезнью почек: распространенность, особенности патогенеза и клиническое значение. Нефрология. 2021;25(1):47-58. doi:10.36485/1561-6274-2021-25-1-47-58.

Gasanov MZ. Sarcopenia in patients with chronic kidney disease: prevalence, pathogenesis and clinical significance. Nephrology (Saint-Petersburg). 2021;25(1):47-58. (In Russ.) doi:10.36485/1561-6274-2021-25-1-47-58.

1572

Scott D, de Courten B, Ebeling P. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? Med J Aust. 2016;205(7):329-33. doi:10.5694/mja16.00446.

1573

Zhang Y, Hao Q, Ge M., Dong B. Association of sarcopenia and fractures in community-dwelling older adults: a systematic review and meta-analysis of cohort studies. Osteoporos Int. 2018;29(6):1253-62. doi:10.1007/s00198-018-4429-5.

1574

Dos Santos L, Cyrino E, Antunes M, et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017;8(2):245-50. doi:10.1002/jcsm.12160.

1575

Hayashi T, Umegaki H, Makino T, et al. Association between sarcopenia and depressive mood in urban-dwelling older adults: A cross-sectional study. Geriatr Gerontol Int. 2019;19(6):508-12. doi:10.1111/ggi.13650.

1576

Tsekoura M, Kastrinis A, Katsoulaki M, et al. Sarcopenia and Its Impact on Quality of Life. Adv Exp Med Biol. 2017;987:213-8. doi:10.1007/978-3-319-57379-3_19.

1577

Мокрышева Н. Г., Крупинова Ю. А., Володичева В. Л., Мирная С. С., Мельниченко Г. А. и др. Саркопения глазами эндокринолога. Остеопороз и остеопатии. 2019;22(4):19-26. doi:10.14341/osteo12465.

Mokrysheva NG, Krupinova JA, Volodicheva VL, et al. A view at sarcopenia by endocrinologist. Osteoporosis and Bone Diseases. 2019;22(4):19-26. (In Russ.) doi:10.14341/osteo12465.

1578

Григорьева И. И., Раскина Т. А., Летаева М.В и др. Саркопения: особенности патогенеза и диагностики. Фундаментальная и клиническая медицина. 2019;4(4):105-16. doi:10.23946/2500-0764-2019-4-4-105-116.

Grigorieva II, Raskina TA, Letaeva MV, et al. Sarcopenia: pathogenesis and diagnosis. Fundamental and Clinical Medicine. 2019;4(4):105-16. (In Russ.) doi:10.23946/2500-0764-2019-4-4-105-116.

1579

Rodríguez-Mañas L, Féart C, Mann G, et al. Searching for an Operational Definition of Frailty: A Delphi Method Based Consensus Statement. The Frailty Operative Definition-Consensus Conference Project. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2013;68(1):62-7. doi:10.1093/gerona/gls119.

1580

Ткачева О. Н., Котовская Ю. В., Рунихина Н. К. и др. Комплексная гериатрическая оценка у пациентов пожилого и старческого возраста с сердечно-сосудистыми заболеваниями. Экспертное мнение Российской Ассоциации геронтологов и гериатров. Кардиология. 2021;61(5):71-8. doi:10.18087/cardio.2021.5.n1349.

Tkacheva ON, Kotovskaya YuV, Runihina NK, et al. Comprehensive geriatric assessment in elderly and senile patients with cardiovascular diseases. Expert opinion of the Russian Association of Gerontologists and Geriatricians. Kardiologiia. 2021;61(5):71-8. (In Russ.) doi:10.18087/cardio.2021.5.n1349.

1581

Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. doi:10.1093/gerona/56.3.m146.

1582

Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Scientific World J. 2001;1:323-36.

1583

Vermeiren S, Vella-Azzopardi R, Beckwée D, et al.; Gerontopole Brussels Study group. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. J Am Med Dir Assoc. 2016;17(12):1163.e1-1163.e17. doi:10.1016/j.jamda.2016.09.010.

1584

Weiss OC. Frailty and Chronic Diseases in Older Adults. Clin. Geriatr. Med. 2011;27:39-52.

1585

Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752-62. doi:10.1016/S0140-6736(12)62167-9. Erratum in: Lancet. 2013;382(9901):1328.

1586

Kojima G. Prevalence of frailty in nursing homes: A systematic review and metaanalysis. J.Am. Med. Dir. Assoc. 2015;16:940-5.

1587

Tkacheva ON, Ostapenko VS. The prevalence of geriatric syndroms among patient in Moscow outpatient setting. European Geriatric Medicine. 2016;7(1):114.

1588

Саприна Т. В., Файзулина Н. М. Сахарный диабет 2 типа у лиц пожилого возраста — решенные и нерешенные вопросы. Сахарный диабет. 2016;19(4):322-30.

Saprina TV, Fayzulina NM. Type 2 diabetes mellitus in the elderly — resolved and unresolved issues. Diabetes mellitus. 2016;19(4):322-30. (In Russ.)

1589

Хмельницкий А. В., Седова Е. В., Белоусова О.Н. и др. Влияние синдрома старческой астении на исходы в зависимости от выбранной тактики лечения у пациентов с острым коронарным синдромом. Современные проблемы науки и образования. 2017;(3):4-5. 2017;(3):4-5. (In Russ.) Хмельницкий А. В., Седова Е. В., Белоусова О.Н. и др. Влияние синдрома старческой астении на исходы в зависимости от выбранной тактики лечения у пациентов с острым коронарным синдромом. Современные проблемы науки и образования. 2017;(3):4-5.

Khmelnitsky AV, Sedova EV, Belousova ON, et al. The effect of senile asthenia syndrome on outcomes, depending on the chosen treatment tactics in patients with acute coronary syndrome. Modern problems of science and education. 2017;(3):4-5. (In Russ.)

1590

Ткачева О. Н., Рунихина Н. К., Остапенко В. С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30(2):236-42.

Tkacheva ON, Runikhina NK, Ostapenko VS, et al. Validation of the questionnaire for screening of senile asthenia syndrome in outpatient practice. The successes of gerontology. 2017;30(2):236-42. (In Russ.) Ткачева О. Н., Рунихина Н. К., Остапенко В. С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30(2):236-42.

1591

Ткачева О. Н., Котовская Ю. В., Рунихина Н.К. и др. Клинические рекомендации "Старческая астения". Российский журнал гериатрической медицины. 2020;1:11-46. doi:10.37586/2686-8636-1-2020-11-46.

Tkacheva ON, Kotovskaya YuV, Runikhina NK, et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020;(1):11-46. (In Russ.) doi:10.37586/2686-8636-1-2020-11-46.

1592

Shrauner W, Lord EM, Nguyen XT, et al. Frailty and cardiovascular mortality in more than 3 million US Veterans. Eur Heart J. 2022;43(8):818-26. doi:10.1093/eurheartj/ehab850.

1593

Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022.

1594

Mitnitski A, Howlett SE, Rockwood K. Heterogeneity of Human Aging and Its Assessment. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2016;72(7):877-84. doi:10.1093/gerona/glw089.

1595

Foebel AD, Hirdes JP, Heckman GA, et al. A profile of older community-dwelling home care clients with heart failure in Ontario. Chronic Diseases in Canada. 2011;31(2):49-57.

1596

Dodson JA, Truong T-TN, Towle VR, et al. Cognitive Impairment in Older Adults with Heart Failure: Prevalence, Documentation, and Impact on Outcomes. The American Journal of Medicine. 2013;126(2):120-6. doi:10.1016/j.amjmed.2012.05.029.

1597

Perry LP. To All Doctors: What You Can Do to Help as a Bunch of Older People Are About to Get Sick and Die. J Am Geriatr Soc. 2020; 68(5):944-6. doi:10.1111/jgs.16482.

1598

Cruz-Jentoft AJ, Bahat G, Bauer J, et al Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169.

1599

Braun T, Gruneberg C, Thiel C. German translation, cross-cultural adaptation and diagnostic test accuracy of three frailty screening tools: PRISMA-7, FRAIL scale and Groningen Frailty Indicator. Z Gerontol Geriatr. 2018;51(3):282-92. doi:10.1007/s00391-017-1295-2.

1600

Sourial N, Bergman H, Karunananthan S, et al. Implementing Frailty Into Clinical Practice: A Cautionary Tale. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2013;68(12):1505-11. doi:10.1093/gerona/glt053.

1601

Ткачева О. Н., Рунихина Н. К., Бабенко И. В. и др. Современная гериатрия для врачей первичного звена здравоохранения: Методическое пособие. 2-е издание. М.: Прометей, 2021. 174 с.

Tkacheva ON, Runikhina NK, Babenko IV, et al. Modern geriatrics for primary care physicians: A methodological guide. 2nd edition. Moscow: Prometheus, 2021. 174 p. (In Russ.)

1602

Ушкалова Е. А., Ткачева О. Н., Рунихина Н. К. и др. Особенности фармакотерапии у пожилых пациентов. Введение в проблему. Рациональная Фармакотерапия в Кардиологии. 2016;12(1):94-100. doi:10.20996/1819-6446-2016-12-1-94-100.

Ushkalova EA, Tkacheva ON, Runikhina NK, et al. Features of pharmacotherapy in the elderly patients. Introduction to the problem. Rational Pharmacotherapy in Cardiology. 2016;12(1):94-100. (In Russ.) doi:10.20996/1819-6446-2016-12-1-94-100.

1603

Charlesworth CJ, Smit E, Lee DS, et al. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989-95.

1604

Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2(4):274-302.

1605

Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. doi:10.1517/14740338.2013.827660.

1606

Беловол А. Н., Князькова И. И. Клиническая фармакология в гериатрии. Medix Anti-aging. 2012;1(25):50-5.

Belovol AN, Knyazkova II. Clinical pharmacology in geriatrics. Medix Anti-aging. 2012;1(25):50-5. (In Russ.) Беловол А. Н., Князькова И. И. Клиническая фармакология в гериатрии. Medix Anti-aging. 2012;1(25):50-5.

1607

Wong DF, Pearlson GD, Tune LE, et al. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab. 1997;17(3):331-42.

1608

Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014;36(11):1489-511.

1609

Topinková E, Baeyens JP, Michel JP, Lang PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29(6):477-94.

1610

Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older subjects from ongoing clinical trials in heart failure. Arch Intern Med. 2011;171(6):550-6.

1611

Tjia J, Velten SJ, Parsons C, et al. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013;30:285-307.

1612

Rossi MI, Young A, Maher R, et al. Polypharmacy and health beliefs in older outpatients. Am J Geriatr Pharmacother. 2007;5:317-23.

1613

Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay and inpatient mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67:507-19.

1614

Bronskill S, Sudeep S, Gill MD, et al. Exploring variation in rates of polypharmacy across long term care homes. JAMDA. 2012:309, e15-e21.

1615

Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46-54.

1616

Lattanzio F, Landi F, Bustacchini S, et al. Geriatric conditions and the risk of adverse drug reactions in older adults: a review. Drug Saf. 2012;35 Suppl 1:55-61.

1617

Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):CD000011.

1618

Bloom BS. Daily regimen and compliance with treatment. BMJ. 2001;323(7314):647.

1619

Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61.

1620

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.

1621

Bridle C, Spanjers K, Patel S, et al. Effect of exercise on depression severity in older people: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2012;201:180-5.

1622

Dickens AP, Richards SH, Greaves CJ, et al. Interventions targeting social isolation in older people: a systematic review. BMC Public Health. 2011;11:647.

1623

Cruwys T, Dingle GA, Haslam C, et al. Social group memberships protect against future depression, alleviate depression symptoms and prevent depression relapse. Soc Sci Med. 2013;98:179-86.

1624

Forsman AK, Schierenbeck I, Wahlbeck K. Psychosocial interventions for the prevention of depression in older adults: systematic review and meta-analysis. J Aging Health. 2011;23:387-416.

1625

Alamo C, Lopez-Munoz F, Garcia-Garcia P, Garsia-Ramos S. Risk-benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics. 2014;14(4):261-8.

1626

Sultana J, Spina EG. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol. 2015;11(6):883-92.

1627

MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian journal of psychiatry. 2016;61(9):588-603.

1628

Косивцева О. В., Яворская С. А., Фатеева Т. Г. Лечение вестибулярного головокружения у полиморбидного пациента. Неврология, нейропсихиатрия и психосоматика. 2018;10(1): 96-101.

Kosintseva OV, Yavorskaya SA, Fateeva TG. Treatment of vestibular vertigo in a polymorbid patient. Neurology, neuropsychiatry and psychosomatics. 2018;10(1): 96-101. (In Russ.)

1629

Кунильская Н. Л., Гусева А. Л., Байбакова Е. В. и др. Головокружение в пожилом возрасте: особенности течения и возможности реабилитации. Consilium Medicum. 2017; 19(2.1): 94-7.

Kunelskaya NL, Guseva AL, Baibakova EV, et al. Dizziness in old age: features of the course and possibilities of rehabilitation. Consilium Medicum. 2017; 19(2.1): 94-7. (In Russ.)

1630

Furman JM, Hain TC. "Do try this at home": self-treatment of BPPV. Neurology. 2004;63(1):8-9. doi:10.1212/01.wnl.0000133548.86475.fa.

1631

Brandt T, Dieterich M. Vertigo and dizziness: common complains. London: Springer. 2004; 503 p. doi:10.1007/978-0-85729-591-0. ISBN: 978-1-4471-5925-4.

1632

Teggi R, Giordano L, Bondi S, et al. Residual dizziness after successful repositioning maneuvers for idiopathic bening paroxysmal positional vert: go in the elderly. Eur arch Otorhinolaryndol. 2011;268(4):507-11.

1633

Lowsky DJ, Olshansky SJ, Bhattacharya J, Goldman DP. Heterogeneity in healthy aging. J Gerontol A Biol Sci Med Sci. 2014; 69(6):640-9. doi:10.1093/gerona/glt162.

1634

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012; 2:1-138.

1635

Chawla L, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nature Reviews Nephrology. 2017;13(4):241-57. doi:10.1038/nrneph.2017.2.

1636

Piccinni P, Cruz DN, Gramaticopolo S, et al.; NEFROINT investigators. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol. 2011;77:1072-83.

1637

Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72:208-12.

1638

Lewington AJP, Cerda J, Mehta RL. Raising awareness of Acute Kidney Injury: A global perspective of a silent killer. Kidney Int. 2013;84(3):457-67.

1639

Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411-23. doi:10.1007/s00134-015-3934-7.

1640

Tao Li PK, Burdmann EA, Mehta RL. Acute kidney injury: global health alert. Int. J.Organ Transplant. Med. 2013;4:1-8.

1641

Zeng X, McMahon GM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12-20.

1642

Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract. 2013;2013:479730.

1643

Sawhney S, Bell S, Black C, et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney Int. 2022;101(6):1271-81. doi:10.1016/j.kint.2022.02.033.

1644

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. GBD Chronic Kidney Disease Collaboration. Lancet 2020;395:709-33. doi:10.1016/S0140-6736(20)30045-3.

1645

Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease — A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765.

1646

Смирнов А.В., Каюков И.Г., Есаян A.M. и др. Превентивный подход в современной нефрологии. Нефрология. 2004;8(3):7-14. doi:10.24884/1561-6274-2004-8-3-7-14.

Smirnov AB, Kayukov IG, Yesayan AM, etc. A preventive approach in modern nephrology. Nephrology. 2004;8(3):7-14. (In Russ.) doi:10.24884/1561-6274-2004-8-3-7-14.

1647

Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология. 2006;10(1):7-13.

Smirnov AB, Dobronravov VA, Kayukov IG, et al. Epidemiology and socio-economic aspects of chronic kidney disease. Nephrology. 2006;10(1):7-13. (In Russ.)

1648

Ощепкова Е. В., Долгушева Ю.А., Жернакова Ю.В. и др. Распространенность нарушения функции почек при артериальной гипертонии (по данным эпид. исследования ЭССЕ-РФ). Системные гипертензии. 2015;12(3):19-624.

Oshchepkova EV, Dolgusheva YuA, Zhernakova YuV, et al. The prevalence of renal dysfunction in arterial hypertension (according to epid. research ESSAYS-RF). Systemic hypertension. 2015;12(3):19-624. (In Russ.)

1649

Кобалава Ж. Д., Виллевальде С. В., Боровкова Н. Ю. и др. от имени исследователей программы ХРОНОГРАФ. Распространенность маркеров хронической болезни почек у пациентов с артериальной гипертонией: результаты эпидемиологического исследования ХРОНОГРАФ. Кардиология. 2017;57(10):39-44.

Kobalava JD, Villevalde SV, Borovkova NYu, et al. on behalf of the CHRONOGRAPH program researchers. The prevalence of markers of chronic kidney disease in patients with arterial hypertension: the results of an epidemiological study CHRONOGRAPH. Kardiologiia. 2017;57(10):39-44. (In Russ.)

1650

Шамхалова М.Ш., Викулова О.К., Железнякова А. В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным Федерального регистра взрослых пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет. 2018;21(3):160-9. doi:10.14341/DM9687.

Shamkhalova MSh., Vikulova OK, Zheleznyakova AV, et al. Epidemiology of chronic kidney disease in the Russian Federation according to the Federal Register of Adult Patients with Diabetes Mellitus (2013-2016). Diabetes mellitus. 2018;21(3):160-9. (In Russ.) doi:10.14341/DM9687.

1651

Андрусев А. М., Томилина Н. А., Перегудова Н. Г., Шинкарев М. Б. Заместительная терапия терминальной хронической почечной недостаточности в российской федерации 2014-2018 гг. Отчет по данным общероссийского регистра заместительной почечной терапии российского диализного общества. Нефрология и диализ. 2020;22(S1):1-71.

Andrusev AM, Tomilina NA, Peregudova NG, Shinkarev MB. Substitution therapy of terminal chronic renal failure in the Russian Federation 2014-2018 A report on the data of the All-Russian register of renal replacement therapy of the Russian Dialysis Society. Nephrology and dialysis. 2020;22(S1):1-71. (In Russ.)

1652

Wu VC, Wu PC, Wu CH, et al. The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc. 2014;3(4). doi:10.1161/JAHA.114.000933.

1653

Hansen MK, Gammelager H, Mikkelsen MM, et al. Post-operative acute kidney injury and five-year risk of death, myocardial infarction, and stroke among elective cardiac surgical patients: a cohort study. Crit Care. 2013;17(6):R292.

1654

Wu VC, Wu CH, Huang TM, et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol. 2014;25(3):595-605.

1655

Lai TS, Wang CY, Pan SC, et al. Risk of developing severe sepsis after acute kidney injury: a population-based cohort study. Crit Care. 2013;17(5):R231.

1656

Wang WJ, Chao CT, Huang YC, et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. J Bone Miner Res. 2014;29(3):676-84.

1657

Chao CT, Wang CY, Lai CF, et al. Dialysis requiring acute kidney injury increases risk of long-term malignancy: a population-based study. J Cancer Res Clin Oncol. 2014;140(4):613-21.

1658

Wu PC, Wu CJ, Lin CJ, Wu VC, National Taiwan University Study Group on Acute Renal Failure G. Long-term risk of upper gastrointestinal hemorrhage after advanced AKI. Clin J Am Soc Nephrol. 2015;10(3):353-62.

1659

Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345-52. doi:10.1681/ASN.2009060636.

1660

Stads S, Fortrie G, van Bommel J, et al. Impaired kidney function at hospital discharge and long-term renal and overall survival in patients who received CRRT. Clin J Am Soc Nephrol. 2013;8(8):1284-91.

1661

Sawhney S, Mitchell M, Marks A, et al. Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review. BMJ Open. 2015;5(1): e006497.

1662

Ponte B, Felipe C, Muriel A, et al. Long-term functional evolution after an acute kidney injury: a 10-year study. Nephrol Dial Transplant. 2008;23(12):3859-66.

1663

Pereira MB, Zanetta DM, Abdulkader RC. The real importance of pre-existing comorbidities on long-term mortality after acute kidney injury. PLoS One. 2012;7(10):e47746.

1664

Coca SG, King JT Jr, Rosenthal RA, et al. The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans. Kidney Int. 2010;78(9):926-33.

1665

Bucaloiu ID, Kirchner HL, Norfolk ER, et al. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int. 2012;81(5):477-85.

1666

Han SS, Shin N, Baek SH, et al. Effects of acute kidney injury and chronic kidney disease on long-term mortality after coronary artery bypass grafting. Am Heart J. 2015;169(3):419-25.

1667

Pannu N, James M, Hemmelgarn B, Klarenbach S, Alberta Kidney Disease N. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin J Am Soc Nephrol 2013;8(2):194-202.

1668

Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-8. doi:10.1038/ki.2011.379.

1669

Lo LJ, Go AS, Chertow GM, et al. Dialysis requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009;76(8):893-9.

1670

Odutayo A, Wong CX, Farkouh M, et al. Acute kidney injury and long-term risk for cardiovascular events and mortality. J.Am. Soc. Nephrol. 2017;28:377-87.

1671

Tangren JS, Powe CE, Ankers E, et al. Pregnancy Outcomes after Clinical Recovery from AKI. J Am Soc Nephrol. 2017;28(5):1566-74. doi:10.1681/ASN.2016070806.

1672

Schytz PA, Blanche P, Nissen AB, et al. Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study. Nefrologia (Engl Ed). 2021:S0211-6995(21)00140-5. English, Spanish. doi:10.1016/j.nefro.2021.06.007.

1673

Siew ED, Peterson JF, Eden SK, et al. Outpatient nephrology referral rates after acute kidney injury. J Am Soc Nephrol. 2012;23(2):305-12.

1674

Harel Z, Wald R, Bargman JM, et al. Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int. 2013;83(5):901-8.

1675

MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021;71(704):e243-e249. doi:10.3399/bjgp20X714125.

1676

Lee W-C, Lee Y-T, Li L-C, et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease. Journal of Clinical Medicine. 2018;7(12):493. doi:10.3390/jcm7120493.

1677

Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns — NHANES 2007-2012. BMJ Open Diabetes Research and Care. 2016;4:e000154. doi:10.1136/bmjdrc-2015-000154.

1678

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115.

1679

Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883. doi:10.2337/dc14-1296.

1680

Дедов ИИ, Шестакова МВ. Осложнения сахарного диабета: лечение и профилактика. Москва: МИА, 2017, 743 с.

Dedov II, Shestakov MV. Complications of diabetes mellitus: treatment and prevention. Moscow: MIA, 2017, 743 p. (In Russ.)

1681

Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002;(13)5:1338-49.

1682

Böhm M, Thoenes M, Danchin N, et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens. 2007;25 (11):2317-24.

1683

Segura J, Garcia-Donair J, Praga M, et al. Chronic kidney disease as a situation of high added risk in hypertensive patients J Am Soc Nephrol. 2006;17 (Suppl 2.):136-40.

1684

Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.

1685

Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1): 47-55.

1686

Foley R, Murray A, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-95.

1687

Middleton RJ, Foley RN, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 2006;21:88-92.

1688

K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45 (Suppl 3):S1-153.

1689

Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J. 2008; 155:725-31.

1690

Gibson CM, Dumaine RL, Gelfand EV, et al: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004;25(22):1998-2005.

1691

Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.

1692

Collins AJ, Vassalotti JA, Wang C, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. Am J Kidney Dis. 2009;53 (Suppl 3):71-7.

1693

Herzog C. Kidney disease in cardiology. Nephrol Dial Transplant. 2008;23(8):42-46.

1694

Ronco C, McCullough P, Anker S, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31:703-11.

1695

Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;149:209-16.

1696

Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007; 50:768-77.

1697

Wilson P, D’Agostino Rb, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-72.

1698

Кобалава Ж. Д., Моисеев В. С. Концепция кардиоренальных и метаболических соотношений в современной профилактической кардиологии. Кардиоваскулярная терапия и профилактика. 2008;4:4-7.

Kobalava JD, Moiseev VS. The concept of cardiorenal and metabolic ratios in modern preventive cardiology. Cardiovascular Therapy and Prevention. 2008;4:4-7. (In Russ.)

1699

Мухин Н. А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевтический архив 2004;9:5-10.

Mukhin NA, Balkarov IM, Moiseev VS, et al. Chronic progressive nephropathies and the lifestyle of modern man. Therapeutic Archive 2004;9:5-10. (In Russ.)

1700

Кобалава Ж. Д., Котовская Ю. В., Толкачева В. В., Мильто А. С. Мочевая кислота — ключевой компонент кардиренометаболического континуума. Кардиоваскулярная терапия и профилактика. 2008;4:95-100.

Kobalava JD, Kotovskaya YV, Tolkacheva VV, Milto AS. Uric acid is a key component of the cardiorenometabolic continuum. Cardiovascular Therapy and Prevention. 2008;4:95-100. (In Russ.)

1701

Desai RJ, Franklin JM, Spoendlin-Allen J, et al. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One. 2018;13(2): e0193622. doi:10.1371/journal.pone.0193622.

1702

Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006;8 (suppl. B):4-12.

1703

Pommer W. Preventive Nephrology: The Role of Obesity in Different Stages of Chronic Kidney Disease. Kidney Dis. 2018;4:199-204. doi:10.1159/000490247.

1704

Navaneethan SD, Schold JD, Jolly SE, et al. Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney Int. 2017;92(5):1272-81. doi:10.1016/j.kint.2017.04.03027.

1705

Chen SC, Hung CC, Kuo MC, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One 2013;8(2):e55643. doi:10.1371/journal.pone.005564328.

1706

Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with AllCause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-21. doi:10.1159/00047980229.

1707

Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(ll):119-27. doi:10.1001/jama.2011.308 30.

1708

Malhotra R, Nguyen HA, Benavente О, et al. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med 2017;177(10):1498-505. doi:10.1001/jamainternmed.2017.43770001.

1709

Ku E, Sarnak MJ, Toto R, et al. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. J Am Heart Assoc. 2019;8(16):e012749. doi:10.1161/JAHA.119.0127490003.

1710

Wright, Jr JT, Bakris G, Greene T, et al. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial. JAMA. 2002;288(19):2421-31. doi:10.1001/jama.288.19.2421.

1711

Ruggenenti P, Perna A, Loriga G, et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-46. doi:10.1016/S0140-6736(05)71082-5.

1712

de Galan BE, Perkovic V, Ninomiya T, et al. ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am SocNephrol. 2009;20:883-92.

1713

Bakris GL, Seraﬁdis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different ﬁxed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespeciﬁed secondary analysis of randomized controlled trial. Lancet 2010;375:1173-8.

Bakris GL, Seraﬁdis PA, Weir MR, et al. ACCOMPLISH Trial Investigators. Renal outcomes with different ﬁxed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a pre-speciﬁed secondary analysis of randomized controlled trial. Lancet 2010;375:1173-8.

1714

The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.

1715

Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41. doi:10.1053/j.ajkd.2015.10.011.

1716

Huang RS, Cheng YM, Zeng XX, et al. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chin Med J (Engl). 2016;129(5):562-9. doi:10.4103/0366-6999.176987.

1717

Huang Q, Li K, Li M, Xu G. Comparisons of Three Main Treatments on Renoprotective Effects in Diabetes Mellitus. Iran J Kidney Dis. 2019;13(1):36-47.

1718

Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012;7:1234-41.

1719

Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015;16:2205-15.

1720

Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.

1721

Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-903.

1722

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:1269-324.

1723

Zelniker TA, Wiviott SD, RazfI, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-9.

1724

Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators, et al. Canaglifozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306.

1725

Giugliano D, De Nicola L, Maiorino MI, et al. Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes:the role of kidney. Cardiovasc Diabetol. 2020;19:35.

1726

Bhatt DL, Szarek M, Pitt B, et al.; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-39. doi:10.1056/NEJMoa2030186.

1727

Docherty KF, Jhund PS, Anand I, et al. Effect of dapaglifozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142:1623-32.

Docherty KF, Jhund PS, Anand I, et al. Effect of dapaglifozin on outpatient worsening of patients with heart failure and reduced ejection fraction:a prespecified analysis of DAPA-HF. Circulation. 2020;142:1623-32.

1728

Wanner C, Tonelli M; Kidney Disease: Improving Global Out-comes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-9. doi:10.1038/ki.2014.31.

1729

Baigent C, Landray MJ, Reith C, et al, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181-92.

1730

Herrington WG, Emberson J, Mihaylova B, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration, Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829-39.

1731

Barylski M, Nikfar S, Mikhailidis DP, et al., Lipid and Blood Pressure MetaAnalysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35-44.

1732

Charytan DM, Sabatine MS, Pedersen TR, et al., FOURIER Steering Committee and Investigators. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol 2019;73:2961-70.

1733

Mach F, Baigent C, Catapano AL, et al., ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.

1734

Wanner C, Krane V, Marz W, et al., German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353: 238-48.

1735

Fellstrom BC, Jardine AG, Schmieder RE, et al., AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.

1736

Giugliano D, Bellastella G, Longo M, et al. Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes Obes Metab. 2020;22:1397-405.

1737

Essa H, Dobson R, Wright D, Lip GYH. Hypertension management in cardio-oncology. J Hum Hypertens. 2020;34(10):673-81. doi:10.1038/s41371-020-0391-8.

1738

Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Front Microbiol. 2017;8:1041. doi:10.3389/fmicb.2017.01041.

1739

Колбин А. С., Гомон Ю. М., Балыкина Ю. Е. и соавт. Социально-экономическое и глобальное бремя COVID-19. Качественная Клиническая Практика. 2021;(1):24-34. doi:10.37489/2588-0519-2021-1-24-34.

Kolbin AS, Gomon YuM, Balykina YuE, et al. Socioeconomic and global burden of COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2021;(1):24-34. (In Russ.) doi:10.37489/2588-0519-2021-1-24-34.

1740

Dong M, Liu T, Li G. Association between acute infections and risk of acute coronary syndrome: a meta-analysis. Int J Cardiol. 2011;147(3):479-82. doi:10.1016/j.ĳcard.2011.01.035.

1741

Wiegand JA, Torgersen C, Bloechlinger S, et al. Influenza A(H1N1) infection and severe cardiac dysfunction in adults: a case series. Wien Klin Wochenschr. 2011;123(3-4):120-3. doi:10.1007/s00508-010-1520-0.

1742

Tseng GS, Hsieh CY, Hsu CT, et al. Myopericarditis and exertional rhabdomyolysis following an influenza A (H3N2) infection. BMC Infect Dis. 2013;13:283. doi:10.1186/1471-2334-13-2834-6.

Tseng GS, Hsieh CY, Hsu CT, et al. Myopericarditis and exertional rhabdomyolysis following an infl uenza A (H3N2) infection. BMC Infect Dis. 2013;13:283. doi:10.1186/1471-2334-13-2834-6.

1743

Hu Y, Sun Z, Yu C, et al China Kadoorie Biobank Collaborative Group. Association between pneumonia hospitalisation and long-term risk of cardiovascular disease in Chinese adults: A prospective cohort study. E Clinical Medicine. 2022;55:101761. doi:10.1016/j.eclinm.2022.101761.

1744

Al-Sayyar A, Hulme KD, Thibaut R, et al Respiratory Tract Infections in Diabetes — Lessons From Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity. Front Endocrinol (Lausanne). 2022;13:919223. doi:10.3389/fendo.2022.919223.

1745

Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022;65:949-54. doi:10.1007/s00125-022-05670-0.

1746

Kang SH, Cheong HJ, Song JY, et al. Analysis of Risk Factors for Severe Acute Respiratory Infection and Pneumonia and among Adult Patients with Acute Respiratory Illness during 2011-2014 Influenza Seasons in Korea. Infect Chemother. 2016;48(4):294-301. doi:10.3947/ic.2016.48.4.294.

1747

Docherty AB, Harrison EM, Green CA, et al.; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi:10.1136/bmj.m1985.

1748

Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature. 2020;584(7821):430-6. doi:10.1038/s41586-020-2521-4.

1749

Pearce DC, McCaw JM, McVernon J, Mathews JD. Influenza as a trigger for cardiovascular disease: An investigation of serotype, subtype and geographic location. Environ Res. 2017;156:688-96. doi:10.1016/j.envres.2017.04.024.

1750

Han J, Mou Y, Yan D, et al. Transient cardiac injury during H7N9 infection. Eur J Clin Invest. 2015;45(2):117-25. doi:10.1111/eci.12386.

1751

Платонова Е. В., Деев А. Д., Лукьянов М. М. и др. Риск сердечно-сосудистых заболеваний после острой респираторной инфекции или ежегодной противогриппозной вакцинации в течение 5 лет. Профилактическая медицина. 2018;21(2-2):19.

Platonova EV, Deev AD, Lukyanov MM, et al. The risk of cardiovascular disease after acute respiratory infection or annual influenza vaccination for 5 years. Preventive medicine. 2018;21(2-2):19. (In Russ.)

1752

Nguyen JL, Yang W, Ito K, et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1(3):274-81. doi:10.1001/jamacardio.2016.0433.

1753

Bazaz R, Marriott HM, Francis SE, Dockrell DH. Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J Infect. 2013;66(1):1-17. doi:10.1016/j.jinf.2012.09.009.

1754

Jeserich M, Olschewski M, Kimmel S, et al. Acute results and long-term follow-up of patients with accompanying myocarditis after viral respiratory or gastrointestinal tract infection. Int J Cardiol. 2014;174(3):853-5. doi:10.1016/j.ijcard.2014.04.196.

1755

Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069-77. doi:10.1093/cid/cit471.

1756

Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56-62. doi:10.1093/infdis/jis309.

1757

Ciuraszkiewicz K, Sielski J, Janion-Sadowska A, et al. Influenza infection in intensive cardiac care unit patients. Pol Merkur Lekarski. 2014;36(213):203-5.

1758

Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol. 2011;40(3):819-27. doi:10.1093/ije/dyr012.

1759

Frasson S, Gussoni G, Di Micco P, et al. Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. J Thromb Thrombolysis. 2016;41(3):404-12. doi:10.1007/s11239-015-1242-2.

1760

Grimnes G, Isaksen T, Tichelaar YIGV, et al. Acute infection as a trigger for incident venous thromboembolism: Results from a population-based case-crossover study. Res Pract Thromb Haemost. 2017;2(1):85-92. doi:10.1002/rth2.12065.

1761

Селькова Е. П., Гренкова Т. А., Гудова Н. В., Оганесян А. С. Итоги эпидсезона 2017/18 гг. по гриппу и острой респираторной вирусной инфекции. Особенности этиотропной терапии. РМЖ “Медицинское обозрение”. 2018;11:49-53.

Selkova EP, Grenkova TA, Gudkova NV, Oganesyan AS. The results of the 2017/18 epidemic season for influenza and acute respiratory viral infection. Features of etiotropic therapy. RMJ “Medical review”. 2018;11:49-53. (In Russ.)

1762

Miravitlles M, Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2015;21(3):278-83. doi:10.1097/MCP.0000000000000154.

1763

Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618-23. doi:10.1164/ajrccm.164.9.2105011.

1764

Satia I, Cusack R, Greene JM, et al. Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma. PloS One. 2020;15(2):e0228544. doi:10.1371/journal.pone.0228.

1765

Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26(2):227-34. doi:10.1016/j.cmi.2019.06.011.

1766

Mulpuru S, Li L, Ye L, et al. Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest. 2019;155(1):69-78. doi:10.1016/j.chest.2018.10.044.

1767

Halpin DMG, Rabe AP, Loke WJ, et al. Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses. J Asthma Allergy. 2022;15:811-25. doi:10.2147/JAA.S360985.

1768

Stridsman C, Vanfleteren LEGW, Konradsen JR, et al. Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with COPD. Eur Respir J. 2021;58(5):2101920. doi:10.1183/13993003.01920-2021.

1769

Elbeddini A, Tayefehchamani Y. Amid COVID-19 pandemic: Challenges with access to care for COPD patients. Res Social Adm Pharm. 2021;17(1):1934-7.

1770

Press VG, Gershon AS, Sciurba FC, Blagev DP. Concerns About Coronavirus Disease-Related Collateral Damage for Patients With COPD. Chest. 2020;158(3):866-8.

1771

Kunisaki KM, Dransfield MT, Anderson JA, et al.; SUMMIT Investigators. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med. 2018;198(1):51-7. doi:10.1164/rccm.201711-2239OC.

1772

Rothnie KJ, Connell O, Mullerova H, et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2018;15:935946.

1773

Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66:764768.

1774

Шпагина Л. А., Котова О. С., Шпагин И. С. и др. Клинико-функциональные особенности хронической обструктивной болезни легких после вирус-ассоциированных обострений. Терапевтический архив. 2023;95(3):217-22. doi:10.26442/00403660.2023.03.202086.

Shpagina LA, Kotova OS, Shpagin IS, et al. Clinic and functional features of chronic obstructive pulmonary disease after virus-induced acute exacerbations. Terapevticheskii arkhiv. 2023;95(3):217222. (In Russ.) doi:10.26442/00403660.2023.03.202086.

1775

Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations — a GA² LEN-DARE systematic review. Allergy. 2011;66(4):458-68. doi:10.1111/j.1398-9995.2010.02505.x.

1776

Лещенко И.В., Эсаулова Н.А., Глушкова Т.В., Скорняков С.Н. Респираторные нарушения при постковидном синдроме. Терапевтический архив. 2023;95(3):203-9. doi:10.26442/00403660.2023.03.202072.

Leshchenko IV, Esaulova NA, Glushkova TV, Skornyakov SN. Respiratory disorders of post-COVID-19 syndrome. Terapevticheskii arkhiv. 2023;95(3):203-9. (In Russ.) doi:10.26442/00403660.2023.03.202072.

1777

Guilbert TW, Denlinger LC. Role of infection in the development and exacerbation of asthma. Expert Rev Respir Med. 2010;4(1):71-83. doi:10.1586/ers.09.60.

1778

Schwarze J, Openshaw P, Jha A, et al. Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force. Allergy. 2018;73(6):1151-81. doi:10.1111/all.13333.

1779

Li L, Cheng Y, Tu X, et al. Association between asthma and invasive pneumococcal disease risk: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2020;16(1):94. doi:10.1186/s13223-020-00492-4.

1780

Авдеев С. Н., Гайнитдинова В. В., Позднякова А. А. и др. Факторы риска неблагоприятных исходов у пожилых пациентов с бронхиальной астмой и тяжелой формой COVID-19 на госпитальном и раннем постгоспитальном этапах. Терапевтический архив. 2023;95(1):57-65. doi:10.26442/00403660.2023.01.202049.

Avdeev SN, Gaynitdinova VV, Pozdniakova AA, et al. Risk factors for adverse outcomes in elderly patients with asthma and severe COVID-19 at the hospital and early post-hospital stages. Terapevticheskii arkhiv. 2023;95(1):57-65. (In Russ.) doi:10.26442/00403660.2023.01.202049.

1781

Laorden D, Domínguez-Ortega J, Carpio C, et al. ASMA@ COVIDHULP group. Long COVID outcomes in an asthmatic cohort and its implications for asthma control. Respir Med. 2023;207:107092. doi:10.1016/j.rmed.2022.107092.

1782

Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-44. doi:10.1056/NEJMoa0906695.

1783

Малышев НА, Базарова МВ, Кареткина ГН, и др. Особенности пандемического гриппа A (H1N1) pdm09. Инфекционные болезни: Новости. Мнения. Обучение. 2013;(2 (3)):12-8.

Malyshev NA, Bazarova MV, Karetkina GN, et al. Features of pandemic influenza A (H1N1) pdm09. Infectious diseases: News. Opinions. Training. 2013;(2 (3)):12-8. (In Russ.)

1784

Samson SI, Konty K, Lee WN, et al. Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact. J Diabetes Sci Technol. 2021;15(1):44-52. doi:10.1177/1932296819883340.

1785

Owusu D, Rolfes MA, Arriola CS, et al. Rates of Severe Influenza-Associated Outcomes Among Older Adults Living With Diabetes-Influenza Hospitalization Surveillance Network (FluSurv-NET), 2012-2017. Open Forum Infect Dis. 2022;9(5):ofac131. doi:10.1093/ofid/ofac131.

1786

Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33(7):1491-3. doi:10.2337/dc09-2215.

1787

Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health. 1999;89(11):1715-21. doi:10.2105/ajph.89.11.1715.

1788

Dicembrini I, Silverii GA, Clerico A, et al. Influenza: Diabetes as a risk factor for severe related-outcomes and the effectiveness of vaccination in diabetic population. A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2023;33(6):1099-110. doi:10.1016/j.numecd.2023.03.016.

1789

Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372-93. doi:10.1111/irv.12470.

1790

Thomas S, Ouhtit A, Al Khatib HA, et al. Burden and disease pathogenesis of influenza and other respiratory viruses in diabetic patients. J Infect Public Health. 2022;15(4):412-24. doi:10.1016/j.jiph.2022.03.002.

1791

Ситников И. Г., Фазылов В. Х., Силина Е. В. Опыт лечения гриппа и ОРВИ у больных сахарным диабетом. Терапевтический архив. 2019;91(10):39-47. doi:10.26442/00403660.2019.10.000333.

Sitnikov IG, Fazylov VK, Silina EV. Treatment of influenza and other acute respiratory viral infections in patients with diabetes mellitus. Terapevticheskii arkhiv. 2019;91(10):39-47. (In Russ.) doi:10.26442/00403660.2019.10.000333.

1792

Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-5. doi:10.2337/dc08-0138.

1793

Yende S, van der Poll T, Lee M, et al.; GenIMS and Health ABC study. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010;65(10):870-7. doi:10.1136/thx.2010.136317.

1794

Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta-analysis. Diabetes, Obes Metab. 2021;23(3):870-4. doi:10.1111/dom.14269.

1795

Wu L, Girgis CM, Cheung NW. COVID‐19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol (Oxf). 2020;93(4):390-3. doi:10.1111/cen.14288.

1796

Caussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes Endocrinol. 2020;30160-1. doi:10.1016/S2213-8587(20)30160.

1797

Маркова Т. Н., Пономарева А. А., Самсонова И. В. и др. Факторы риска летального исхода у больных сахарным диабетом 2 типа и новой коронавирусной инфекцией. Эндокринология: новости, мнения, обучение. 2022:11(1):8-16. doi:10.33029/2304-9529-2022-11-1-8-16.

Markova TN, Ponomareva AA, Samsonova IV, et al. Risk factors for fatal outcome in patients with type 2 diabetes mellitus and a new coronavirus infection. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022;11(1):8-16. (In Russ.) doi:10.33029/2304-9529-2022-11-1-8-16.

1798

Cariou B, Hadjadj S, Wargny M, et al.; CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500-15. doi:10.1007/s00125-020-05180-x.

1799

Verket M, Jacobsen M, Schütt K, et al. Influenza vaccination in patients affected by diabetes. Eur Heart J Suppl. 2023;25(Suppl A):A36-A41. doi:10.1093/eurheartjsupp/suac119.

1800

van Niekerk, G, van der Merwe, M, Engelbrecht, A-M. Diabetes and susceptibility to infections: Implication for COVID-19. Immunology. 2021;164:467-75. doi:10.1111/imm.13383.

1801

Куркин Д. В., Морковин Е. И., Бакулин Д. А. и др. Современные представления о патогенезе сахарного диабета 2-го типа. Вестник Волгоградского государственного медицинского университета. 2022;19(4):34-49.

Kurkin DV, Morkovin EI, Bakulin DA, et al. Modern ideas about the pathogenesis of type 2 diabetes mellitus. Bulletin of the Volgograd State Medical University. 2022;19(4):34-49. (In Russ.)

1802

Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218-38. doi:10.1111/j.1600-065X.2012.01151.x.

1803

Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-50. doi:10.1016/S2213-8587(20)30152-2.

1804

Wang IK, Lin CL, Chang YC. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine. 2013;31(4):718-24. doi:10.1016/j.vaccine.2012.11.017.

1805

Heymann AD, Shapiro Y, Chodick G, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care. 2004;27(11):2581-4. doi:10.2337/diacare.27.11.2581.

1806

Vasilev G, Kabakchieva P, Miteva D, et al. Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy. World J Diabetes. 2022;13(9):738-51. doi:10.4239/wjd.v13.i9.738.

1807

Pieralice S, D’Onofrio L, Pozzilli P, Buzzetti R. Third dose of COVID-19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy. Diabetes Metab Res Rev. 2022;38(5):e3533. doi:10.1002/dmrr.3533.

1808

Gilbertson DT, Rothman KJ, Chertow GM, et al. Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. J Am Soc Nephrol. 2019;30(2):346-53. doi:10.1681/ASN.2018060581.

1809

Berman SJ, Johnson EW, Nakatsu C, et al. Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis. 2004;39(12):1747-53. doi:10.1086/424516.

1810

Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72. doi:10.1016/S0140-6736(13)60687-X.

1811

Изможерова Н.В., Попов А.А., Гаврилова Е.И., и др. Особенности течения внебольничной пневмонии у коморбидных пациентов, госпитализированных в стационар в период эпидемии респираторных вирусных инфекций. Терапия. 2020;6(6):103-13.

Izmozherova NV, Popov AA, Gavrilova EI, et al. Features of the course of community-acquired pneumonia in comorbid patients hospitalized during the epidemic of respiratory viral infections. Therapy. 2020;6(6):103-13. (In Russ.)

1812

James MT, Quan H, Tonelli M, et al.; Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54(1):24-32. doi:10.1053/j.ajkd.2009.04.005.

1813

McDonald HI, Nitsch D, Millett ER, et al. Are pre-existing markers of chronic kidney disease associated with short-term mortality following acute community-acquired pneumonia and sepsis? A cohort study among older people with diabetes using electronic health records. Nephrol Dial Transplant. 2015;30(6):1002-9. doi:10.1093/ndt/gfu401.

1814

Su G, Xu H, Marrone G, et al. Chronic kidney disease is associated with poorer in-hospital outcomes in patients hospitalized with infections: Electronic record analysis from China. Sci Rep. 2017;7(1):11530. doi:10.1038/s41598-017-11861-2.

1815

Su G, Iwagami M, Qin X, et al. Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. Clin Kidney J. 2020;14(2):602-11. doi:10.1093/ckj/sfz188.

1816

See KC. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines (Basel). 2022;10(5):800. doi:10.3390/vaccines10050800.

1817

D’Marco L, Puchades MJ, Romero-Parra M, et al. Coronavirus disease 2019 in chronic kidney disease. Clin Kidney J. 2020;13(3):297-306. doi:10.1093/ckj/sfaa104.

1818

Выхристенко Л. Р., Счастливенко А. И., Бондарева Л. И. и др. Поражение почек при инфекции COVID-19. Вестник Витебского государственного медицинского университета. 2021;20(1):7-23.

Vykhristenko LR, Shchastvenko AI, Bondareva LI, et al. Kidney damage in COVID-19 infection. Bulletin of the Vitebsk State Medical University. 2021;20(1):7-23. (In Russ.)

1819

Flythe JE, Assimon MM, Tugman MJ, et al.; STOP-COVID Investigators. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. Am J Kidney Dis. 2021;77(2):190-203.e1. doi:10.1053/j.ajkd.2020.09.003.

1820

Ji W, Huh K, Kang M, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. J Korean Med Sci. 2020;35(25):e237. doi:10.3346/jkms.2020.35.e237.

1821

Zhang Y, Zhao Y, Wang J, et al. Long-term renal outcomes of patients with COVID-19: a meta-analysis of observational studies. J Nephrol. 2023;36(9):2441-56. doi:10.1007/s40620-023-01731-8.

1822

Mahallawi WH, Ibrahim NA, Mumena WA. Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. Risk Manag Healthc Policy. 2021;14:5081-8. doi:10.2147/RMHP.S345686.

1823

Джумабаева БТ, Бирюкова ЛС, Капранов НМ, и др. Cубпопуляции T-и B-лимфоцитов у пациентов с терминальной стадией хронической болезни почек. Нефрология и диализ. 2018;20(4):385-93.

Dzhumabaeva B, Biryukova LS, Kapranov NM, et al. Subpopulations of T and B lymphocytes in patients with end-stage chronic kidney disease. Nephrology and dialysis. 2018;20(4):385-93. (In Russ.)

1824

Wang IK, Lin CL, Lin PC, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One. 2013;8(3):e58317. doi:10.1371/journal.pone.0058317.

1825

Pierre É, Pladys A, Bayat-Makoei S, et al. Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year. Vaccine. 2023;41(24):3655-62. doi:10.1016/j.vaccine.2023.05.003.

1826

Windpessl M, Bruchfeld A, Anders HJ, et al. COVID-19 vaccines and kidney disease. Nat Rev Nephrol. 2021;17:291-3. doi:10.1038/s41581-021-00406-6.

1827

Quiroga B, Soler MJ, Ortiz A, et al.; SENCOVAC Collaborative Network. Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transplant. 2022;37(10):1868-78. doi:10.1093/ndt/gfab313.

1828

Зубкин М. Л., Шило В. Ю., Новикова Л. И. и др. Частота инфицирования SARS-CoV-2 среди больных, получающих лечение программным гемодиализом. Инфекционные болезни: новости, мнения, обучение. 2021;10(3):23-32. doi:10.33029/2305-3496-2021-10-3-23-32.

Zubkin ML, Shilo VYu, Novikova LI, et al. Frequency of SARS-CoV-2 infection in hemodialysis patients. Economic aspects of COVID-19 treatment in a hospital setting. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2021;10(3):23-32. (In Russ.) doi:10.33029/2305-3496-2021-10-3-23-32.

1829

Bertrand D, Laurent C, Lemée V, et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. Kidney Int. 2022;102(2):440-2. doi:10.1016/j.kint.2022.05.007.

1830

Lam F, Chen TL, Shih CC, et al. Protective effect of influenza vaccination on outcomes in geriatric stroke patients: A nationwide matched cohort study. Atherosclerosis. 2019;282:85-90. doi:10.1016/j.atherosclerosis.2019.01.008.

1831

Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine. 2003;348(14):1322-32.

1832

Vohora D, Jain S, Tripathi M, Potschka H. COVID-19 and seizures: Is there a link? Epilepsia. 2020;61:1840-53. doi:10.1111/epi.16656.

1833

Radzišauskienė D, Vitkauskaitė M, Žvinytė K, Mameniškienė R. Neurological complications of pandemic A(H1N1)2009pdm, postpandemic A(H1N1) v, and seasonal influenza A. Brain Behav. 2021;11(1):e01916. doi:10.1002/brb3.1916.

1834

Paksu MS, Aslan K, Kendirli T, et al. Neuroinfluenza: evaluation of seasonal influenza associated severe neurological complications in children (a multicenter study). Childs Nerv Syst. 2018;34:335-47. doi:10.1007/s00381-017-3554-3.

1835

Surtees R, DeSousa C. Influenza virus associated encephalopathy. Arch Dis Child. 2006;91(6):455-6. doi:10.1136/adc.2005.092890.

1836

Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 2003;28(3):225-32. doi:10.1016/s1386-6532(03)00119-7.

1837

Ambrozaitis, A., Radzišauskienė, D., Žagminas, K., et al. Influenza A(H1N1) pdm09 and postpandemic influenza in Lithuania. Open Medicine. 2016;11(1):341-53.

1838

Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Critical Care Medicine. 2010;38(4 Suppl), e91-e97.

1839

Ferrari S, Toniolo A, Monaco S, et al. Viral encephalitis: Etiology, clinical features, diagnosis and management. The Open Infectious Diseases Journal. 2009;3(1):1-12. doi:10.2174/1874279300903010001.

1840

Wei ZD, Liang K, Shetty AK. Complications of COVID-19 on the Central Nervous System: Mechanisms and Potential Treatment for Easing Long COVID. Aging Dis. 2023;14(5):1492-510. doi:10.14336/AD.2023.0312.

1841

Moro E, Priori A, Beghi E, et al.; EAN core COVID-19 Task Force. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. Eur J Neurol. 2020;27(9):1727-37. doi:10.1111/ene.14407.

1842

Танашян М. М., Кузнецова П. И., Раскуражев А. А. Неврологические аспекты COVID-19. Анналы клинической и экспериментальной неврологии. 2020;14(2):62-9.

Tanashyan MM, Kuznetsova PI, Raskurazhev AA. Neurological aspects of COVID-19. Annals of clinical and experimental neurology. 2020;14(2):62-9. (In Russ.)

1843

Zhao F, Han Z, Wang R, Luo Y. Neurological Manifestations of COVID-19: Causality or Coincidence? Aging Dis. 2021;12(1):27-35. doi:10.14336/AD.2020.0917.

1844

Merkler AE, Parikh NS, Mir S, et al. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. JAMA Neurol. 2020;77(11):1366–1372. doi:10.1001/jamaneurol.2020.2730.

1845

Elkind MS, Carty CL, O’Meara ES, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke. 2011;42(7):1851-6. doi:10.1161/STROKEAHA.110.608588.

1846

Cowan LT, Alonso A, Pankow JS, et al. Hospitalized Infection as a Trigger for Acute Ischemic Stroke: The Atherosclerosis Risk in Communities Study. Stroke. 2016;47(6):1612-7. doi:10.1161/STROKEAHA.116.012890.

1847

Boehme AK, Luna J, Kulick ER, et al. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456-63. doi:10.1002/acn3.545.

1848

Wang C-S, Wang S-T, Lai C-T, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine. 2007;25:1196-203.

1849

Grau AJ, Fischer B, Barth C, et al. Influenza vaccination is associated with a reduced risk of stroke. Stroke. 2005;36(7):1501-6. doi:10.1161/01.STR.0000170674.45136.80.

1850

McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1-and neutrophil-dependent mechanisms. J Neurosci. 2007;27:4403-12.

1851

Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. doi:10.1371/journal.pone.0051452.

1852

Руженцова Т.А., Хавкина Д.А., Мешкова Н.А. и др. Стратегия рациональной терапии острых респираторных инфекций у пациентов с коморбидной соматической патологией. Безопасность и риск фармакотерапии. 2020;8(2):77-83. doi:10.30895/2312-7821-2020-8-2-77-83.

Ruzhencova TA, Khavkina DА, Meshkova NA, et al. Strategy of Rational Therapy of Acute Respiratory Infections in Patients with Comorbidity. Safety and Risk of Pharmacotherapy. 2020;8(2):77-83. (In Russ.) doi:10.30895/2312-7821-2020-8-2-77-83.

1853

Knežević Praveček M, Hadžibegović I, Coha B, et al. Pericardial effusion complicating swine origin influenzae A (H1N1) infection in a 50-year-old woman. Med Glas (Zenica). 2013;10(1):173-6.

1854

Davoudi AR, Maleki AR, Beykmohammadi AR, Tayebi A. Fulminant myopericarditis in an immunocompetent adult due to pandemic 2009 (H1N1) influenza A virus infection. Scand J Infect Dis. 2012;44(6):470-2. doi:10.3109/00365548.2011.631575.

1855

Davidović G, Simović S, Mitrović S, et al. Fulminant myocarditis as a primary manifestation of H1N1 infection: A first reported case from Serbia. J Cardiol. 2016;57(3):181-4. doi:10.1016/j.hjc.2015.06.001.

1856

Buzon J, Roignot O, Lemoine S, et al. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. Novy EIntern Med. 2015; 54(16):2017-9. doi:10.2169/internalmedicine.54.3606.

1857

Larsen TR, Kinni V, Zaks J, et al. A lethal case of influenza and type 5 cardiorenal syndrome. Blood Purif. 2013;36(2):112-5. doi:10.1159/000355398.

1858

Kwong JC, Schwartz KL, Campitelli MA. Acute Myocardial Infarction after Laboratory Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345-53. doi:10.1056/NEJMc1805679.

1859

Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Hear t. 2015;101(21):1738-47. doi:10.1136/heartjnl-2015-307691.

1860

Iwanaga N, Nakamura S, Fukuda Y, et al. A fatal case of acute myocardial infarction following the improvement of influenza A(H1N1) pdm2009-related acute myocarditis. Intern Med. 2014;53(18):2153-7.

1861

Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017;196(5):609-20. doi:10.1164/rccm.201701-0104OC.

1862

Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014;10(9):e1004383. doi:10.1371/journal.ppat.1004383.

1863

Deng LH, Zeng YL, Feng P, et al. Clinical characteristics of critical patients with pandemic influenza A (H1N1) virus infection in Chengdu, China. J Zhejiang Univ Sci B. 2012;13(1):49-55. doi:10.1631/jzus.B1100168.

1864

Barbandi M, Cordero-Reyes A, Orrego CM, et al. A case series of reversible acute cardiomyopathy associated with H1N1 influenza infection. Methodist Debakey Cardiovasc J. 2012;8(1):42-5.

1865

Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: A new biomarker for the cardiologist. Int J Cardiol. 2016;223:390-7. doi:10.1016/j.ijcard.2016.08.204.

1866

Farber AJ, Suarez K, Slicker K, et al. Frequency of Troponin Testing in Inpatient Versus Outpatient Settings. Am J Cardiol. 2017;119(8):1153-5. doi:10.1016/j.amjcard.2016.12.030.

1867

Renko M, Leskinen M, Kontiokari T, et al. Cardiac troponin-I as a screening tool for myocarditis in children hospitalized for viral infection. Acta Paediatr. 2010;99(2):283-5. doi:10.1111/j.1651-2227.2009.01580.x.

1868

Leung CH, Tseng HK, Wang WS, et al. Clinical characteristics of children and adults hospitalized for influenza virus infection. J Microbiol Immunol Infect. 2014;47(6):518-25. doi:10.1016/j.jmii.2013.06.002.

1869

Zhang PJ, Cao B, Li XL, et al. Risk factors for adult death due to 2009 pandemic influenza A (H1N1) virus infection: a 2151 severe and critical cases analysis. Chin Med J (Engl). 2013;126(12):2222-8.

1870

Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother. 2013;47(12):1618-26. doi:10.1177/1060028013509973.

1871

Marchesi S, Lupattelli G, Lombardini R, et al. Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis. 2005;178(2):345-50. doi:10.1016/j.atherosclerosis.2004.08.036.

1872

Task Force Members; Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi:10.1093/eurheartj/eht296. Erratum in: Eur Heart J. 2014;35(33): 2260-1.

1873

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619. doi:10.1093/eurheartj/ehs215.

1874

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999-3054.

1875

ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation. 2013;127:529-55.

1876

Mavrogeni S, Bratis K, Kitsiou A, Kolovou G. Streptococcal tonsillitis and acute streptococcal myocarditis: an unusual combination assessed by cardiac magnetic resonance imaging and endomyocardial biopsy. Ann Otol Rhinol Laryngol. 2012;121(9):604-8.

1877

Liao YC, Hsieh YC, Chang WC, et al. Fulminant myocarditis in an adult with 2009 pandemic influenza A (H1N1 influenza) infection. J Chin Med Assoc. 2011;74(3):130-3. doi:10.1016/j.jcma.2011.01.028.

1878

Тихонова Е.П., Кузьмина Т.Ю., Андронова Н.В. и др. Изучение эффективности противовирусных препаратов (умифеновира, триазавирина) в отношении острых респираторных вирусных инфекций. Казанский медицинский журнал. 2018;99(2):215-23. doi:10.17816/KMJ2018-215.

Tikhonova EP, Kuz’mina TY, Andronova NV, et al. Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections. Kazan medical journal. 2018;99(2):215-23. (In Russ.) doi:10.17816/KMJ2018-215.

1879

Токин И.И., Цветков В.В., Голобоков Г.С. Сравнительная клинико-экономическая оценка двух альтернативных схем противовирусной терапии больных гриппом. Журнал инфектологии. 2018;10(2):110-6. doi:10.22625/2072-6732-2018-10-2-110-116.

Tokin II, Tsvetkov VV, Golobokov GS. Comparative clinical and economic evaluation of two alternative antiviral therapy regimens for influenza patients. Journal Infectology. 2018;10(2): 110-6. (In Russ.) doi:10.22625/2072-6732-2018-10-2-110-116.

1880

Rafalsky V, Averyanov A, Bart B, et al. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. Int J Infect Dis. 2016;51:47-55. doi:10.1016/j.ĳid.2016.09.002.

1881

Arabi H, Zaid AA, Alreefi M, Alahmed S. Suspected Oseltamivirinduced bradycardia in a pediatric patient: a case report from King Abdullah Specialist Children’s Hospital, Riyadh, Saudi Arabia. Clin Pract. 2018;8(4):1094. doi:10.4081/cp.2018.1094.

1882

Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869-76. doi:10.7326/0003-4819-158-12-201306180-00004.

1883

Руженцова Т.А., Плоскирева А.А., Алешина Н.И. и др. Возможности повышения эффективности терапии острых респираторных вирусных инфекций различной этиологии у детей. Инфекционные болезни. 2019;17(2):46-52. doi:10.20953/1729-9225-2019-2-46-52.

Ruzhentsova TA, Ploskireva AA, Aleshina NI, et al.Increasing treatment efficacy in children with acute respiratory viral infections. Infekc. bolezni (Infectious diseases). 2019;17(2):46-52. (In Russ.) doi:10.20953/1729-9225-2019-2-46-52.

1884

Pinson GM, Beall JW, Kyle JA. A review of warfarin dosing with concurrent acetaminophen therapy. J Pharm Pract. 2013;26(5):518-21. doi:10.1177/0897190013488802.

1885

Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-infl ammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf. 2017;8(6):173-82. doi:10.1177/2042098617690485.

1886

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi:10.1136/bmj.324.7329.71.

1887

Рафальский В.В., Крикова А.В., Багликов А.Н. Особенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препарата. Кардиоваскулярная терапия и профилактика. 2009;8(7): 102-7.

Rafalsky V, Krikova AV, Baglikov AN. Features of the clinical pharmacology of acetylsalicylic acid as an antithrombotic drug. Cardiovascular therapy and prevention. 2009;8(7):102-7. (In Russ.)

1888

Wen YC, Hsiao FY, Lin ZF, et al. Risk of stroke associated with use of nonsteroidal anti-infl ammatory drugs during acute respiratory infection episode. Pharmacoepidemiol Drug Saf. 2018;27(6):645-51. doi:10.1002/pds.44289-14.

1889

Дехнич А.В., Хачатрян Н.Н. Новые и старые оксазолидиноны. Тедизолид и линезолид — в чем отличия? Клиническая микробиология и антимикробная химиотерапия. 2017;19(2):121-9.

Dehnich AV, Khachatryan NN. New and old oxazolidinones. Tedizolid and linezolid — what are the differences? Clinical microbiology and antimicrobial chemotherapy. 2017;19(2):121-9. (In Russ.)

1890

Oh PC, Kang WC, Moon J, et al. Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study. Am J Cardiovasc Drugs. 2016;16(3):221-8. doi:10.1007/s40256-016-0168-1.

1891

Denardo SJ, Gong Y, Cooper-DeHoff RM, et al. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy. PLoS One. 2015;10(4):e0122726. doi:10.1371/journal.pone.0122726.

1892

Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15(1):116-21. doi:10.1093/europace/eus204.

1893

van Noord C, Aarnoudse AJ, Eijgelsheim M, et al. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics. 2009;19(4):260-6. doi:10.1097/FPC.0b013e328324e556.

1894

Nagahama S, Norimatsu T, Maki T, et al. The effect of combination therapy with an L/NType Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30(9):815-22.

1895

Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105 Suppl 1:S44-9. doi:10.1016/S0954-6111(11)70010-5.

1896

Carpentiere G, Castello F, Marino S. Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics. Chest. 1990;98(2):263-5.

1897

Леонова М. В., Белоусов Д. Ю., Галицкий А. А. и др. Характеристика нежелательных лекарственных реакций ингибиторов ангиотензин-превращающего фермента у пациентов с артериальной гипертонией. Артериальная гипертензия. 2010;16(4):412-7.

Leonova MV, Belousov DYu, Galitsky AA, et al. Characteristics of undesirable drug reactions of angiotensin converting enzyme inhibitors in patients with arterial hypertension. Arterial hypertension. 2010;16(4):412-7. (In Russ.)

1898

Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect. 2010;138(9):1281-8. doi:10.1017/S0950268810000105.

1899

Грибовская И. А., Маль Г. С., Звягина М. В. Изучение особенностей течения и лечения ИБС у больных с гиперлипидемиями в период острой респираторной инфекции. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2015;16(213):84-9.

Gribovskaya IA, Mal GS, Zvyagina MV. Studying the features of the course and treatment of coronary heart disease in patients with hyperlipidemia during acute respiratory infection. Scientific Bulletin of Belgorod State University. Series: Medicine. Pharmacy. 2015;16(213):84-9. (In Russ.)

1900

Lin CF, Chang YH, Liu JC, et al. Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study. BMC Cardiovasc Disord. 2016;16:24. doi:10.1186/s12872-016-0202-x.

1901

Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598-606.e2. doi:10.1016/j.amjmed.2013.01.036.

1902

Kim JH, Choi HG, Kwon MJ, et al. The Influence of Prior Statin Use on the Prevalence and Exacerbation of Chronic Obstructive Pulmonary Disease in an Adult Population. Front Med (Lausanne). 2022;9:842948. doi:10.3389/fmed.2022.842948.

1903

Kim JH, Wee JH, Choi HG, et al. Association Between Statin Medication and Asthma/Asthma Exacerbation in a National Health Screening Cohort. J Allergy Clin Immunol Pract. 2021;9(7):2783-91. doi:10.1016/j.jaip.2021.04.014.

1904

Karlsson L, Gnarpe J, Bergqvist D, et al. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms — a prospective randomized double-blind trial. J Vasc Surg. 2009;50(1):23-9. doi:10.1016/j.jvs.2008.12.048.

1905

Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3.

1906

Hansen TW, Thijs L, Li Y, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of reading-toreading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55:1049-57.

1907

Fraley DS, Bruns FJ, Segel DP, Adler S. Propranolol-related bronchospasm in patients without history of asthma. Southern medical journal. 1980;73:238-40.

1908

Wells Q, Hardin B, Raj SR, Darbar D. Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza. Heart Rhythm. 2010;7(10):1454-7. doi:10.1016/j.hrthm.2010.07.025.

1909

Wagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015;135(5):e1333-6. doi:10.1542/peds.2014-2578.

1910

Shah SP, Patel KM, Subedi R, Gambhir HS. Review of potential drug interaction between Oseltamivir and Warfarin and why it is important for emergency medicine physicians. Am J Emerg Med. 2017;35(8):1207.e3-4. doi:10.1016/j.ajem.2017.03.040.

1911

Yu S, Lee SC, Hong JH, et al. Cardiovascular and cerebrovascular mortality in patients with preceding asthma exacerbation. Respirology. 2023;28:281-6.

1912

Ansaldi F, Turello V, Lai P, et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res. 2005;33(5):490-500. doi:10.1177/147323000503300503.

1913

Антонов В. Н., Игнатова Г. Л. Эффективность и безопасность иммунизации пациентов с хронической обструктивной болезнью легких моноклональными антителами. Терапевтический архив. 2023;95(3):243-7. doi:10.26442/00403660.2023.03.202146.

Antonov VN, Ignatova GL. Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies. Terapevticheskii arkhiv. 2023;95(3): 243-7. (In Russ.) doi:10.26442/00403660.2023.03.202146.

1914

Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333-e465. doi:10.1093/ehjci/jeac106. Erratum in: Eur Heart J Cardiovasc Imaging. 2023;24(6):e98.

1915

Sebio Garcia R, Yáñez Brage MI, Giménez Moolhuyzen E, et al. Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2016;23(3):486-97. doi:10.1093/icvts/ivw152.

The authors declare that there are no conflicts of interest present.